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Abstract 
 
The research surrounding delivery carriers of hydrophobic drugs has evolved 
with the help of efficient tools brought together by nature’s most important 
process, self-assembly. This enabled scientists to create and tailor materials 
with multiple functionalities in order to suite specific needs. One such 
nanomaterial is the disc-shaped cargo carrier, named nanodiscs. Nanodiscs 
are noncovalent assemblies consisting of a phospholipid bilayer, whose 
hydrophobic edge is stabilized by two or more copies of membrane scaffold 
protein.  
Despite an abundance of research directed towards the development of an 
effective nanosystem for delivery into mammalian cells, superficial focus is 
given to characterizing the incorporation of hydrophobic drugs. This thesis 
describes the development of a simple approach to systematically study the 
relation between physical parameters related to loading and release of poorly 
water soluble drugs from nanodisc systems. 
For the nanodiscs reconstitution, two strategies have been studied, the first 
comprised of adding the protein to a mixture of lipid and detergent micelles, and 
second strategy involved adding protein stabilised in detergent micelles to the 
lipid. Two more strategies were employed for studying the loading of drugs into 
nanodiscs - the drugs were added either to a solution of nanodiscs, or loaded 
during the reconstitution of nanodiscs. The latter strategy showed an increase 
in drug incorporated per nanodiscs and a slower release rate. In the case of 
amiodarone and chlorambucil incorporation, a decrease in membrane thickness 
was seen to be correlated with the efficiency of drug loading within the POPC 
bilayer. In addition, the lipid composition within nanodiscs was varied in order 
to investigate its effect on nanodisc formation, drug loading and release kinetics. 
Finally, the protein component of empty and drug loaded nanodiscs was site-
specifically modified via Sortase A mediated ligation, for traceable delivery in 
in vitro cell studies. Good internalisation of MSP by HeLa cells was observed 
when cells were treated with empty and chlorambucil loaded nanodiscs.   
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Introduction 
1 Chapter 1 - Introduction 
In this introduction chapter, the broad category of self-assembled structures, 
with applications in nanomedicine, will be outlined. There are several excellent 
reviews summarising the emerging field of nanomedicine1, 2 and the vast pool of 
nanoscale systems engineered for its application. In the last decade, the huge 
potential benefits of these system’ application in nanomedicine have attracted 
the interest of researchers,3, 4 leading to an increasingly fast and diversified 
progress of such research. With this in mind, a thorough review is difficult to 
attain and, more so, beyond the scope of this chapter. The following discussion 
will focus particularly on drug delivery systems, specifically designed and 
engineered for hydrophobic drugs. In addition, the lipid based discoidal systems, 
named nanodiscs, their design and emerging applications will be introduced. 
 The importance of nanotechnology 
Nanotechnology is the branch of technology that involves the design, 
engineering and characterisation of man-made, novel materials by controlling 
their shape and size at the nanometer scale. Typically, this nanometer scale is 
described to be in the range of less than 100 nanometers.5, 6 The concepts of 
this technology stirred the interest of many researchers because the difference 
from macro scale to nanoscale might have an impact on the properties of 
materials. For example, the high surface area to mass ratio found in nanoscale 
materials could lead to their reactivity being enhanced.2  
The concepts and ideas behind nanotechnology have been amongst us for 
some time. The possibility to examine and manipulate atoms and molecules 
individually was first mentioned by the ‘father of nanotechnology’, physicist 
Richard Feynman, in 1959. However, the development of nanotechnologies has 
only bloomed over the past decade as more innovative tools are being created 
in order to facilitate an accurate examination of small molecules. This ability to 
thoroughly understand and accurately tailor the fundamental properties of all 
materials - man-made or natural - at the nanoscale, will eventually impact all 
engineered materials, regardless of their applications. With the help of 
nanotechnology, many areas of research will greatly improve. 
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 The field of nanomedicine 
Over the recent years, advances in nanotechnology, materials science and 
biotechnology have come together to give rise to the state-of-the-art field of 
nanomedicine.7 Due to its key ability in using engineered nanostructures for 
diagnosis and treatment of disease, nanomedicine is considered a promising 
field in improving the quality of life. Advances in nanoparticle engineering, as 
well as the importance of nanoparticle characteristics such as size, shape and 
surface properties for biological interactions, are creating new opportunities for 
the development of nanomaterials for nanomedicine applications.  
Nanomaterials used in medicine have numerous advantages such as controlling 
the biodistribution of drugs by changing the nanoparticle properties, enhancing 
the therapeutic index of the cargo drug resulting in a decrease in drug’s toxicity 
and side effects or effectively escape removal by the reticuloendothelial 
system.8, 9 In addition, nanomaterials can systemically deliver hydrophobic 
compounds via active targeting specific cells with the help of highly selective 
ligands attached on to their surface, or passive targeting to sites through the 
enhanced permeability and retention effect (EPR).10 More so, the circulation 
half-life of nanoparticles could be extended by creating a stealth coating, thereby 
reinforcing this EPR effect to passively deliver drug molecules. Furthermore, 
upon delivery of drugs, the nanoparticles can use various mechanisms to 
release the cargo either slowly or under controlled conditions. For example, drug 
can diffuse out of the nanoparticle, drug can escape the carrier under swelling 
conditions (influenced by the rate of water diffusing in and the size of the cross-
linked network which makes up the carrier), or it can be released as a response 
to an internal or external stimuli (such as temperature, pH or ionic strength).11 
In order to engineer new nanomaterials for such applications, the basic design 
principles and their formation have to be understood. Self-assembly can be used 
to create nanoparticles with multiple functionalities, the process of which will be 
outlined, in more detail, in the following section. 
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 The principles behind self-assembled structures 
Self-assembly can be defined as the spontaneous and reversible organisation 
of molecular units into thermodynamically stable and ordered structures through 
non-covalent interactions.12 The weak nature of these interactions is responsible 
for the flexibility of the structure. Thus, self-assembly is the main strategy that 
biological systems use to build-up complex molecular assemblies. Many of 
these complex biological structures have evolved with the help of specific non-
covalent interactions, such as hydrogen bonds and electrostatic interactions, 
which promoted the spontaneous organization between the components. 
The self-assembly process starts when an entropic loss is balanced by an 
enthalpic gain. Hence, the ordered state forms as the system approaches 
equilibrium, reducing its free energy.13 For example, in the case of amphiphilic 
molecules - consisting of a hydrophilic head group and a hydrophobic tail - the 
unfavourable entropy is balanced by the presence of a driving force, which 
stimulates the spontaneous self-association of molecules. This driving force is 
the hydrophobic effect – the tendency of hydrophobic tails to exclude water 
molecules by self-aggregating and forming water free cores shielded by the 
hydrophilic head groups. As a result of this self-organisation, the tension, at the 
interface, between apolar tails and water is reduced.14 However, once the self-
association of molecules has started, the molecules must arrange themselves 
into the most favourable structure. This favourable arrangement is determined 
by molecular geometry. In order to analyse the geometrical packing of the 
molecules, a dimensionless packing parameter is introduced. This parameter is 
determined by the optimum head group area, the volume of the tail and the 
maximum effective length to which the tail can extend to. 
𝑣𝑐 𝑎0⁄ 𝑙𝑐 
The dimensionless packing parameter; 𝑣𝑐 is the volume of hydrocarbon chains, 𝑎0 is 
the optimal head group area per molecule and 𝑙𝑐 is the critical chain length – the 
maximum effective length to which they can extend 
 
The aggregate of molecules will assemble into the most favourable shape, 
influenced by the packing parameter. For example, under the category of 
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amphiphilic molecules two types of molecules may be found: surfactants, which 
form micelles of different geometrical packing (spherical – packing parameter 
< 1/3, rod-like – cylindrical (1/3 < packing parameter < 1/2) or inverted hexagonal 
(packing parameter > 1) - and cubic) (Figure 1.1), and lipids (discussed in a later 
section - packing parameter ~ 1), that possess larger hydrophobic tails 
compared to their hydrophilic head group and, as such, form bilayer structures. 
These amphiphilic molecules are examples of self-assembled structures that 
follow a nucleated self-assembly process. 
 
Figure 1.1 - Cartoon representation of surfactants assembly in water environment into 
micellar structures 
 
In nucleated self-assembly, the average aggregate size in solution depends on 
the concentration of the substance in solution. This size distribution at 
equilibrium is entropically driven, meaning that, at low concentrations, the 
entropic dissociation is too strong to allow the formation of assemblies. As a 
result, the formation of the initial aggregates takes place only above a certain 
concentration, called critical micelle concentration, CMC. The system balances 
the loss of entropy by limiting the growth of the aggregates and by causing a 
vast distribution of sizes. Therefore, after reaching CMC, self-assembled 
aggregates and free amphiphilic molecules will coexist simultaneously in 
solution.  
The molecular architecture of an amphiphilic molecule plays an important role 
in defining its CMC, in such that, the longer the hydrophobic tail of the molecule 
the smaller its CMC. Examples of these self-assembled molecules can be found 
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in nature, in abundance, as they are essential in creating a living, functional 
structure. Among the most significant self-assembly process found in biological 
systems is the formation of cellular membranes from phospholipids, the 
hydrophobic tails of which cluster together under the hydrophobic effect.  
Taking inspiration from biological systems, self-assembly has become an 
important tool in designing and controlling the pattern organisation of building 
blocks. Quite possibly, using this fundamental process has enabled scientists to 
work towards a versatile solution with multiple functionalities. This is the case of 
drug delivery carriers, where research has bloomed in the past years, due to the 
way self-assembly has brought together efficient tools for creating and tailoring 
materials to suite specific needs.15-18 Advantages of such materials range from 
improved solubilisation and drug availability, to controlled drug release, reduced 
toxicity and prevention of uptake by the reticuloendothelial system. Whatever 
the enhancements these self-assembled nanomaterials bring to the cargo, 
which will be discussed in Section 1.5, firstly the challenges faced by poorly 
water soluble drugs need to be understood.  
 Poorly water soluble (hydrophobic) drugs and their challenges 
The word ‘hydrophobic’ is derived from the Greek Hydro, meaning water, and 
Phobos, meaning fear. Hydrophobicity is the physical property of a nonpolar 
molecule to avoid a mass of water, predominantly due to the water-water 
hydrogen bonding being stronger than the intermolecular attraction between 
nonpolar molecules.19, 20 The degree of hydrophobicity is affected by how 
soluble the nonpolar molecule is in both immiscible phases, e.g. water and oil. 
This difference in solubility, at equilibrium, written as a ratio, is called the partition 
coefficient (P), commonly found as its logarithm (Log P).21  
log Pnonpolar solv/wat = log (
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑛𝑜𝑛𝑝𝑜𝑙𝑎𝑟 𝑠𝑜𝑙𝑣
𝑢𝑛−𝑖𝑜𝑛𝑖𝑧𝑒𝑑
[𝑠𝑜𝑙𝑢𝑡𝑒]𝑤𝑎𝑡𝑒𝑟
𝑢𝑛−𝑖𝑜𝑛𝑖𝑧𝑒𝑑
) 
Equation 1.1 Equation of the partition coefficient, written as its logarithm 
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Despite the fact that the hydrophobic small molecules used in our studies 
(discussed in Chapter 3) were first chosen based on a variety of Log P - from 3 
to 8 – most of these molecules are charged at physiological pH, making the 
values for Log P unreliable. Therefore, the water solubility of these molecules 
was also taken into account. The water solubility of a drug is an important 
property that has high influence in the absorption and bioavailability of the drug. 
Poorly water soluble (hydrophobic) drugs tend to have a high toxicity because 
they are retained longer, have a wider distribution within the body and are 
challenging to formulate.22  
In recent years, the number of new drug candidates with poor water solubility 
has increased, reaching 70% of all drug discoveries.23 In order to improve the 
poor solubility of drugs and minimise their side effects, researchers have 
employed particle technologies, varying from size reduction techniques to 
formulation of drug-cyclodextrin complexes and drug delivery systems via top-
down (deconstructing large structures into small pieces, for a better 
understanding of the structure, such as milling) or bottom-up approaches 
(building molecule by molecule, such as self-assembly). These methods of 
enhancing drug solubility are very well highlighted in recent reviews.24-26 In the 
following subchapters, our focus will be on discussing nano-sized materials for 
the incorporation and delivery of poorly water soluble drugs, their advantages 
and limitations, as well as suggestions for improving these systems.  
 Self-assembled materials as nanocarriers for poorly water soluble 
drugs  
In the last few decades, a new generation of nanomaterials (Figure 1.2) has 
been investigated for their potential applications in drug delivery and imaging.27-
30 The rationale behind their investigation is that these materials have distinct 
functional and structural properties when scaled down in the nanometer range. 
For example, nanomaterials can transport high-dose therapeutic cargos as a 
result of their high surface area to volume ratio.  
Another important aspect of these synthetic nanosystems is their 
biocompatibility. The uptake of these nanocarriers by undesired systems can 
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lead to toxic side effects. This problem can be prevented either by coating the 
surface of nanoparticles with a hydrophilic polymer, to protect them from 
opsonisation31 (adsorption of opsonin proteins on the surface of nanoparticles 
in order to be easily recognised by phagocytes), or by forming the nanoparticles 
from block co-polymers or lipids with hydrophilic and hydrophobic domains. 
The size and shape of nanocarriers are also important factors in controlling the 
life time of nanoparticle systems. The size should be smaller than 500 nm to 
escape the fixed macrophages but larger than 8 nm to avoid rapid kidney 
clearance; the particle shape can have an effect on cellular internalisation and 
can also affect the transport and alignment of the particle once inside the cell.32, 
33 For example, it has been shown that anisotropic particles, such as discs, can 
undergo cellular uptake at a much slower rate than isotropic particles 
(spheres).34  
The benefits of using these nanomaterials are enhanced by their increased 
solubility and in vivo stability, the possibility of being used in both active and 
passive targeting, and their contribution to simultaneously lessen the side effects 
of their cargo and improve its biocompatibility. Other advantages of using 
nanocarriers include prolonged circulation time, done by controlling their size 
and surface characteristics, enhanced intracellular penetration, and stimuli-
sensitivity that allows nanocarriers to release the drug.35 All these reasons are 
behind the belief that, with the help of nanomaterials, the area of nanomedicine 
will revolutionise the treatment of many diseases. 
 
Figure 1.2 – Cartoon representation of multifunctional pharmaceutical nanocarrier 
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1.5.1 Theranostic nanocarriers 
Theranostic nanocarriers are nanosystems designed as a biocompatible and 
biodegradable system for both imaging and therapeutic applications.36 The 
components are strategically combined, due to their optical and structural 
functionalities, in order to create a nanosystem with enhanced delivery 
outcomes.  
In order to provide a suitable platform, theranostic nanocarriers are ideally 
designed with characteristics which include selective accumulation in tumour, 
high loading and efficient release of drugs, imaging contrast and increased 
circulation lifetime. The resulting nanocarriers are, simultaneously, capable of 
diagnosis, drug delivery and monitoring of therapeutic response. 
Several types of nanosystems have already been employed as theranostic 
nanocarriers, including gold nanocarriers,37 polymer based nanocarriers,38 
quantum dots39 and silica nanocarriers (Figure 1.3). For example, nanoparticles 
consisting of a hydrophobic Fe3O4 inner core grafted with poly (tert-butyl 
acrylate), and a mesoporous silica shell have been developed for bimodal 
imaging (magnetic resonance imaging/ near-infrared fluorescence) and the 
targeted delivery of paclitaxel.39 The silica shell was modified with transferrin 
and near-infrared fluorescent dye. Their results successfully demonstrated that 
the paclitaxel loaded nanoparticles cluster selectively in tumour tissues, and 
exhibit a higher cell cytotoxicity then free drug.  
Despite the growing interest of researchers in engineering various types of 
theranostic nanocarriers, there are still difficulties, which need to be addressed, 
in developing a biocompatible, highly specific tumour targeting nanosystem.  
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Figure 1.3 Schematic illustration of the self-assembly process of, from left to right, 
nanocarriers composed of Fe3O4 inner core with poly (tert-butyl acrylate) on the surface, 
and a mesoporous silica shell,39 Doxorubicin incorporated into PEGylated gold 
nanoparticles, coated with a layer of calcium phosphate37, Pluronic P105-doxorubicin 
conjugate (red) and Pluronic F127 (blue) micelles loaded with paclitaxel40  
1.5.2 Drug delivery systems 
Self-assembled nanomaterials applied as drug delivery systems are nano-sized 
particles or systems that can be designed with different shapes and from a 
variety of materials including polymers (nanoparticles, micelles, or dendrimers), 
lipids (liposomes or solid lipid nanoparticles), viruses (viral nanoparticles), and 
hybrid structures. For example, polymer-based drug carriers may have the 
structure of capsules (nanoparticle shape), amphiphilic core/shell (micelle 
shape), or hyper-branched macromolecules (dendrimers); liposomes are 
colloidal structures composed of lipid bilayers and have a spherical shape; 
hybrid nanocarriers have a spherical structure, with an amphiphilic core/shell 
composed of hydrophobic polymer, lipid and hydrophilic polymer.  
 Amphiphilic block co-polymers nanocarriers 
Over the past years, researchers have developed nano-encapsulation systems 
that can satisfy most of the required attributes. Self-assembled polymeric 
systems, composed of block co-polymers, have emerged as promising drug 
nanocarriers for the delivery of chemotherapeutic agents, due to their versatility. 
For instance, the chemical and physical properties of the polymeric structure 
could be easily adjusted just by selecting different monomers or polymerisation 
degrees.41  
The structure of these amphiphilic micelles consists of a hydrophobic core and 
a hydrophilic shell (Figure 1.4). The hydrophobic part of the co-polymer non-
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covalently associates, through hydrophobic interactions, with the hydrophobic 
drug, forming a tightly packed core. The hydrophilic part acts as a protective 
layer between the aqueous phase and the hydrophobic core and stabilises the 
system. 
The incorporation of hydrophobic drugs into amphiphilic polymer nanocarriers 
can be done by several different methods (during the formation of nanocarriers, 
incubated with formed nanocarriers or chemically conjugated).42 However, the 
loading efficiency may be influenced significantly by them. For example, Shen et 
al. incorporated doxorubicin to light responsive spiropyran-poly (2-
methacryloyloxyethyl phosphorylcholine) micelles by adding the drug to already 
formed micelles.43 After removing the excess drug by dialysis, the drug loading 
content was determined to be 5.7%. The release profile of doxorubicin was 
established by diffusion of drug molecules from the nanocarriers, over a period 
of time. The study showed that only 20% of doxorubicin was released in 24 h, in 
the absence of UV irradiation. Whereas, the drug amount released increased to 
50% when the micelles were UV irradiated, likely because the disassembly of 
micelles was photochemically triggered.  
Another example of incorporating doxorubicin into a self-assembled system was 
developed by Zhai and his group.44 In this study, drug carriers based on 
amphiphilic block co-polyphosphates with different hydrophobic block lengths 
were used. Doxorubicin was preloaded to the polymeric nanocarriers, 
suspended in dimethylformamide – added during the polymeric micelles 
formation. The solvent and free doxorubicin were subsequently removed by 
dialysis against phosphate buffer. The drug loading content was calculated to 
be up to 3.5 wt%, depending on the length of the hydrophobic block used. Apart 
from their established biocompatibility and biodegradability, these drug-loaded 
micelles have improved drug release behaviour with an initial burst release and 
a subsequent slower constant release. The release profile reached a maximum 
of 25% drug released, in 80 h, from the micelles assembled with the shortest 
block. In addition, the systems’ toxicity, attributed to solvent residue, may be 
enhanced.  
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Furthermore, the drug loading efficiency was not only influenced by the 
incorporation method, but also by the balance of hydrophobic and hydrophilic 
parts within the amphiphilic polymer. In this case the polymer with the longest 
hydrophobic block had the highest incorporation efficiency. Similar results were 
also shown by Tran et al. for the incorporation of doxorubicin into 
polynorbonene-cholesterol/ poly(ethylene glycol) nanocarriers.45  
The long circulating time of co-polymer nanocarriers is considered an advantage 
for stably retaining the loaded drug molecules in the blood stream. However, the 
drug loading efficiency is greatly dependent on the compatibility between drug 
and polymer blocks and the balance between the hydrophobic and hydrophilic 
segments. More so, little is known about the interactions of polymeric 
nanocarriers with biological systems. Further investigation is required to 
overcome the above limitations of nanocarriers based on block co-polymers. 
 
Figure 1.4 Cartoon representation of an amphiphilic block co-polymers nanocarrier; the 
hydrophilic polymer is represented in blue, the hydrophobic polymer, in red and the 
hydrophobic drug molecule, in green  
 
 Virus-based carriers 
Virus based particles are the genome-free components of native viruses. The 
particles possess caged structures with a hollow interior, and consist of self-
assembled virus protein subunits.46 Due to their use, in nature, as containers for 
the delivery of molecules to specific cells and tissues, virus-like carriers have 
attracted the attention of many researchers, as potential vehicles for drug 
delivery.47-49  
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Virus like particles can be produced in living hosts, and therefore can provide 
three platforms - interior, exterior, and subunit interface – for genetic and 
chemical functionalisation. These features, along with their non-toxic 
biodegradability and precise shape and size, makes virus like carriers ideal for 
drug delivery. For instance, in their study, Zeng et al. showed that, after diffusion 
through the particles’ pores, doxorubicin was entrapped into the cucumber 
mosaic virus particles by association with the native RNA.48 After removing free 
drug via sucrose gradient centrifugation, the encapsulation efficiency of 
doxorubicin loaded in the particles was calculated at 14%. Virus like particles 
derived from plant viruses, such as cucumber mosaic virus48 and cowpea 
mosaic virus50, have been widely studied as cargo carriers for the delivery of 
drug molecules. However, their poor blood circulation limits their applicability.  
Nanocarriers derived from animal viruses have also been researched as delivery 
vehicles because of their low immunogenicity and low toxicity. In literature, 
researchers have reported the encapsulation of paclitaxel, inside particles of 
adenovirus49 or human JC polyomavirus,51 and their subsequent release in the 
target cells.  
The multitude of encapsulation methods - coupling to the carrier in order to form 
a prodrug, loading via disulphide bonds, disassembly and reassembly of the 
carrier - and the relatively high encapsulation efficiency have proven virus like 
particles to be a suitable platform for drug entrapment. However, effective 
delivery of drugs depends also on other factors, such as the rate of cellular 
uptake or release kinetics. For example, Ren et al. has shown that, when 
compared to free doxorubicin, drug loaded virus like particles exhibited a similar 
or less effective cytotoxicity.52 In contrast, when same drug was covalently 
attached to cowpea mosaic virus, the complex showed enhanced cytotoxicity, 
despite a time-delayed drug release.50 This inconsistent efficacy of drug 
encapsulation suggests that further investigation is required to find the optimum 
conditions. 
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Figure 1.5 Cartoon representation of a drug loaded virus-like carrier 
 
 Lipid-based nanocarriers 
Lipid based nanocarriers are biocompatible vesicles, with a closed bilayer 
structure surrounding an aqueous core (Figure 1.6). Over the past decades, lipid 
nanocarriers have been extensively used for the encapsulation of drug 
molecules - either inside the aqueous core or within the enclosed hydrophobic 
environment of the lipid bilayer – with the purpose of improving the drugs’ 
pharmacokinetic profile and biodistribution.32, 53 Once inside, the nanocarrier 
protects the encapsulated drug molecules from external environment, avoiding 
degradation, improving the biodistribution and enhancing the drugs’ efficiency. 
Furthermore, the membrane like environment of lipid nanocarriers can have a 
positive input on tasks such as delivery into cells. As a result of this intense study 
of lipids, a new class of therapeutics with improved drug delivery, and low 
cytotoxicity and immunogenicity, has already been developed into clinically 
approved products, such as Abelcet®, AmBisome®, and Visudyne®, for the 
delivery of amphotericin B and verteporfrin.54 
The advantages of liposome nanocarriers rely upon its versatility when tailoring 
the physicochemical properties of the systems, regardless of the stage the 
formulation process is at. For example, bilayer thickness and phase transition 
temperature can be controlled by the length of the hydrocarbon chain. These 
properties can also be adjusted for improved drug release. For instance, the 
antiarrhythmic drug amiodarone showed prolonged release profile, lacking an 
initial burst, and high loading efficiency when encapsulated into lipid 
nanocapsules.17 However, despite its adaptability, tailoring the properties of 
liposomal carriers is not the only contributor to an enhanced efficiency of drug 
encapsulation. Drug properties, such as Log P or molecular weight, may be 
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important factors in determining the loading efficiency within the liposomal 
bilayer domain. 
 
Figure 1.6 Cartoon representation of phospholipids assembling in water environment 
 
 Hybrid nanocarriers 
Hybrid nanoparticles are core/shell structures which exhibit a combination of 
complimentary characteristics from both components, polymer and lipids.55 The 
particles are typically composed of a hydrophobic polymeric core, surrounded 
by a shell, constituted from an inner lipid layer and an outer PEGylated lipid layer 
(Figure 1.7). Drug molecules can be encapsulated inside the polymeric core, 
while the shell acts as a protective layer, conferring biocompatibility to the 
sequestered molecules. The PEGylated outer layer functions as a ‘stealth’ 
coating, providing steric stabilisation and extending the circulation time of the 
complex.  
Among the benefits of lipid-polymer hybrid nanoparticles the stability during 
storage, its high structural integrity and prolonged drug release due to the 
core/shell structure, are the most prominent.56 Zhang et al. designed, in the late 
2000s, a lipid-polymer hybrid nanoparticle system with tuneable size and 
surface charge, high drug loading yield, good cellular targeting ability and 
sustained drug release profile. These hybrid nanoparticles were formed from a 
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hydrophobic polymeric core, a hydrophilic polymeric shell and a lipid monolayer 
at the interface of the core and the shell.57 
 
Figure 1.7 Cartoon representation of the lipid-polymer hybrid nanocarrier 
 
The hybrid nanocarriers, however, may have limitations, such as wide size 
distribution, depending on the preparation method (nanoprecipitation or 
emulsification–solvent–evaporation). More so, despite their enhanced 
characteristics, the research of hybrid nanocarriers in vivo is still in its incipient 
stage.58 
Although nanoparticles offer many advantages as drug carriers, these systems 
still have many limitations such as content leakage and instability during storage, 
instability in circulation or poor bioavailability. In addition to the possible toxicity 
of nanoparticles, some of the materials used to constitute these systems may 
have toxic effects and therefore may not be viable for developing therapeutic 
products.59 Furthermore, the distribution of nanocarriers within the body has to 
be understood, as well as their biodegradation and excretion routes. Last but 
not least, designing more efficient methods for the encapsulation of drugs 
coupled with activated release while tailoring the surface shape and stability of 
the nanosystem may become another barrier in developing these advanced 
drug delivery systems.  
 Nanodisc systems 
Disc-shaped micelles are a group of amphiphilic structures that follow the self-
assembly process. Because of their geometrical packing, phospholipids form 
the basic component for these nanostructures. Phospholipids are a class of 
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lipids that represent a major component of all cell membranes.60 Due of their 
hydrophilic head and hydrophobic tail, when exposed to water, phospholipids 
tend to organize into a two-layered sheet with all of their tails pointing toward the 
center of the sheet (Figure 1.6). The center contains almost no water and 
excludes hydrophilic molecules, making them ideal for secluding hydrophobic 
small molecules. Most phospholipids contain a diglyceride, a phosphate group 
and a simple organic molecule such as choline (Figure 1.8).  
 
Figure 1.8 Structure of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)  
 
To stop these phospholipids from assembling into systems such as liposomes, 
a second component is introduced. This second component consists of either 
another phospholipid or a scaffold protein, adding to the formation of a versatile 
platform for investigating the dynamics and structure of amphiphilic molecules. 
The work described in the following subsections attempts to introduce these two 
self-assembled nanostructures, with similar shape, composition and 
applications, but distinct limitations. 
1.6.1 Lipid discs – bicelles 
One example of structures that adopts the disc-shape morphology are bicelles 
(Figure 1.9). Bicelles are generally composed of long-chain (12 to 18 carbons) 
and short-chain (6 to 8 carbons) phospholipids. The bilayer region is formed by 
the long-chain lipids and surrounded at the edge by the short-chain lipids, 
protecting the hydrocarbon tails from water molecules. Most commonly used 
phospholipids in the formation of bicelles are 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1, 2-diheptanoyl-sn-glycero-3-phosphocholine 
(DHPC).  
The size of bicelles is controlled by the ratio between long-chain and short-chain 
lipids. If the ratio is over three, the bicelles are large and magnetically oriented.61 
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In addition, the bicelles have an adaptable morphology, characteristic with 
changes in lipid composition and temperature.62 More so, the long term stability 
of bicelles is limited by the hydrolysis of the ester bonds connecting the saturated 
chains and the headgroup, therefore it is strongly dependent of pH changes. 
One method to stabilise lipid bicelles discs is the addition of a PEGylated lipid. 
In a recent study, Liu et al. demonstrated that, by inclusion of PEGylated lipids 
along the edge of the bicelles, the structures are stabilised and the formation of 
multilamellar vesicles is inhibited.63 
Many recent studies have showed the advantages of using bicelles in NMR 
investigations of membrane proteins61, 64, 65 - due to their spontaneous self-
orientation when exposed to a magnetic field – or in studies of partition, transport 
and delivery of hydrophobic drugs66 – because the inside of bicelles is water 
free. However, their poor stability, pH, temperature and concentration 
dependence makes them ineffective in terms of providing an efficient controlled 
delivery system.67 
 
Figure 1.9 Cartoon representation of disc-shaped micelles (bicelles) 
1.6.2 HDL inspired discs  
Another example of disc-shaped amphiphilic nanostructures is the nanodisc 
(ND). As in the case of bicelles, the basic components that form the bulk of the 
disc-shaped bilayer are phospholipids. The second component added to the 
nanostructure is an amphipathic membrane scaffold protein (MSP) derived from 
Apolipoprotein A1 (ApoA-I), and lacking the globular N-terminal domain. ApoA-
I is the predominant constituent of high density lipoproteins (HDL), which have 
an important role in reverse cholesterol transport68 (Figure 1.10). The N-terminal 
helix 44–65 and the C-terminal helix 210–241 of ApoA-I have an affinity to 
18 
Introduction 
initially bind to the hydrocarbon chains of phospholipids whenever in their 
presence,69 making this specific scaffold protein ideal for using as a protein belt. 
The helical conformation of ApoA-I promotes interactions between its 
hydrophobic face and phospholipids, while the hydrophilic side forms 
interactions with the aqueous phase. This amphipathic α-helices formation is 
driven by the 22-mer repeats identified in the structure of ApoA-I.70  
 
Figure 1.10 Cartoon representation of high density lipoproteins 
 
Designed for the first time by Sligar’s group,71 ND are nanoscale noncovalent 
assemblies whose hydrophobic edge of the phospholipid bilayer is stabilized by 
two or more copies of MSP, called the protein ‘belt’. Their size ranges from 9.7 
to 12 nm, depending on the scaffold protein used in the reconstitution. 
Therefore, the small size of nanodiscs is considered a major advantage.  
One such model of a lipid/protein disc with a cylindrical lipid bilayer in the center 
and two helical protein molecules around the lipid is illustrated in Figure 1.11. 
Nanodiscs are relatively monodisperse, if a correct ratio of MSP to phospholipid 
is used. The scaffold protein interacts with the hydrophobic fatty acyl chains of 
phospholipids at the edge of the disk, conferring stability and, at the same time, 
water solubility to the ND.  
ND are formed using a process that takes place when the detergent added to 
the self-assembling mixture, is removed, by dialysis or adsorption to 
hydrophobic beads. Simultaneously, the assembly process between MSP and 
phospholipids starts, arranging them into a discoidal bilayer. Their formation 
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process, along with design changes adapted for hydrophobic drug incorporation 
will be further discussed in the results chapters. 
 
Figure 1.11 Bayburt’s illustration of the ND structure based on theoretical simulations 
using coarse grain and whole-atom molecular dynamics and solution X-ray scattering72 
 
Subsequent to their design, optimum formulation and stability studies, the 
researchers have observed that the “native like” lipid bilayer portion of the ND 
provides an environment capable of solubilising and sequestering hydrophobic 
molecules.73 Therefore, they can serve as ‘model membranes’ for characterising 
embedded proteins or as carriers for the delivery of drugs. 
 Changes in ND structure 
The nanodisc system, earlier mentioned, was developed, in the early 2000s, in 
order to study the phase transition behaviour of the incorporated lipids. The 
membrane scaffold proteins first used were MSP1 and MSP2. The sequence of 
MSP1 contained 200 amino acids, designed with a histidine tag and a Factor X 
recognition site. MSP2 was a genetic fusion of two MSP1, using a glycine–
threonine linker. To form the nanodiscs, each MSP was self-assembled with 
DPPC or POPC, in order to find the optimum conditions for the formation of 
homogeneous populations of nanodiscs.71 The phase behaviour of the 
nanodiscs demonstrated that the incorporated phospholipids retain the basic 
thermodynamic properties of a lipid bilayer. This behaviour resembled that of a 
cellular membrane and provided an excellent platform for studying insoluble 
membrane proteins in soluble systems,74 such as cytochrome P450,75 
bacteriorhodopsin,76 bacterial chemoreceptors77 and G-protein coupled 
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receptors (GPC).78 Examples of these nanodiscs systems will be further 
summarised.  
The nanodisc system designed with MSP1 was further researched by Bayburt 
et al., for the self-assembling of bacteriorhodopsin, as a model protein 
containing seven-transmembrane segments.76 The result was found to provide 
a soluble and monodisperse structure. MSP1 was again used alongside POPC 
in the assembly of nanoscale phospholipid bilayer system with the purpose of 
incorporating the β (2)-adrenergic receptor; the first GPC receptor assembled 
into a nanodisc. The resulting compound allowed antagonists, agonists and 
G proteins to access the physiologically intracellular and extracellular faces of 
the receptor79 (Figure 1.12). 
 
Figure 1.12 GPC receptor embedded in a nanodisc system79 
 
Following the design and production of the engineered scaffold proteins, Sligar’s 
research group, in collaboration with Denisov, have demonstrated the influence 
of N-terminal residues in membrane scaffold protein and its overall length, in 
forming the nanodiscs and controlling their size.80 Their study found that, for the 
formation of nanodiscs, the first 20-22 amino acids of the scaffold protein are 
not required. More so, the histidine tag engineered at the N-terminal is not 
involved in the self-assembly process between scaffold protein and 
phospholipids. 
One of the newly generated scaffold protein was MSP1D1. This protein was 
obtained from MSP1 via the deletion of the first 11 N-terminal amino acids. One 
study in which MSP1D1 self-assembled with phospholipids to form ND was for 
the immobilisation of cytochrome P450.81 The protein embedded into the ND 
system was investigated by Nath et al. using single-molecule fluorescence 
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spectroscopy. By using total internal reflection fluorescence microscopy 
(TIRFM), fluorescence correlation spectroscopy (FCS) and Förster resonance 
energy transfer (FRET), they demonstrated that the developed ND system 
successfully immobilised single membrane proteins without covalent 
modification.  
MSP1D2, derived from MSP1 via the removal of the first 22 N-terminal amino 
acids, was also used as scaffold protein in self-assembled ND, for a better 
understanding of the electron transfer between Nicotinamide adenine 
dinucleotide phosphate (NADPH) and cytochrome P450. The study involved the 
characterisation of cytochrome P450 reductase (CPR) embedded into ND.82 
Using spectro-potentiometry, Das et al. researched the electrochemical 
behaviour of this reductase when in a membrane environment, and observed 
changes in the redox potentials of the di-flavin domains, which deliver electrons, 
towards more positive values. These changes led to the possible conclusion that 
the lipid environment of the ND affected the redox potential of the inserted CPR. 
Other scaffold proteins were engineered from MSP1 via insertion of additional 
amphipathic helices into the core MSP sequence.80 These extended proteins, 
called MSP1E1, MSP1E2, and MSP1E3, had one, two or three extra 22-mer 
amphipathic helices added to the central part of the MSP1 sequence, 
respectively. Literature reveals that these engineered MSP have been employed 
in studies of chemoreceptor transmembrane signalling,77 catalytic activity of 
ATP-binding cassette transporters83 or solubilisation of integral membrane 
proteins.84 
These ND systems, assembled with various ApoA185 or MSP of tailored 
lengths86, 87 were primarily reconstituted as model membranes to functionally 
and structurally characterise membrane proteins. However, the lipid 
environment of the ND could sequester an assortment of hydrophobic 
molecules. With this in mind, researchers have conducted preliminary studies of 
nanodisc complexes formulated with various types of hydrophobic drugs, in 
order to show their predilection for sequestering small hydrophobic drug 
molecules.  
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One such study was done by Nelson et al. to test the efficiency of incorporated 
amphotericin B, used as an antifungal drug.88 The group designed a system 
based on nanodiscs-associated Amphotericin B (AMB), in the assembly of which 
recombinant human ApoA-I was used as the protein belt. In addition, they 
demonstrated the ND-drug systems’ enhanced effects at a lower dosage 
frequency, produced by a possible altered clearance time. The group also 
observed no significant differences in the cytokine response assayed between 
AMB-ND treatment groups and those treated with phosphate buffer or empty 
ND. 
Another example of complex based on integrating all-trans retinoic acid (ATRA) 
into a nanodisc assembled with recombinant human ApoA-I was developed by 
Redmond et al.73 Their purpose was to design a potentially useful vehicle for 
solubilisation and in vivo delivery of ATRA. The resulted system effectively 
induced apoptosis in cultured hepato-carcinoma cells. Their group 
demonstrated that the properties of ATRA were unaffected and its bioavailability 
was enhanced by incorporation into ND compared to free ATRA. Similar results 
have been shown by Buehler et al. The group developed a drug delivery system 
using a vault-binding lipoprotein complex that formed a lipid bilayer nanodisc. 
The resulted engineered vaults loaded with ATRA showed enhanced cytotoxicity 
against the hepatocellular carcinoma cell line HepG2.89  
The multitude of engineered ApoA-I and MSP found in literature and mentioned 
above, had the initial purpose of optimising and creating monodisperse, stable 
ND assemblies. This was done for a better, subsequent usage in characterising 
integral membrane proteins. The protein belt only interacts with the hydrophobic 
edge of the lipid bilayer. The stable model membrane, thus created, is the main 
interactor with the embedded molecule to be characterised.  
ND systems have been assembled with various phospholipid compositions. 
Initially, this was investigated following concerns regarding which lipids facilitate 
the formation of stable, monodisperse ND.71, 86 However, later studies have 
investigated different lipid compositions, depending on the incorporated system 
that required characterisation. For example, DPPC and DMPC, lipids with high 
transition temperature, were used in providing an understanding of the phase 
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transitions lipids are susceptible to, when assembled in a nanoscale, enclosed 
structure.90 In other studies, anionic lipids were used in the formulation of ND, 
either for the characterisation of clotting proteins, which have affinity towards 
assembly in membranes rich in anionic lipids,91 or to determine the redox 
potential of cytochrome P450.82  
These nanoscale structures because of their disc-shaped structure, with a lipid 
bilayer surrounded by a protein belt have advantages over liposomes in terms 
of smaller size, increased stability due to the protein belt. In addition, nanodiscs 
can be prepared with controlled size and stoichiometry and have access to both 
sides of the phospholipid bilayer domain. Thus the nanodisc system provides an 
innovative platform for understanding membrane protein functions as well as 
creating a water-free environment for targeted delivery of various hydrophobic 
agents protecting the inside content during circulation in the body. They have 
promising affinities for surface modifications such as polymer coating to prolong 
circulation half-life or functionalization with ligands to achieve targeting to 
specific cells or tissues. Furthermore, the ND systems promise substantially 
fewer side effects than current drugs, while enhancing efficacy and are expected 
to bring an improvement in patient life quality. 
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 Outline of the project 
The research of the project was aimed at investigating the encapsulation and 
release kinetics of poorly water soluble drugs from self-assembled 
nanosystems. As discussed in the previous section, researchers have already 
shown the potential of nanodiscs in providing a membrane like environment for 
incorporating membrane proteins, or even hydrophobic small molecules. 
However, the need for a simple approach to systematically study the relation 
between physical parameters related to loading and release of poorly water 
soluble drugs from ND systems, still exists. 
The main objective of the project was to formulate an optimised ND system for 
further incorporating and releasing a range of hydrophobic small molecules, 
with the aim of finding common criteria for creating an effective nanosystem for 
delivery into mammalian cells. Hydrophobic drug molecules tend to be 
superficially characterised when incorporated into a delivery system, as the 
primary focus usually turns towards the systems’ performance in cellular uptake 
compared to free drug. Therefore, after the initial optimisation of ND assembly, 
the research was focused on investigating a combination of strategies for 
incorporating twelve hydrophobic drugs (Figure 1.13). For the nanodiscs 
reconstitution, two strategies have been studied, the first comprises of adding 
the MSP to a mixture of lipid and detergent micelles, and second strategy 
involves adding MSP stabilised in Na cholate micelles to a dried lipid film. 
Loading the drug molecules into the ND systems was studied by using two 
strategies, the drugs were added either passively, under overnight shaking 
conditions, to a solution of ND (post-incorporation), or by loading the drug during 
the reconstitution of ND (pre-incorporation). In Chapter 3 is discussed the work 
conducted for reaching this goal.  
The second objective was to vary the lipid composition within the ND, and 
observe the efficiency of incorporating and releasing two of the selected drugs. 
Charged lipids, small chain lipids, PEGylated lipids and lipids with high transition 
temperature were investigated for the reconstitution of empty and drug loaded 
ND. Subsequent drug loading capacity and release kinetics were also studied. 
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Figure 1.13 Incorporation of hydrophobic small molecules into ND systems 
 
The final objective was to site-specifically modify the scaffold protein for in vitro 
imaging during cell studies, by using the Sortase A mediated ligation (Figure 
1.14). The labelling of MSP while in the ND formation and the presence of 
incorporated drug molecules were investigated. Subsequent delivery of the 
fluorescein modified ND-drug system into mammalian cells was studied.  
 
Figure 1.14 Strategy for modifying the ND systems with fluorescein using Sortase A 
mediated ligation; the labelling process has been done also on empty ND 
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2 Chapter 2 - Assembly and characterisation of POPC nanodiscs  
 Introduction 
Due to their geometrical packing, phospholipids form the basic component of 
the amphiphilic structures investigated. Previous studies71 have identified 
POPC, a zwitterionic phospholipid (Figure 2.1), as a suitable building block for 
creating nanodisc assemblies, therefore POPC was utilised in initial efforts to 
reconstitute the nanoscale structures. In order to stop phospholipids from 
assembling into liposomes, MSP1D1, an amphipathic membrane scaffold 
protein, was introduced as a second component. This scaffold protein was 
derived from MSP1 by removing the first eleven N-terminal amino acids. This 
chapter describes the development of such nanoscale assemblies using SDS-
PAGE electrophoresis, size exclusion chromatography (SEC), dynamic light 
scattering (DLS) and circular dichroism (CD). 
 
Figure 2.1 The structure of POPC 
 MSP expression and purification 
The first step in formulating ND assemblies was to produce the protein. The 
pMSP1D1 plasmid was purchased in DH5α strain and following inoculation, this 
was transformed into E. coli cells. The His6 tagged MSP protein was expressed 
in TB (Terrific Broth) using E. coli cells (Figure 8.1, Figure 8.2). The scaffold 
protein expressed in TB medium followed the method of Sligar et al.71 This 
consisted of inducing the cells with IPTG when an OD600 of 2.5 was reached 
and reducing the temperature of the incubation from 37 °C to 28 °C after 
induction. 
After protein expression, the cells were harvested and lysed. The scaffold 
protein released in the supernatant was purified on a Ni column at 4 °C. The 
histidine residues in the His6 tag of MSP binds to nickel ions on the resin, thus 
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enabling separation from impurities and other proteins expressed alongside 
MSP1D1. For better solubilisation of MSP, sodium cholate (40 mM) was added 
in the elution buffer.  
Above its CMC of 14 mM, the cholate detergent forms micelles, which act as a 
protective coating for the scaffold protein (Figure 2.2). In an aqueous 
environment, this coating is formed by the hydrophobic tail of sodium cholate, 
which undergo hydrophobic interactions with the exposed amino acids of 
MSP1D1, and the hydrophilic head group of the detergent forms hydrogen 
bonds with the water molecules. 
 
Figure 2.2 Cartoon representation of the sodium cholate micelles forming a protective 
coating for MSP  
 
The investigation of MSP1D1 was conducted by SDS-PAGE electrophoresis 
and MS (mass spectroscopy) with the purpose of confirming its expression and 
purity. However, these techniques are using conditions which lead to the 
denaturing of the analysed protein, and therefore are causing the MSP to unfold 
to its monomeric structure. As a result, it is difficult to determine if the protein 
has an oligomeric structure after being isolated from the Ni column. Therefore, 
other techniques – SEC and DLS – were also adopted as methods of 
characterisation to confirm the size of the purified MSP. 
The MSP1D1 was further purified by SEC. A set of calibrants with different 
molecular weights (MW), which can be found in Chapter 7, were run through 
the column. The analysis helped identify the oligomeric and monomeric states 
from exceedingly aggregated protein, and estimate their apparent mass. 
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Following purification by SEC, DLS was used to confirm the size of MSP in 
solution.  
SDS-PAGE electrophoresis was performed to test the expression and purity of 
the MSP. When compared with the protein standards showed in lane 1, the 
MSP migrated on the SDS-PAGE gel to around 25 kDa, confirming its expected 
mass of 24.6 kDa. The SDS-PAGE gel of the expressed MSP during (lanes 2 
to 5) and after the purification process at 4 °C (lanes 6 and 7) indicated that the 
MSP was well expressed in TB medium (Figure 2.3). This can be attributed to 
the use of a controlled promoter for induction (0.1 mM IPTG), which drove the 
expression of MSP. Additionally, it is presumed that lowering the temperature 
after induction, from 37 °C to 28 °C, may facilitate the correct folding of the 
protein. The SDS-PAGE gel also indicated negligible MSP loss during the 
purification process (lanes 2-5). The purity of MSP1D1 expressed by E. coli was 
evaluated and confirmed by mass spectroscopy (MS) (Figure 2.3). The protein 
mass calculated from the measurements was 24,663 Da (expected 
MW = 24,662 Da).  
The analysis by SEC of MSP, overexpressed in TB medium, confirmed the 
absence of large aggregates, which might interfere with nanodiscs formation. 
However, protein oligomers, with an apparent MW of 175 kDa and 80 kDa, can 
be observed in Figure 2.4, A. These oligomers were probably formed due to 
most scaffold protein in solution consisting of heterogeneous agglomerates. 
MSP1D1 is derived from ApoA-I, therefore a reason behind the formation of 
these oligomers could be due to the temperature dependent self-association 
property ApoA-I possesses.92 
Unfiltered samples of pure MSP collected in fractions eluted between 12 mL 
and 19 mL after the SEC analysis, were characterised by size distribution using 
DLS. The results showed formation of pure oligomer scaffold protein with a 
diameter of around 2 nm and a population of heterogeneous aggregates with a 
diameter of 6.5 nm (Figure 2.4, B).  
The overexpression of protein was performed in two media with the aim of 
optimising and increasing the protein yield. MSP1D1 was also overexpressed 
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in Auto Induction media (AIM), however in this instance low levels of scaffold 
protein, in its monomeric state, were present after expression and purification. 
Comparing results obtained via SDS-PAGE and SEC, it could be deduced that 
the optimum conditions were decreasing the temperature during the purification 
process. This was done to avoid aggregation of the MSP. In addition, TB 
medium had a better yield in expressing MSP1D1 - which has a tendency to 
oligomerise – and therefore, was chosen to continue the production of protein 
in bacteria.  
 
Figure 2.3 12% SDS PAGE of MSP purified on Ni column: 1 - Marker; 2 – Flow through; 
3 –1st wash; 4 – 2nd wash; 5 – 3rd wash; 6 – 8: eluted MSP with sodium cholate; Mass 
spectrum of monomeric MSP in acid after SEC analysis; MW of 24,663 Da (expected 
MW = 24,662 Da) 
 
Figure 2.4 A - SEC chromatogram and B - DLS of pure MSP in elution buffer 
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 The reconstitution of POPC nanodisc assemblies  
2.3.1 Original method of reconstitution 
Nanodiscs are formed following Sligar et al. method of reconstitution - named 
method A (Chapter 7), as schematically shown in Figure 2.5. The scaffold 
protein is added to a mixture of lipid and detergent micelles. Subsequently, the 
detergent is removed by adsorption to hydrophobic bio-beads (adsorbent beads 
composed of a large number of cross-linked microspheres used for adsorbing 
molecules from aqueous solutions). Simultaneously the self-assembly, via 
H bonding and hydrophobic interactions, between MSP and POPC starts, 
arranging them into a disc-shaped nanostructure. 
In order to reconstitute monodisperse ND with an exact molar ratio of MSP to 
POPC, an accurate concentration of both constituents was determined. The 
pure MSP concentration was calculated using the absorbance measured at 
280 nm and it was found to be between 1 and 3.2 mg/mL. Assay of total 
phosphorus was used to estimate the total amount of phospholipids to be added 
in the assembly process of ND (Chapter 7). The calculated concentrations were 
further used to reconstitute ND assemblies.  
The subsequent SEC analysis of ND showed no void volume peak except for a 
trace with the same retention time as Alcohol dehydrogenase, used as a MW 
standard for column calibration (Figure 2.6). The ND was found to have an 
apparent MW of 150 kDa. 
 
Figure 2.5 Schematic representation of the POPC ND reconstitution process based on 
the method developed by Sligar (method A)  
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Figure 2.6 SEC chromatogram of ND assemblies; the assembly has approximately the 
same retention time as Alcohol dehydrogenase (AD) indicating an apparent MW of 150 
kDa  
2.3.2 Improved method of reconstitution 
Nanodiscs were reconstituted successfully by initially following Sligar’s method 
of assembly. However, occasional increase in room temperature affected the 
formation of POPC and detergent micelles, thus altering the formation of 
monodisperse ND. To avoid such situations an adapted method – method B – 
was employed. Because detergent, at a concentration above its CMC, was 
already present in the pure MSP solution (for stability purposes), in this new 
method one step of the reconstitution was avoided. Instead of mixing MSP to 
already formed POPC and detergent micelles, MSP stabilised in Na cholate 
micelles was added to a dried POPC film (Figure 2.7). Subsequently, upon 
addition of bio-beads and removal of cholate detergent, the self-assembly 
between MSP and POPC started, arranging them in a disc-shaped bilayer. 
The analysis by SEC of newly reconstituted ND was carried out to check the 
formation of ND assemblies and to dismiss the development of other 
aggregates. Previous SEC experiments of the scaffold protein had suggested 
the formation of oligomeric forms of the protein in solution. However, when the 
MSP in detergent micelles is added to the POPC layer, it arranges as a protein 
belt around the hydrophobic edge of the POPC bilayer, and together they 
assemble into ND structures (Figure 2.8). ND were found to have the same 
elution volume as Alcohol dehydrogenase, suggesting an apparent MW of 
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approximately 150 kDa (138 kDa, apparent mass calculated with the equation 
generated by the calibration curve found in Chapter 7) (Figure 2.9). The 
apparent size and diameter of 10 nm (Figure 2.10), as expected from previous 
studies80 is associated with two or more MSP and 126 lipids per nanodisc. Lipid 
concentration in these samples was measured using a total phosphorus assay. 
 
Figure 2.7 Schematic representation of the POPC ND reconstitution process using the 
shorter assembly protocol (method B) 
 
Figure 2.8 SEC chromatograms of ND sample in 20 mM Tris, 0.1 M NaCl and MSP in 
elution buffer 
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Figure 2.9 SEC chromatogram of ND reconstituted using method B; the assembly has 
the same retention time as AD  
 
Figure 2.10 DLS measurements of MSP in elution buffer and reconstituted ND using 
method B  
2.3.3 Circular dichroism (CD) 
CD spectroscopy was used to observe how the secondary structure of the 
scaffold protein changes when interacting with other molecules such as lipids. 
The CD measurements were conducted by Mr. Nasir Khan on an APP Chriscan 
CD spectropolarimeter, part of the Astbury Centre for Structural Molecular 
Biology facilities.  
The secondary structure of the scaffold protein alone and when in the presence 
of POPC was investigated. In Figure 2.11, the negative peaks at 210 nm and 
225 nm93 and the positive peak at 195 nm specific to α helix conformation94 are 
present in the ND system. Furthermore, a prominent increase in peak intensity 
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detected for all three peaks (195 nm, 210 nm and 225 nm) demonstrated an 
increase in α helix content from MSP alone to ND assemblies. This rise is 
probably caused by lipid-protein interactions within the ND, as the lipid free 
scaffold protein consists mostly of heterogeneous aggregates95. 
 
Figure 2.11 Circular dichroism of MSP in elution buffer and ND; the peaks specific to 
α helix conformation are at 195 nm, 210 nm and 225 nm  
 Summary 
MSP was expressed in AIM and TB media and purified at room temperature 
and 4 °C with the purpose of finding the optimum environment for protein 
production. Decreasing the temperature during purification process was the key 
factor in avoiding MSP aggregation. Nevertheless, TB medium had a better 
yield in expressing the insoluble protein and was further chosen to continue 
protein overexpression in E. coli cells. Protein overexpression and purity were 
confirmed by SDS-PAGE electrophoresis and MS analysis. The presence of 
oligomeric structures and their size were observed by SEC and DLS 
techniques. 
Following MSP overexpression and purification, the ND assemblies were 
reconstituted. The protocol for ND assembly was adapted to add pure MSP 
stabilized in Na cholate micelles to a layer of POPC. The ND thus reconstituted 
were found to have an apparent molecular weight of approximately 150 kDa, 
which was associated with two or more MSP and 126 lipids per nanodisc. 
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A combination of SEC and DLS used to characterise the ND assemblies has 
demonstrated the influence of MSP aggregation on the reconstitution and MW 
of the ND. CD measurements have shown changes in α helix content of the 
scaffold protein during formation of protein belt around the phospholipid bilayer. 
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3 Chapter 3 - Incorporation of poorly water soluble drugs into ND 
Poorly water-soluble (hydrophobic) drugs tend to have high toxicity, wider 
distribution within the body and are often extensively metabolised.22 These side 
effects can be minimised by using self-assembled nanocarriers to transport 
such hydrophobic drugs. This can protect the cargo during circulation, enhance 
the drugs’ bioavailability and decrease the side effects that unincorporated 
drugs inherently possess.  
The nanoscale size and particle geometry of the previously reconstituted stable 
ND may provide a suitable environment for targeted delivery of poorly water-
soluble molecules. However, as shown in Chapter 1, little is known about the 
capacity of these ND assemblies to load and release hydrophobic small 
molecules. In order to show their function as drug carrier, a series of 
hydrophobic drugs were incorporated into ND. This chapter will discuss the 
loading, release and interactions between the drug molecules and the 
phospholipid domain of the ND. 
 The poorly water soluble small molecules 
The hydrophobic molecules studied for loading and release from ND 
assemblies vary from high to low hydrophobicity, have planar or bulky 
structures, different physicochemical properties and pharmacology indications 
(Tables 3.8 to 3.12).  
It was hypothesised that all the selected hydrophobic drug molecules have 
favourable properties for loading into ND and therefore were investigated to 
generate design rules for drug loading into ND and the optimum conditions for 
incorporation and release from the self-assembled nanostructures. Firstly, 
different methods for reconstituting drug loaded ND were investigated, in order 
to find the optimum approach. If the incorporation was successful and the best 
route for reconstituting loaded ND was chosen, then the question concerning 
how many molecules were incorporated per ND would arise. To assess the drug 
load per ND, three methods of characterisation were selected. The drug 
molecules could then be separated into groups based on their loading 
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capability. Once the drug incorporation was optimised and calculated, the rate 
of drug release from ND and the interactions between drug molecules and the 
phospholipid bilayer were investigated. 
 Finding the optimum approach for drug loading within ND 
The optimum approach for loading the hydrophobic drugs into ND was found by 
investigating four routes: two methods of reconstituting ND assemblies were 
used, and for each method, the drug was incorporated via two pathways. In the 
previous chapter we have demonstrated the successful reconstitution of 
monodisperse ND using 1:65 as the molar ratio between MSP and POPC. 
However, in these experiments, other molar ratios were also used, 1:50 and 
1:30, in order to accurately determine the optimum incorporation conditions.  
One method of reconstituting ND was achieved by following Sligar’s method of 
assembly - method A. This has been shown in a number of studies to be an 
efficient drug carrier for loading hydrophobic small molecules.88, 96 However, 
with the aim of decreasing the formulating steps and overall time and due to 
occasional increases in room temperature affected the formation of POPC and 
detergent micelles, the adapted method - method B - was employed.  
Method 1 of incorporating drug molecules into ND – postloading 
Initially, to incorporate the hydrophobic molecules within the reconstituted ND, 
the drugs were added passively, under overnight shaking conditions, to a 
solution of stable ND assemblies (Figure 3.1 and Figure 3.2). This method of 
incorporation will be referred to as postloading or post-incorporation method. 
Studies conducted by Luo et al.97 and Song et al.98 showed successful passive 
drug encapsulation into carrier systems, such as co-polymer micelles and lipid-
based nanospheres, and release of camptothecin and chlorambucil, 
respectively.  
As a starting point, ND were reconstituted before attempting to incorporate the 
hydrophobic drugs. For this, either method A or method B of reconstitution was 
employed. To the solution of reconstituted ND, the drugs, in power form, were 
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added and left overnight at 4 °C, with gentle shaking. The unincorporated drug 
was then eliminated by centrifugation or, more efficiently, by SEC partition. 
 
Figure 3.1 Schematic representation of the POPC ND reconstitution process, using 
method A, followed by postloading the drug into ND assemblies 
 
Figure 3.2 Schematic representation of the POPC ND reconstitution process, using 
method B, followed by postloading the hydrophobic molecules into ND assemblies 
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Method 2 of incorporating drug molecules into ND – preloading 
The second drug incorporation method applied involved loading the drug 
molecules during the reconstitution of ND assemblies. The method of 
incorporation will be referred to as preloading or pre-incorporation method. This 
incorporation technique was often seen in literature where studies shown good 
loading efficiency and sustained release of drugs such as amphotericin B, 
curcumin and camptothecin.99-101  
The drug molecules were dissolved in chloroform and dried with POPC into a 
thin film, in which the drug molecules were trapped between the hydrocarbon 
chains. Subsequently, following the two methods of ND reconstitution, the drug 
molecules were incorporated into lipid/MSP and detergent micelles (Figure 3.3, 
Figure 3.4). After detergent removal via adsorption to bio-beads, the assembly 
process between MSP, POPC and drug molecules started arranging them into 
a discoidal bilayer, with the drug molecules, presumably, loaded into the 
phospholipid domain.  
A series of methods were applied to investigate the efficiency of the loading 
process, the loading capacity and drug release kinetics and how these are 
affected by the structural and physical properties of the loaded hydrophobic 
drugs. First technique, SEC, was used to confirm drug loading and to examine 
the influence hydrophobic molecules incorporation has on the size of the 
assemblies, which could further be used to calculate an apparent MW. 
Subsequently, the ND assemblies with loaded drug molecules were separate 
on the SEC column from unincorporated drug molecules. The chromatograms, 
at 280 nm (protein absorbance) and at drug’s absorbance are of empty ND and 
different ND-drug assemblies (the drug’s absorbance could be found in Chapter 
7, Table 7.2). A CD experiment was conducted, in parallel, to study the change 
in secondary structure of the scaffold protein when amiodarone and curcumin 
were pre-incorporated to ND. Subsequently, filtered ND and drug-loaded ND 
samples collected after SEC partition were characterised by size distribution. 
These experiments were carried out to analyse the effect that drug loading has 
on the diameter of the systems. After separating the ND containing drug 
molecules from unincorporated drug by SEC, UV-spectroscopy and High 
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Performance Liquid Chromatography (HPLC) were chosen to identify the most 
advantageous way to analyse how many drug molecules were loaded within the 
ND assemblies. Spectrophotometric measurements of ND and ND-drug 
assemblies were performed in the 200-600 nm wavelength range. HPLC 
experiments were conducted at 280 nm and drug’s absorbance wavelength. For 
both methods, the nanostructures were dried under vacuum and disassembled 
by resuspension in TFE (2,2,2-Trifluoroethanol). Experiments of drug release 
were performed with the successful loaded and poorly loaded drug molecules 
(loaded using method B of reconstitution). This allowed observations on the rate 
of drug release from the systems. 
 
Figure 3.3 Schematic representation of the assembly of drug loaded ND; the drug 
molecules were preloaded to ND assemblies using method A of reconstitution 
 
 
Figure 3.4 Schematic representation of the assembly of drug loaded ND; the drug 
molecules were preloaded to ND assemblies using method B of reconstitution 
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3.2.1 Nanodiscs loaded with amiodarone 
Amiodarone (AMD) is an antiarrhythmic drug, frequently used in clinics to 
decrease heart rate and increase vascular resistance.102 Despite its preferred 
usage, amiodarone has a low water solubility (4.76 µg/mL), is extensively 
metabolised in the liver and its high toxicity can generate dangerous side 
effects.  
 Analysis by size-exclusion chromatography 
Amiodarone showed successful loading within the ND for both methods of 
incorporation and reconstitution of ND. This was demonstrated by the single 
peak present at the elution time of ND. At a molar ratio of 1:30 MSP to POPC 
and a postloading reconstitution, the SEC chromatogram showed, in addition to 
the ND peak at 11 mL, a smaller peak at 20.5 mL probably corresponding to 
unincorporated amiodarone (Figure 3.5, A).  
When the molar ratio changed to 1:65 MSP to POPC, regardless of the 
reconstitution approach, a slight difference in elution time could be observed for 
the ND with loaded amiodarone (Figure 3.5, B and C). The faster elution time 
indicated an increase in the apparent MW resulted, presumably, from the 
agglomeration of amiodarone at the water phospholipid head group interface 
rather than loading within the phospholipid domain of the ND (230 kDa MW for 
ND AMD from 140 kDa MW for empty ND).  
Comparatively, when amiodarone was preloaded to ND at a 1:65 MSP to POPC 
molar ratio, using method A, the elution times of ND AMD and ND were almost 
identical (Figure 3.6, A). Furthermore, the chromatogram of ND AMD showed a 
small shoulder attached to the peak corresponding to ND. A possible 
explanation could be that the loading of amiodarone generated instability during 
ND formation, which resulted in the reconstitution of polydisperse ND AMD 
assemblies.  
The chromatogram of ND AMD formed following method B of reconstitution, 
where, the drug was preloaded to assemblies, showed a single narrow peak at 
the elution time specific to ND (apparent MW of 111 kDa), (Figure 3.6, B).  
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Figure 3.5 SEC chromatograms of ND AMD, ND and the elution time of AD: A - ND 
reconstituted with 1:30, 1:50 and 1:65 molar ratio using method A; B – ND reconstituted 
with 1:65 molar ratio using method A; AMD was added in three different quantities; 
C - ND reconstituted with 1:65 molar ratio using method B; AMD was postloaded to 
ND; ND and AD were measured at 280 nm, ND AMD were measured at 242 nm 
 
Figure 3.6 SEC chromatograms of ND AMD, ND and the elution time of AD: A - ND 
reconstituted using method A; B - ND reconstituted using method B; for all ND AMD 
assemblies, AMD was preloaded to ND (1:65 molar ratio); ND and AD were measured 
at 280 nm, ND AMD were measured at 242 nm 
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 Analysis by dynamic light scattering  
It was determined that stable nanodiscs and nanodiscs with loaded amiodarone 
were formed with distinct diameters (Figure 3.7). The variation in diameter was 
dependent on the drug loading method and the protein to POPC ratio used for 
the ND-drug reconstitution.  
When amiodarone was preloaded to ND, an increase in ND AMD size was 
observed, from 10.1 nm, the diameter of empty ND, to 11.7 nm. On the other 
hand, when amiodarone was postloaded to ND, the drug did not alter the 
diameter (10.1 nm) of the ND reconstituted with 1:50 and 1:65 MSP to POPC. 
It was found that, for ND reconstituted with 1:30 MSP to POPC, large 
aggregates with a diameter of 615.1 nm were formed, as well as smaller 
ND AMD with a diameter of 4.84 nm, presumably as a result of aggregation 
over time.  
Conclusively, the results have shown negligible increase in the diameter of the 
system when amiodarone was loaded within the phospholipid domain of ND. 
This lack of a significant difference in particle size between empty and loaded 
carriers was also described in the study conducted, by Lamprecht et al.,17 on 
the incorporation of amiodarone into lipid nanocapsules. 
 
Figure 3.7 DLS of A – AMD postloaded to ND reconstituted with 1:30, 1:50 and 1:65 
molar ratio; B - AMD preloaded to ND reconstituted with 1:65 molar ratio; assemblies 
were reconstituted using method A  
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 Analysis of the amiodarone load 
3.2.1.3.1 UV spectrophotometry 
For the analysis of amiodarone load, two methods of calculation were 
employed. The UV spectra of ND AMD have shown increased absorbance 
compared to the spectra of empty ND (Figure 3.8). However, the methods were 
chosen because the UV absorbance of MSP might interfere with the 
absorbance of the drugs that were incorporated within stabilised ND. First 
method is based on measuring and equating the POPC concentrations in empty 
and drug loaded ND. Firstly, the absorbance of MSP in ND-drug is calculated 
by relating it to the POPC concentration. This was done based on the 
assumption that, by equating the POPC concentration, the MSP concentration 
remains the same. More explicitly, if the concentration of POPC in empty ND is 
3.6 mM, then the absorbance, at the specific wavelength, for MSP in those 
empty ND is 0.25 Au. Knowing these values, we can subsequently calculate the 
absorbance of MSP in ND-drug at a certain POPC concentration. Following this, 
the difference in absorbance between theoretically empty ND and ND with 
loaded drug is given by the loaded drug (Table 3.1).  
 Calculated drug 
concentration (mM) 
Calculated molecules of drug 
loaded per ND 
ND AMD1 0.8 19 
ND AMD2 3.75 ± 1.7 81 ± 63 
Table 3.1 Calculated drug concentrations and number of AMD molecules loaded per 
ND; AMD was postloaded to ND reconstituted with 11:50 and 21:65, using method A; 
repeat measurements were conducted only for ND AMD2 
 
Subsequent to the calculations, nothing conclusive could be drawn for ND AMD 
reconstituted with 1:65, as the standard deviation was too big. However, for the 
assemblies reconstituted with 1:50, the number of amiodarone incorporated per 
ND was found to be 19.  
In the second method used, a matrix was applied to calculate the amount of 
amiodarone incorporated per ND (Eq. 3.1). This method, independent of POPC 
concentration, involved calculating the MSP and amiodarone concentrations 
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from the absorbance of each sample at drug and MSP wavelength and the 
inverse matrix of their extinction coefficient in TFE, at the specific wavelength. 
From the measured spectra of each drug and MSP, their extinction coefficient 
was calculated with the Beer-Lambert Law (Eq. 7.1) (Table 3.2). The extinction 
coefficients were also calculated for each sample in methanol and hexane – 
data not shown. 
𝐶 = 𝑀−1 𝐴 
Equation 3.1 Equation showing the relationship between MSP and drug 
concentrations, their extinction coefficient and absorbance at a given wavelength  
Where:  
𝐶 =  (
𝐶𝑀𝑆𝑃
𝐶𝑑𝑟𝑢𝑔
),  
𝑀 =  (
𝜀𝑀𝑆𝑃,𝑥 𝜀𝑑𝑟𝑢𝑔,𝑥
𝜀𝑀𝑆𝑃,280 𝜀𝑑𝑟𝑢𝑔,280 
), 
𝐴 =  (
𝐴𝑥
𝐴280
),  
x = wavelength for drug absorbance. 
 𝜀 in TFE at 242 nm 
(mol-1cm-1) 
𝜀 in TFE at 280 nm 
(mol-1cm-1) 
AMD 18391.05 2581.2 
MSP 27281.02 24790.15 
Table 3.2 Extinction coefficient values calculated, with the Beer-Lambert Law, for AMD 
and MSP suspended in TFE; the extinction coefficient was calculated based on the 
absorbance at the specific wavelength 
 
Using the matrix equation and the extinction coefficients from Table 3.2, the 
molecules of amiodarone loaded per ND were calculated (Table 3.3). For the 
assemblies using post-incorporation method and reconstituted with 1:50 and 
1:65 molar ratios (method A), the number of amiodarone incorporated was 
found to be identical. An addition of 2 molecules incorporated per ND was seen 
when amiodarone was preloaded to ND. Presumably, the energy required for 
amiodarone clusters to break the water cages surrounding them and diffuse 
inside the hydrophobic domain of the ND is too high, therefore less molecules 
will be incorporated into ND using postloading103. 
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Sample 
Calculated MSP 
concentration (mM) 
Calculated drug 
concentration (mM) 
Calculated number of drug 
loaded molecules 
ND AMD1 0.23 1.08 9 
ND AMD2 0.14 0.63 9 
ND AMD3 0.37 2.13 11 
Table 3.3 Calculated MSP and drug concentrations, and molecules of AMD loaded per 
ND; method A was used; 1AMD was postloaded to ND reconstituted with 1:50; 2AMD 
was postloaded to ND reconstituted with 1:65; 3AMD was preloaded to ND 
reconstituted with 1:65 
 
Assessing the number of small molecules loaded per ND by UV-spectroscopy 
resulted in an overestimation of MSP concentration which in turn led to 
underestimating the molecules of drug incorporated. This inaccuracy and 
inconsistency of the results combined with the noisy data collected from the UV 
analysis caused us to consider another method for loading evaluation. 
Therefore, the use of HPLC analysis was explored further in the investigation 
of the loading efficiency.  
 
Figure 3.8 UV spectras of ND AMD resuspended in TFE: A – AMD was postloaded to 
ND using method A; B – AMD was preloaded to ND using method A; the analysis was 
conducted at 242 nm  
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3.2.1.3.2 High performance liquid chromatography 
Similarly to analysis by UV spectroscopy, for the investigation using HPLC, 
amiodarone loaded ND were disassembled by resuspension in TFE. This was 
done to facilitate a better separation from the scaffold protein and produce an 
accurate evaluation of the amount of drug incorporated. Once the components 
of the disassembled structure were separated on the HPLC column and 
analysed at protein and drug absorbance, the amount of both MSP and drug in 
the system could be quantified.  
An example of HPLC chromatograms of ND AMD, preloaded using method B 
of reconstitution, could be seen in Figure 3.9. In the amiodarone loaded ND, the 
peaks of MSP and drug were visible at different elution times; comparable to 
the peaks of MSP alone and drug in TFE visible on the diagram inserted in the 
chromatogram. This separation gave an elution time for each component and 
with the help of generated calibration curves (Figure 8.3, Figure 8.4) the 
concentration in mg/mL of MSP and amiodarone in assemblies could be 
calculated. HPLC analysis was also performed on amiodarone postloaded 
within ND using method B of reconstitution and on amiodarone preloaded to ND 
using method A. 
It was found that, for amiodarone post-incorporated to ND formed with 1:65 
MSP to POPC molar ratio, 9.5 ± 2 molecules of drug were loaded per ND. When 
a lower molar ratio was used to reconstitute ND (1:50) the amount of 
amiodarone incorporated was reduced to 5.8 ± 2.5 molecules per ND 
(Table 3.4). When amiodarone was preloaded to ND, the amount of drug 
incorporated per ND was greater – 10 ± 6.8 molecules per ND. These results 
have led to the belief that the loading efficiency was affected by the use of 
different methods for loading drug molecules. 
Additionally, the concentration of ND was calculated based on the calibration 
curve of MSP and the amount of lipids in each sample was determined with 
phosphorous assay. The ND AMD assemblies had a ND concentration of 
48.8 ± 26 µM and 100 ± 22 POPC. In this instance, the number of POPC per 
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ND fluctuated considerably probably as a consequence of different exposure 
times in the presence of hydrophobic bio-beads during ND reconstitution.  
 
Sample 
Measured number of 
POPC per ND via 
phosphorous assay 
Calculated final 
concentration of 
ND via HPLC (µM) 
Calculated number of 
AMD loaded per ND 
via HPLC 
ND AMD1 nc 31.8 ± 25 10 ± 6.8 
ND AMD2 99 63.4 5.8 ± 2.5 
ND AMD3 100 ± 22 48.8 ± 26 9.5 ± 2 
Table 3.4 Measured number of POPC per ND, calculated concentrations of ND and 
amount of AMD loaded per ND; 1AMD was preloaded to ND reconstituted with 1:65; 
2AMD was postloaded to ND reconstituted with 1:50; 3AMD was postloaded to ND 
reconstituted with 1:65; method B of reconstitution; nc – not calculated 
 
Figure 3.9 HPLC chromatograms of ND AMD measured at 242 nm; the inside 
chromatograms are an example of AMD and MSP with a known concentration 
measured at 242 nm and 280 nm, respectively; AMD was preloaded to ND, using 
method B 
 Analysis by circular dichroism 
The negative peaks at 210 nm and 225 nm and the positive peak at 195 nm 
specific to α helix conformation94 are present in the ND systems with 
incorporated amiodarone (Figure 3.10). Furthermore, a shift of the positive peak 
from 195 nm to 192 nm was detected from empty ND assemblies to amiodarone 
loaded ND. The increase can be attributed to the drug molecules loaded into 
the systems. These observations led to the similar belief, demonstrated by 
Nguyen et al.104 In their study, of amphotericin B loaded DMPC nanodiscs, the 
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helical structure of the protein was not affected when drug molecules were 
incorporated into ND.  
CD experiments were not conducted for all successfully loaded drug molecules. 
However, it was inferred that a similar result would be expected because of 
successful ND formation which would require the MSP to fold correctly around 
the lipid-drug domain. 
 
Figure 3.10 CD spectras of ND and ND AMD; AMD was postloaded to ND reconstituted 
with 1:65 ratio; the peaks specific to α helix conformation are at 195 nm, 210 nm and 
225 nm 
 Release of poorly water soluble drugs upon dilution 
Drug release experiments were performed on amiodarone loaded into ND 
reconstituted using method B. A dialysis assay against stirred Tris buffer at 
37°C (Figure 3.11, A) was conducted by changing the equilibrium between 
loaded and unloaded amiodarone concentrations (Figure 3.11, B). Samples 
were taken at specific intervals and measured by UV at drug’s absorbance. The 
release studies of all drug-loaded ND assemblies were performed in triplicate. 
The fractional release of drug molecules (fr) was then calculated using a first 
order rate equation (Eq. 3.2) and an exponential curve fitted to the drug release 
data. The exponential model with 1 parameter (Eq. 3.3, where k is the rate 
parameter) was fitted to describe how rapidly the process of drug release 
occurs. The half-life of the drug (Eq. 3.4, t1/2 is the half-life) was calculated from 
the rate constant value for the drug release given after fitting the exponential 
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model. Half-life, t1/2 values of drug molecules released from ND can be found in 
Table 3.8 to Table 3.12. 
 
Figure 3.11 A - Representation of dialysis assay in buffer; B - Schematic representation 
of equilibrium changes between loaded and unloaded drug concentrations 
𝑓𝑟 =
𝛼𝑡=0 − 𝛼𝑡 
𝛼𝑡=0 − 𝛼𝑒𝑚𝑝𝑡𝑦 
 
Equation 3.2 First order rate equation used for calculating the fractional release of drug 
molecules; αt=0  is the absorption of ND-drug at time, t=0; αt  is the absorption of ND-
drug at specific time; αempty is the absorption of empty ND at the wavelength of the 
loaded drug 
𝑓𝑟 = 1 − 𝑒
(−𝑘𝑡) 
Equation 3.3 The exponential model with 1 parameter fitted to the drug release data; k 
is the rate parameter 
 𝑡1/2 =
𝑙𝑛 (2)
𝑘
;    ∆𝑡1/2 =  
∆𝑘
𝑘
 ×  𝑡1/2 
Equation 3.4 The half-life of the drug and its standard deviation calculated from the rate 
constant value given for the drug release, after fitting the exponential model from Eq. 
3.3 
 
Most amiodarone molecules were released in 24 h with no initial burst observed 
(Figure 3.12). This can probably be attributed to all drug molecules being 
incorporated, as unloaded amiodarone was previously removed by SEC. 
Amiodarone preloaded to ND had a calculated t1/2 of 5.4 h ± 0.67 and its 
constant release was almost complete within 24 h (Figure 3.12, A). In literature, 
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the release of amiodarone from lipid nanocapsules was, likewise, described as 
not displaying an initial burst effect.17 Although the drug release at physiological 
pH was extended over a longer period of time compared to our findings.  
When amiodarone was postloaded to ND assemblies, an exception was found. 
The first stage of amiodarone release showed a significant initial burst effect. 
This involved the release of more than 50% of the loaded drug in the first hour 
(Figure 3.12, B, dark red). The drug release reached a plateau after 2 h for the 
ND AMD reconstituted with 1:65 MSP to POPC. The t1/2 of the drug, 
subsequently calculated from the rate parameter, was 0.62 h ± 0.14.  
In the case of amiodarone postloaded to ND formed with 1:50 MSP to POPC, 
after the initial burst, the drug was released constantly within 6 h (Figure 3.12, 
B, light red). The t1/2 was calculated to be 0.88 h ± 0.03. This notable burst effect 
could be the result of amiodarone accumulation near the phospholipid 
headgroups105. Overall, dissociation of amiodarone loaded ND assemblies 
occurred with an apparent 100% release. The experiments carried out with free 
drug in the absence of ND showed that the equilibrium was achieved much 
quicker (data not shown). 
 
Figure 3.12 Fractional drug release at 37 oC for A – ND AMD, AMD preloaded to ND, 
and B – ND AMD, AMD postloaded to ND; the aliquots were measured at 242 nm; t1/2 
values were: A - 5.4 h ± 0.67; B - 0.62 h ± 0.14, for the ND reconstituted with 1:65, and 
0.88 h ± 0.03 for the ND reconstituted with 1:50; data is shown as the mean ± SD   
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The techniques used to characterise ND AMD assemblies have demonstrated 
the influence drug incorporation has on the MW and size of the assemblies and 
on the secondary structure of the scaffold protein that forms the protein belt. In 
addition, SEC was further used to separate the ND-drug assemblies from 
unincorporated free drug molecules. This separation was completed for the 
better subsequent quantification of the amount of drug molecules loaded.  
Following the thorough characterisation of amiodarone loaded ND, a series of 
drug molecules were also incorporated into ND. Their characterisation adopted 
a similar path to that of amiodarone loading.  
3.2.2 Nanodiscs loaded with chlorambucil 
Chlorambucil (CLB) is a known carcinogen with a higher water solubility than 
amiodarone (77.3 µg/mL), and it is used as antineoplastic agent for the 
treatment of various forms of cancer.  
Method B of reconstituting ND with 1:65 MSP to POPC molar ratio proved 
successful and was straightforward to follow. Thus, for practical reasons, this 
approach was used for loading chlorambucil into ND.  
The analysis by SEC, at 254 nm, of ND CLB showed that incorporation of 
chlorambucil gave contrasting results. The ND CLB assembled by postloading 
chlorambucil to ND, showed a peak, with small absorbance (Figure 3.13, A). 
Although of low intensity, this peak, eluted 0.5 mL faster than empty ND, 
confirmed the incorporation of chlorambucil. The apparent MW of these 
assemblies was 211 kDa. In addition, the SEC trace revealed two peaks with a 
retention time of 20 mL and 24 mL. The high absorbance observed for these 
peaks would imply that most drug molecules were eliminated as aggregates of 
various sizes (apparent MW between 1 and 6 kDa). 
Contrary to postloading of drug, the chromatogram of ND CLB formed via 
preloading the drug, showed a single peak seen at the almost identical elution 
time of empty ND (Figure 3.13, B). Hence, chlorambucil was thought to have 
exhibit successful loading within the ND. The shoulder seen in the SEC trace 
resulted, probably, from the reconstitution of polydisperse ND CLB or 
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aggregation over time of the initially monodisperse ND CLB. In addition, the 
unincorporated chlorambucil was eliminated, around 24 mL, as two peak with 
small absorbance. The analysis by SEC has demonstrating clearly that the best 
route for incorporating chlorambucil into ND was by using the pre-incorporation 
method. 
Subsequently to determining the best route for incorporating chlorambucil, 
HPLC was employed to calculate how many drug molecules were pre-
incorporated per ND. The samples were prepared as in the case of amiodarone. 
An example of HPLC chromatogram of ND CLB could be seen in Figure 8.6. 
The amount of chlorambucil incorporated per ND was calculated at 
6.5 ± 1.7 molecules per ND. 
Due to the successful incorporation of a relatively high number of chlorambucil 
per ND, the rate of drug release was also investigated. Similar to amiodarone, 
most chlorambucil molecules were released in 24 h with no initial burst (Figure 
3.14). The equilibrium between the concentrations of loaded and free 
chlorambucil was achieved after 15 h, with only 80% of the drug being release 
into the buffer. The low release profile was observed to be similar with the 
literature value.42 In the recent study, Rao et al. showed that, in mild acidic 
conditions, only 71% of chlorambucil was released from self-assembled 
norbornene based triblock co-polymers. A reasonable hypothesis for the 
system to reach equilibrium below 100% can be correlated to a high solubility 
in water, but a more favourable interaction within the organic phase. Hence the 
moderate log P value of 3.8. The t1/2 for chlorambucil calculated from the rate 
constant was 5.8 h ± 0.48. An improvement of t1/2 value was observed, as the 
current literature indicates the circulation t1/2 of free drug is 1.5 h.106 
54 
Incorporation of poorly water soluble drugs into nanodiscs 
 
Figure 3.13 SEC chromatograms of ND CLB, ND and the elution time of AD: A - CLB 
was postloaded to ND; B - CLB was preloaded to ND; reconstitution using method B; 
ND and AD were measured at 280 nm, ND CLB were measured at 254 nm  
 
Figure 3.14 Fractional drug release at 37 oC for ND CLB, CLB was preloaded to ND; 
the aliquots were measured at 254 nm; t1/2 value was 5.8 h ± 0.48; data is shown as 
the mean ± SD  
3.2.3 Nanodiscs loaded with curcumin 
Curcumin (CCM), the principal curcuminoid of turmeric, because of its bright 
yellow colour, is used as food colouring. A recent study also showed increased 
fluorescence of curcumin when associated with amyloid-β oligomers which 
could lead to novel therapies in combating Alzheimer disease.107 Regardless of 
the potential therapeutic effect, curcumin displays poor absorption, rapid 
metabolism and low water solubility. Curcumin has a lower water solubility than 
amiodarone, and previous studies have demonstrated its encapsulation into 
PEGylated liposomes18 or even ApoA-I nanodiscs.100 Therefore, curcumin 
incorporation (pre- and post-) was investigated by applying method A.  
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On the analysis of ND CCM by SEC formulated via postloading the drug, a 
narrow peak was present at the elution time of ND (Figure 3.15, A). This was 
observed for both molar ratios involved in the reconstitution process. However 
1:50 ND CCM showed, in addition to the ND peak a peak at a later elution time, 
possibly corresponding to unloaded curcumin. The analysis of ND with 
preloaded curcumin, revealed a wider peak, which could indicate a broader size 
distribution of ND CCM (Figure 3.15, B).  
Alongside amiodarone, curcumin was the second drug for which size 
distribution and changes in the secondary structure of MSP were analysed in 
order to determine the impact of curcumin incorporation (Figure 8.7 and Figure 
8.8). The observations supported the conclusions drawn after SEC analysis and 
had similar outcomes as amiodarone incorporation – minimal difference in size 
and unaltered helical structure of MSP, between empty and loaded ND. Similar 
size distribution was also described in literature by Kupetz et al.,108 on the 
incorporation of curcumin into lipid nanoemulsions. 
These observations suggested the successful formation of ND assemblies, 
however further investigation was needed to determine if curcumin was loaded 
into ND. Using UV spectroscopy (Figure 8.9), the number of curcumin 
molecules postincorporated per ND was determined. This method of evaluating 
the number of drug molecules loaded per ND appeared most promising for 
calculating curcumin incorporation. Applying the method of equating POPC 
concentrations, the calculations showed a higher amount incorporated for the 
assemblies reconstituted with 1:50 molar ratio. This led to the loading of 10 
molecules of curcumin per ND compared to 2 molecules, for the assemblies 
formed with 1:65 molar ratio. The difference in molecules loaded implied that 
there was more space for the drug molecules to be incorporated, as a 
consequence of the phospholipid packing within the bilayer being less compact.  
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 Calculated drug 
concentration (mM) 
Calculated molecules 
of drug loaded per ND 
ND CCM1 0.43 10 
ND CCM2 0.08 ± 0.07 2 ± 1.8 
Table 3.5 Calculated CCM concentrations and number of molecules loaded per ND; 
1CCM was postloaded to ND (1:50 molar ratio); 2CCM was postloaded to ND (1:65 
molar ratio); reconstituted using method A 
 
To verify the accuracy of these calculations the matrix equation was also 
employed. With its help, and knowing the extinction coefficients (Table 3.6), the 
molecules of curcumin loaded per ND were calculated (Table 3.7). The 
postloaded method using 1:50 ratio was again found to incorporate more 
curcumin per ND than the ratio of 1:65 - 4 molecules and 2 molecules, 
respectively. However, the curcumin preloaded to ND (1:65 ratio) provided the 
highest number of loaded molecules - 23 molecules per ND. These calculations 
suggested that, regardless of the reconstitution ratio between MSP and POPC, 
the method of preloading curcumin gave better results. An explanation could be 
that vast amount of energy would be required to break the water cages 
surrounding the curcumin molecules in order to diffuse them into the lipophilic 
environment of the ND. Comparatively, when curcumin is dried with a layer of 
lipids, upon resuspension in aqueous environment, less energy is required for 
rearranging the curcumin molecules and phospholipids into a bilayer formation. 
 𝜀 in TFE at 430 nm 
(mol-1cm-1) 
𝜀 in TFE at 280 nm 
(mol-1cm-1) 
CCM 14403.46 626.24 
MSP 1779.20 24790.15 
Table 3.6 Extinction coefficient values calculated, with Beer-Lambert law, for CCM and 
the MSP suspended in TFE; the extinction coefficient was calculated based on the 
absorbance at the specific wavelength 
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Sample 
Calculated MSP 
concentration (mM) 
Calculated drug 
concentration (mM) 
Calculated molecules of 
drug loaded 
ND CCM1 0.19 0.39 4 
ND CCM2 0.082 0.086 2 
ND CCM3 0.011 0.013 23 
Table 3.7 Calculated MSP and drug concentrations, and molecules of CCM loaded per 
ND; 1CCM was postloaded to ND (1:50 molar ratio); 2CCM was postloaded to ND (1:65 
molar ratio); 3CCM was preloaded to ND (1:65 molar ratio); method A of reconstitution 
 
Observing the rate of curcumin release led to contradictory conclusions 
compared to amiodarone and chlorambucil. Here, the release of curcumin (1:65 
reconstitution ratio) was rapid, reaching 80% after 6 h (t1/2 = 7.4 h ± 0.4) (Figure 
3.16, light brown). More so, a 20% burst release was observed after 30 min for 
ND CCM reconstituted with 1:50 ratio (Figure 3.16, dark yellow). This initial 
burst was followed by a slower loss that did not exceed 40% of curcumin release 
(overall release time was 6 h; t1/2 =3.9 h ± 1.3). In the literature, for curcumin 
loaded PEGylated hybrid liposomes, a similar drug release profile was 
described as a sustained release of 35% curcumin within 24 h, however lacking 
the initial burst.18 The method of postloading the drug within ND contributed to 
curcumin weakly binding to the phospholipid headgroups. Hence, the presence 
of a burst effect could be the result of rapid release of curcumin accumulated 
near the ND surface.  
 
Figure 3.15 SEC chromatograms of ND CCM, ND and the elution time of AD: A - CCM 
was postloaded to ND reconstituted with 1:50 and 1:65 molar ratio; B - CCM was 
preloaded to ND reconstituted with 1:65 molar ratio; for all assemblies, method A was 
followed; samples were measured at 280 nm   
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Figure 3.16 Fractional CCM release at 37 oC from ND; CCM was postloaded to ND; 
the aliquots were measured at 430 nm; t1/2 values were 7.4 h ± 0.4 for the ND 
reconstituted with 1:65, and 3.9 h ± 1.3 for the ND reconstituted with 1:50; data is 
shown as the mean ± SD  
3.2.4 Nanodiscs loaded with thioridazine 
Thioridazine (TRD), a phenothiazine antipsychotic drug with water solubility of 
0.855 µg/mL, is indicated for the treatment of schizophrenia. Thioridazine was 
another drug candidate used to investigate loading and release from ND 
systems. When thioridazine was postloaded to ND, the SEC trace displayed 
multiple peaks, indicating a vast size distribution (Figure 3.17, A). The most 
prominent peak coincided with a slight increase in MW, which confirmed the 
drug loading. Additionally, the presence of aggregates in the void volume 
supported the belief that thioridazine postincorporated led to instability in the 
ND systems. This instability was also seen to depend on the number of 
thioridazine added during reconstitution of ND with preloaded thioridazine 
(Figure 3.17, B). However, its earlier elution time – comparative to drug 
postloaded ND – suggested the possibility that more thioridazine molecules 
may be incorporated per ND. The unincorporated drug was detected as peaks 
eluted at later times. 
Despite the inability to quantify the number of thioridazine content per ND via 
HPLC, due to the difficulty in separating the components (Figure 8.10), but with 
encouragements from the SEC results, the rate of drug release preloaded into 
ND was investigated. Similar to the release of amiodarone and chlorambucil 
preloaded to ND, thioridazine was released over a period of 24 h, at a rate 
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proportional to its concentration in ND - t1/2 was 3 h ± 0.33 (Figure 3.18). 
Subsequently, the absence of an initial burst observed on the release profile 
was in good agreement with literature findings.109 Although, the release of 
thioridazine from ND reached an apparent completion, compared to only 60% 
of thioridazine being released from the polymeric micelles. A reason behind the 
difference in drug released could be based on the higher volume of release 
media used for the drug loaded ND assemblies; hence the buffer had a greater 
capacity for solubilising the free drug. 
 
Figure 3.17 SEC chromatograms of ND, ND TRD and the elution time of AD: A - TRD 
was postloaded to ND; B - TRD was preloaded to ND; reconstituted with method B; ND 
and AD were measured at 280 nm, ND TRD was measured at 262 nm 
 
Figure 3.18 Fractional TRD release at 37 oC from ND; TRD was preloaded to ND; the 
aliquots were measured at 262 nm; t1/2 was 3 h ± 0.33; data is shown as the mean ± SD 
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3.2.5 Nanodiscs loaded with novobiocin 
Novobiocin (NVB) is an aromatic compound with antibiotic properties. 
Novobiocin has a similar MW to amiodarone but higher water solubility 
(9.66 µg/mL) and a voluminous structure. The drug was incorporated to ND via 
postloading and preloading method and an investigation was conducted into the 
efficiency of loading and release from ND. The reconstitution experiments 
conducted for novobiocin postloaded to ND were performed by project student 
Noha Abou El Magd.  
The analysis of novobiocin preloaded and postloaded to ND, via SEC, produced 
narrow peaks, that coincided with the trace characteristic to ND, and confirmed 
the drug loading (Figure 3.19, A). However, polydispersity within the sample 
was observed for novobiocin preloaded to ND, generated, probably, either by 
overtime aggregation or by interactions between drug molecules and the lipid 
bilayer (Figure 3.19, B). The release rate of preloaded novobiocin further 
investigated has demonstrated that release did not go to completion within 24 h 
- t1/2 was 9.8 h ± 0.9 (Figure 3.20, A). Due to its low incorporation rate into ND 
(2 molecules loaded per ND; determined by HPLC - Figure 8.12), log P and the 
predicted solubility, it can be deduced that the drug has neither a preference for 
the aqueous or organic phase. Although the drug exhibited poor loading within 
ND, this prolonged release could allow the delivery of novobiocin to the site of 
action without significant drug loss.  
 
Figure 3.19 SEC chromatograms of ND, ND NVB and the elution time of AD: A - NVB 
was postloaded to ND; B - NVB was preloaded to ND; assemblies reconstituted using 
method B; ND and AD were measured at 280 nm, ND NVB were measured at 324 nm  
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Figure 3.20 Fractional NVB release at 37 oC from ND NVB; NVB was preloaded to ND; 
the aliquots were measured at 324 nm; t1/2 value is 9.8 h ± 0.9; data is shown as the 
mean ± SD  
3.2.6 Nanodiscs loaded with camptothecin 
Camptothecin (CPT) is a heterocyclic compound investigated for the treatment 
of cancer. Although its anticancer activity was demonstrated in preliminary 
clinical trials, camptothecin is also known for its adverse side effects and low 
water solubility (0.511 mg/mL).  
The ND CPT analysis by SEC revealed an increase in the apparent MW 
presumably caused by camptothecin incorporation into ND (238 kDa the MW of 
ND CPT) (Figure 3.21). However, the majority of unincorporated camptothecin 
eluted later as a single peak. These conclusions as well as the later calculated 
loaded drug per ND via HPLC (0.24 molecules per ND, Figure 8.14) suggested 
a low incorporation efficiency. Despite the poor incorporation of camptothecin 
into ND, an apparent 100% drug release was observed. The equilibrium 
between concentrations of loaded and free camptothecin was achieved within 
24 h - t1/2 was 13.8 h ± 3.2 (Figure 3.22, B). Drug exhibited a gradual sustained 
release pattern and no initial burst. This could potentially be associated with 
total drug incorporation, despite only 0.24 molecules of camptothecin being 
loaded per ND.  
62 
Incorporation of poorly water soluble drugs into nanodiscs 
 
Figure 3.21 SEC chromatograms of ND, ND CPT and the elution time of AD; CPT was 
preloaded to ND, reconstituted via method B; ND and AD were measured at 280 nm, 
ND CPT was measured at 218 nm 
 
Figure 3.22 Fractional CPT release at 37 oC from ND; CPT was preloaded to ND; the 
aliquots were measured at 218 nm; t1/2 was 13.8 h ± 3.2; data is shown as the 
mean ± SD  
3.2.7 Nanodiscs loaded with tamoxifen 
Tamoxifen (TMX) is a nonsteroidal agent that binds to estrogen receptors, with 
relevance in the treatment of metastatic breast cancer. Tamoxifen is extensively 
metabolised and has a water solubility value of 1.02 µg/mL.  
On the SEC chromatogram of tamoxifen preincorporated to ND, the formation 
of ND assemblies and clusters of unincorporated drug was observed 
(Figure 3.23). The absorbance used (277 nm) – close to MSP absorbance 
(280 nm) – might suggest the reconstitution of either empty ND or drug loaded 
ND with poor incorporation efficiency. This possibility was emphasised by the 
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low amount of tamoxifen per ND further calculated from HPLC (Figure 8.16) – 
0.4 molecules per ND. Due to its poor incorporation and the previous 
inconclusive observations on the release of novobiocin and camptothecin - with 
similar poor incorporation – it was decided not to examine the rate of tamoxifen 
release from ND.  
 
Figure 3.23 SEC chromatograms of ND, ND TMX and the elution time of AD; TMX was 
preloaded to ND, reconstituted via method B; ND and AD were measured at 280 nm, 
ND TMX was measured at 277 nm 
3.2.8 Nanodiscs loaded with clofazimine 
Clofazimine (CLF), a riminophenazine dye, has similar water solubility to 
amiodarone (1.51 µg/mL) and is used for the treatment of leprosy. Therefore, 
clofazimine was a suitable candidate for loading and release from ND systems. 
After clofazimine was postloaded to ND using method B of reconstitution, 
analysis via SEC indicated an increase in the apparent MW caused by 
clofazimine incorporation (306 kDa MW of ND CLF) (Figure 3.24). The reason 
for the difference in apparent MW could be associated with clofazimine 
molecules attaching to the surface of ND and creating an enlarged particle. 
HPLC analysis and subsequent calculations revealed 4 molecules of 
clofazimine incorporated per ND (Figure 8.17). 
Although the initial investigation showed successful formation of ND, separation 
problems on SEC occurred when ND CLF were analysed. Visible red traces of 
free clofazimine were observed on the top filter of the gel filtration column. In 
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order to not contaminate other ND-drug samples, the investigation of ND CLF 
was interrupted. 
 
Figure 3.24 SEC chromatograms of ND, ND CLF and the elution time of AD; CLF was 
preloaded to ND and reconstituted via method B; ND and AD were measured at 
280 nm, ND CLF was measured at 486 nm  
3.2.9 Nanodiscs loaded with indomethacin 
Indomethacin (IND) is an anti-inflammatory agent for which the water solubility 
can be varied with temperature.110 When indomethacin was preloaded into ND, 
the SEC chromatogram showed the peak characteristic to drug loaded ND, 
corresponding to an apparent MW calculated at 252 kDa (Figure 3.25). A trail 
with high absorbance was observed at a later retention volume. This was 
attributed to aggregates of unincorporated indomethacin. The observation 
concluded was that probably ND was solubilising very little indomethacin. 
However, the subsequent inefficiency to quantify the number of molecules per 
ND via HPLC (Figure 8.18) made the investigation inaccessible. Therefore, 
observation on the release rate was further interrupted.  
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Figure 3.25 SEC chromatograms of ND, ND IND and the elution time of AD; IND was 
preloaded to ND, reconstituted via method B; ND and AD were measured at 280 nm, 
ND IND was measured at 318 nm  
3.2.10 Nanodiscs loaded with fluorescein, chloroquine, oxymethazoline 
and rimantadine 
Fluorescein (FLC) is a synthetic organic compound used as a fluorescent tracer 
for many applications. Chloroquine (CLQ) is an aminoquinoline derivate with 
water solubility of 17.5 µg/mL, used as anti-malarial drug. Oxymethazoline 
(OXM) is a 260 Da compound from phenylpropanes class, mainly used for the 
treatment of nasal congestions. Rimantadine (RMD), a cyclic amine with 
9.15 µg/mL water solubility, is a synthetic antiviral drug which acts by disrupting 
the membrane.  
After analysing the ND-drug systems by SEC, these drugs were grouped 
because of their unsuccessful incorporation into the ND system. For example, 
the chromatograms of fluorescein postloaded to ND, regardless of the molar 
ratio of reconstitution, indicated that despite ND formation, little fluorescein was 
loaded into ND. Most unincorporated fluorescein eluted as aggregates of free 
drug (Figure 3.26). 
In the case of chloroquine, the incorporation within ND displayed similar 
outcomes – absence of drug loaded ND peak (Figure 3.27, A and C). However, 
the chromatograms analysed at 280 nm, revealed that ND assemblies were 
formed (data not shown), demonstrating that the drug incorporation process did 
not affect the formation of empty ND. Only the preloaded chloroquine-ND via 
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method B suggested the formation of drug loaded ND (Figure 3.27, B). The 
increase in apparent MW might have been caused by chloroquine incorporation 
(292 kDa the MW of ND CLQ). Presumably, chloroquine molecules bind weakly 
to the POPC head groups, and partially pack between the hydrocarbon chains 
of the phospholipid domain. A low incorporation efficiency is suggested by the 
height of ND peak compared to the peaks associated with polydisperse 
aggregates of POPC, chloroquine and oligomeric protein, and unloaded free 
chloroquine.  
The SEC analysis found that oxymethazoline postincorporated to ND led to the 
formation of ND-drug with an apparent MW of 272 kDa and of aggregates 
composed of oxymethazoline, POPC and MSP in different proportions – from 
void volume aggregates to clusters of free drug (Figure 3.28, A). The SEC 
chromatogram of oxymethazoline preloaded to ND, revealed that the majority 
of drug was eliminated as free drug molecules (Figure 3.28, B). The peak 
characteristic to ND was seen eluted, but the relatively low absorbance 
indicated that only a small quantity of oxymethazoline was incorporated into the 
assemblies. 
For rimantadine preincorporated into ND, the investigation led to the belief that 
rimantadine loading generated deformations of the lipid bilayer within ND, 
contributing to the formation of aggregates. Nevertheless, the presence of the 
two peaks eluted later suggested few enlarged particle aggregates and smaller 
species, respectively (Figure 3.29).  
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Figure 3.26 SEC chromatograms of ND, ND FLC and the elution time of AD; 
assemblies were reconstituted using method A and 1:30 and 1:65 molar ratios, FLC 
was postloaded to ND; all samples were measured at 280 nm  
 
Figure 3.27 SEC chromatograms of ND CLQ, ND and the elution time of AD: 
A - assemblies were reconstituted with method A.; B and C - assemblies were 
reconstituted with method B; A and B – CLQ was preloaded to ND; C - CLQ was 
postloaded to ND; ND and AD were measured at 280 nm, ND CLQ was measured at 
343 nm  
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Figure 3.28 SEC chromatograms of ND, ND OXM and the elution time of AD: A - OXM 
was postloaded to ND; B - OXM was preloaded to ND; assemblies were reconstituted 
via method B; ND and AD were measured at 280 nm, ND OXM was measured at 
315 nm 
 
Figure 3.29 SEC chromatograms of ND, ND RMD and the elution time of AD; RMD 
was preloaded to ND; assemblies were reconstituted using method B; all samples were 
measured at 280 nm 
 Which drugs are incorporated? 
The investigation of drug loaded ND assemblies on SEC was the first important 
step in dividing the hydrophobic drug molecules into groups of molecules with 
different selectivity towards loading into ND. The second divider was their 
subsequent analysis on HPLC, in order to calculate the number of molecules 
incorporated per ND. Following this classification, the release rate of drug 
molecules (chosen from three groups) was observed.  
In the tables presented below, the hydrophobic small molecules have been 
separated into five different groups. Table 3.8 and Table 3.9 show six 
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hydrophobic molecules successfully loaded within ND. For the hydrophobic 
molecules represented in Table 3.9, the apparent number of molecules loaded 
could not be determined due to separation problems on SEC and HPLC. 
Table 3.10 shows three hydrophobic molecules with poor incorporation within 
the ND; all three tables contain the properties of the drugs analysed and their 
t1/2 values. Table 3.11 and Table 3.12 show three hydrophobic molecules with 
unsuccessful loading into ND, their properties and the impact drug incorporation 
had over the formulation or disruption of ND assemblies, respectively. 
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Drug Structure Log P Isoelectric 
point 
MW 
/gmol-1 
Solubility in 
water/ g/L 
Physiologic
al charge 
Apparent molecules 
of drug loaded 
Half-life t1/2 
value/ h 
 
AMD 
 
 
7.9 
 
- 
 
645.3 
 
4.76×10-3 
 
+1 
10 ± 6.81 
5.8 ± 2.52 
9.5 ± 23 
 
 
5.4 ± 0.671 
0.88 ± 0.032 
0.6 ± 0.143 
 
 
CLB1 
 
 
3.8 
 
3.08 
 
304.2 
 
12.4 
 
-1 
 
6.5 ± 1.7 
 
5.8 ± 0.48 
Table 3.8: Table of hydrophobic molecules with successful loading within ND, their properties110 and results from incorporation and release 
from the ND systems; 1drugs were preloaded to ND; 2drug were postloaded to ND reconstituted with 1:50; 3drug were postloaded to ND 
reconstituted with 1:65 
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Drug Structure Log P Isoelectric 
point 
MW 
/gmol-1 
Solubility in 
water /g/L 
Physiological 
charge 
Half-life t1/2 
value/ h 
 
CLF3,i 
 
 
 
7.6 
 
 
10.84 
 
 
473.4 
 
 
2.25×10-4 
 
 
+1 
 
 
- 
 
CCMi 
 
 
3.6 
 
- 
 
368.4 
 
6×10-4 111 
 
0 
 
3.9 ± 1.32 
7.4 ± 0.43 
 
 
IND1,ii 
 
 
4.2 
 
0.77 
 
357.8 
 
9.37×10-4 at 
25 °C 
 
-1 
 
- 
 
TRD1,ii 
 
 
5.9 
 
- 
 
370.5 
 
3.36×10-5 
 
+1 
 
3 ± 0.33 
Table 3.9 Table of hydrophobic molecules with successful loading within ND and their properties110, 112; apparent molecules of drug loaded 
could not be determined due to separation problems on SECi and HPLCii; 1drugs were preloaded to ND; 2drug were postloaded to ND 
reconstituted with 1:50; 3drug were postloaded to ND reconstituted with 1:65   
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Drug Structure Log P Isoelectric 
point 
MW /gmol-1 Solubility in 
water /g/L 
Physiological 
charge 
Apparent 
molecules of 
drug loaded 
Half-life t1/2 
value/ h 
 
NVB 
 
 
4.1 
 
1.92 
 
612.6 
 
9.66×10-3 
 
-1 
 
2 
 
9.8 ± 0.9 
 
TMX 
 
 
7.1 
 
- 
 
371.5 
 
1.76×10-4 at 
25 °C 
 
+1 
 
0.4 
 
- 
 
CPT 
 
 
2 
 
7.39 
 
348.3 
 
5.11×10-1 
 
0 
 
0.24 
 
13.8 ± 3.2 
Table 3.10 Table of hydrophobic molecules with poor loading within ND, with their properties110 and results from incorporation and release 
from the ND systems; all drugs were preloaded to ND 
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Drug Structure Log P Isoelectric 
point 
MW 
/gmol-1 
Solubility in 
water g/L 
Physiological 
charge 
 
CLQ 
 
 
4.3 
 
- 
 
515.9 
 
1.06×10-4 
 
+2 
 
OXM 
 
 
3.4 
 
10.47 
 
260.4 
 
5.15×10-2 
 
+1 
 
FLC 
 
 
3.88 
 
2.4 
 
332.3 
 
0.0255 
 
0 
Table 3.11 Table of hydrophobic molecules with unsuccessful loading and their 
properties;110 all drugs were preloaded to ND; drug incorporation did not affect the 
formulation of ND assemblies 
 
Drug Structure Log P Isoelectric 
point 
MW 
/gmol-1 
Solubility in 
water/ g/L 
Physiological 
charge 
 
RMD 
 
 
3.2 
 
- 
 
179.3 
 
9.15×10-3 
 
+1 
Table 3.12 Table of hydrophobic molecules with unsuccessful loading and their 
properties;110 drug was preloaded to ND; drug incorporation disrupted the formulation 
of ND assemblies 
 
The SEC and HPLC analyses showed that the ND systems had favourable 
results when loading amiodarone and chlorambucil. Amiodarone also exhibited 
much slower release from ND, when was preloaded using method B of 
reconstitution. An understanding of the selectivity of amiodarone and 
chlorambucil for preferential loading within the phospholipid domain can be 
associated with their log P and insolubility in water (Figure 3.30, Figure 3.31). 
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These are causing the phospholipids within the ND to bond the drug molecules 
primarily by hydrophobic interactions.  
Other drugs such as tamoxifen, novobiocin and camptothecin, with similar log P 
and MW as amiodarone and chlorambucil (Figure 3.30, Figure 3.32), had a 
much lower preference to loading within ND. The reason as to why the 
molecules had poor incorporation can be that tamoxifen has a bulky rigid 
structure with three aromatic rings, which would give less flexibility when 
packing within the phospholipid domain. In the case of novobiocin, a 
presumable explanation would be that the drug interacts only with the head 
groups of POPC arranging itself on the surface of the bilayer. Although 
camptothecin has a long structure consisted of chains of cyclic and aromatic 
rings, it has a low hydrophobicity and comparatively high water solubility (Figure 
3.31) making it less suitable to be packed between the lipid hydrocarbon chains.  
Although showing successful incorporation, the apparent molecules of 
thioridazine, indomethacin, curcumin and clofazimine loaded could not be 
determined due to separation problems. Clofazimine and curcumin were difficult 
to work with because of solubility problems caused during the SEC 
experiments. As regards to thioridazine and indomethacin, the obstacle in 
quantifying the number of molecules incorporated was found during analysis via 
HPLC, as the elution time for drugs coincided with the elution time of MSP. 
Thioridazine had a relatively low half-life of 3 h ± 0.33 for a molecule with such 
low water solubility and high log P. An apparent 100% release profile was also 
observed, probably associated with the high capacity of the buffer used to 
solubilise the free drug  
The hydrophobic drugs, listed in Table 3.11 and Table 3.12 and having a Log P 
between 3 and 4.5, but a broad range of water solubility and MW, were proven 
unsuccessful after the samples were studied on SEC (Figure 3.30 to Figure 
3.32, grey rotated triangles). This observation was reached from the small-scale 
or absence of a ND-drug peak at the elution time of ND, although empty ND 
formation was noticed. The experiments conducted with rimantadine showed 
the drug disassembled almost all the ND systems - a small peak present at ND 
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elution time compared to a much longer peak in the void volume. This result is 
unsurprising as rimantadine - an antiviral agent with bulky, non-planar molecular 
geometry – may be disrupting the POPC membrane and forming aggregates 
with the scaffold protein and POPC.  
In the case of chloroquine and oxymethazoline empty ND were formed. 
Chloroquine had an unsuccessful rate of loading probably due to its compact 
structure and aromatic rings which makes it more rigid and therefore less likely 
for favourable packing within the lipid bilayer. The results arising from the 
unsuccessful loading of oxymethazoline were associated with the anchoring 
site being too small, leading to weak interactions with the head groups of 
phospholipids.  
 
Figure 3.30 A - Relation between Log P of the hydrophobic drugs and the number of 
molecules incorporated per ND; B - Relation between Log P of the hydrophobic drugs 
and t1/2; 1 and unmarked drugs drugs were preloaded to ND; 2drug were postloaded to ND 
reconstituted with 1:50; 3drug were postloaded to ND reconstituted with 1:65 
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Figure 3.31 A - Relation between water solubility of the hydrophobic drugs and the 
number of molecules incorporated per ND; B - Relation between water solubility of the 
hydrophobic drugs and t1/2; 1 and unmarked drugs drugs were preloaded to ND; 2drug were 
postloaded to ND reconstituted with 1:50; 3drug were postloaded to ND reconstituted 
with 1:65 
 
Figure 3.32 A - Relation between MW of the hydrophobic drugs and the number of 
molecules incorporated per ND; B - Relation between MW of the hydrophobic drugs 
and t1/2; 1 and unmarked drugs drugs were preloaded to ND; 2drug were postloaded to NDs 
reconstituted with 1:50; 3drug were postloaded to ND reconstituted with 1:65 
  
It was difficult to establish simple criteria by which hydrophobic drug molecules 
with different physico-chemical properties would be incorporated and released 
from the ND assemblies. Many considerations had to be taken in account when 
incorporating the drug molecules into ND. Their loading capacity was not only 
determined by their insolubility in water and MW but also by the interactions 
with the hydrophilic head groups and hydrophobic hydrocarbon chains of the 
phospholipids within the ND. Additional investigations via SAXS analysis were 
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required for a better understanding of the interactions between drug molecules 
and the phospholipid domain of ND systems.  
3.4 SAXS investigation of drug loaded MLV and ULV 
For this investigation, the MSP component was removed from the systems as 
our previous experiments demonstrated no considerable interaction between 
the drugs and MSP. Thus, the ND were replaced with multilamellar vesicles of 
POPC, suspended in deionised water, and used to incorporate the drug 
molecules. The multilamellar vesicles (MLV) and unilamellar vesicles (ULV) 
were used as model membrane systems for the loading of amiodarone, 
chlorambucil, indomethacin, tamoxifen and rimantadine. Drug loaded systems 
were analysed by small angle X-ray scattering (SAXS) for a better 
understanding of the influence drug incorporation has on the model 
membranes. The measurements and subsequent analysis of the scattering 
patterns were done by Dr. Amin Dilmaghani, from School of Food Science and 
Nutrition, University of Leeds.  
The collected data was fitted by applying the modified Caillé theory, previously 
described by Drasler et al.113 Examples of the obtained diffraction patterns for 
drug loaded POPC systems could be observed in Figure 3.33.  
It is believed that amphiphilic molecules tend to partition at the lipid-water 
interface.114 Amiodarone, tamoxifen and rimantadine possess a positive 
physiological charge, due to the protonated amino group. The other two drugs 
investigated, chlorambucil and indomethacin, have a carboxyl group, that when 
deprotonated, gives a negative charge to the molecule. The fitting parameters 
subtracted after analysis of SAXS patterns have indicated that the ratio of ULV 
to MLV formation is affected by the physiological charge of the incorporated 
drugs. Subsequent to analysing the data, the ratio of ULV to MLV present in the 
sample, quantified by the fitting parameter Ndiff (Table 3.13), was 1 for the 
model membrane system with positively charged drug molecules incorporated. 
This suggested that the presence of cationic drugs has led to the formation of 
a population composed entirely of ULV. Comparatively, when chlorambucil and 
indomethacin are incorporated into the model membrane, the formation of MLV 
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is observed. This was indicated by the values of Ndiff being close to 0. More so, 
these conclusions are also indicated by the diffraction pattern of the POPC and 
drug loaded POPC systems (Figure 3.33). Two sharp peaks could be observed 
on the diffraction pattern of the samples containing the majority of MLV. In 
contrast, on the diffraction pattern of the samples consisting of ULV, the two 
peaks were replaced by a broad curve. 
The electron density profile described by Gaussian distributions (Figure 3.34) 
was used to estimate the head group positions (zH), and thus estimate the 
membrane thickness. When chlorambucil, indomethacin and amiodarone were 
incorporated into POPC systems, a decrease in the membrane thickness was 
observed. The decrease in membrane thickness could be related to the drug 
molecules disrupting the packing of the head group region due to partitioning 
close to the head group and water interface rather than near the hydrocarbon 
chains. However, the thickness of the POPC membrane was negligibly 
increased by the incorporation of tamoxifen and rimantadine. In addition, this 
perturbation of the membrane could be directly correlated with the efficiency of 
the drug loading within the phospholipid domain. For example, amiodarone 
loading, which led to the highest decrease in membrane thickness, was 
demonstrated to have the highest incorporation efficiency – 10 molecules per 
ND. Comparatively, lower decrease in membrane thickness generated by 
chlorambucil loading is associated with lesser number of drug molecules loaded 
per POPC domain – 6.5 molecules per ND. However, amiodarone and 
chlorambucil had similar release profiles, exhibiting no initial burst and having a 
half-life between 5 and 6 h, presumably demonstrating that the variation in 
membrane thickness did not affect the efficiency of their release. 
In addition, POPC membrane fluctuations, given by the mean of inter-
membrane distance, σ, were seen to increase by 29% when chlorambucil and 
indomethacin were incorporated into the bilayers. This has demonstrated that 
the incorporation of drug molecules into the POPC domain was correlated with 
an increase in membrane softness. The fluctuation of inter-membrane distance 
is obtained from the Caillé parameter, η, via the equation, described below.113: 
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 σ =  √𝜂  ×  
𝑑
𝜋
 
Equation 3.5 The relationship between Caillé parameter (η) and the mean fluctuation 
of inter-membrane distance (σ), d is the lamellar repeat distance (d-spacing in 
Table 3.13) 
 
Fitting parameters POPC POPC
CLB 
POPC
IND 
POPC 
TMX 
POPC 
RMD 
POPC 
AMD 
d-spacing/ nm 6.38 6.41 6.37 na na na 
Number of layers 23 11 11 na na na 
Caillé parameter, η 0.073 0.121 0.125 na na na 
the mean fluctuation of inter-
membrane distance, σ 
0.55 0.71 0.72 na na na 
The head group position,  
zH/ nm 
1.83 1.76 1.79 1.85 1.84 1.67 
Ndiff 0.0020 0.0071 0.074 1 1 1 
Table 3.13 Table of fitted parameters subtracted after analysis of SAXS patterns, for 
empty POPC MLV, MLV loaded with CLB, IND, and ULV loaded with TMX, RMD and 
AMD; na – not applicable 
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Figure 3.33 Diffraction pattern and corresponding fitting (black lines) and desmeared 
curves (blue lines). Data for POPC in deionized H2O, POPC with CLB, IND, TMX, AMD 
and RMD; data was recorded at 25 °C 
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Figure 3.34 The electron density profile described by Gaussian distributions for empty 
POPC MLV, MLV loaded with CLB, IND, and ULV loaded with TMX, RMD and AMD 
3.5 Summary 
Because of favourable properties for loading into ND, twelve hydrophobic drug 
molecules were investigated. This was successfully done in order to generate 
the optimum conditions for incorporation and release, and to determine the 
impact their incorporation has on the size and structure of the ND systems.  
The protocol for ND assembly was adapted to load the hydrophobic drugs into 
the systems arranging the components into a discoidal bilayer with the drug 
molecules loaded into the phospholipid domain. The optimised protocol showed 
an increase in drug incorporated per ND and a slower release rate.  
Following the drug loading, a series of techniques used to characterise the ND-
drug assemblies have demonstrated the influence drug incorporation has on 
the MW and size of the assemblies, and on the secondary structure of the 
scaffold protein that forms the protein belt.  
Subsequently, an optimised method of characterisation, using HPLC, was 
developed to accurately determine the amount of hydrophobic small molecules 
loaded into ND. Consecutively, the drug molecules were separated into groups 
based on their loading capability and the rate of release from ND. The 
separation gave insights on the influence of drug properties on the incorporation 
and release from ND.  
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The analysis of SAXS patterns suggested that incorporation of amiodarone, 
rimantadine and tamoxifen (positive physiological charge) into POPC model 
membranes has led to the formation of ULV. Whereas, incorporating 
chlorambucil and indomethacin (negative physiological charge) into POPC 
model membranes resulted in MLV formation. The incorporation of chlorambucil 
and indomethacin has increased the fluctuation inter-membrane distance by 
around 30% and decreased the membrane thickness. For amiodarone and 
chlorambucil incorporation, this decrease in membrane thickness was seen to 
be correlated with the efficiency of drug loading within the POPC bilayer. 
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4 Chapter 4 
 Part I – Influence of lipid composition on drug incorporation 
4.1.1 Introduction 
Nanodiscs can be readily formed using POPC, and can be loaded with a variety 
of drugs. However, little is known about the effect of variation in lipid 
composition, either on ND formation or drug loading. In the following chapter 
the effect of lipid composition on the incorporation and release of amiodarone 
and chlorambucil from ND was investigated.  
Amiodarone and chlorambucil molecules were incorporated into lipid, MSP and 
detergent micelles, following the method of preloading drug into ND 
reconstituted via method B. This method involved loading the drug molecules 
during the reconstitution of ND, as previously described in Chapter 3. Briefly, 
the drug molecules were dried with various lipid compositions (Table 4.1), into 
a thin film. Subsequently, by addition of MSP/detergent, the drug molecules 
incorporated into lipid, MSP and detergent micelles, were incubated at 4 °C. 
The exception was ND reconstituted with DPPC, for which the mixture was 
incubated at 42 °C. After detergent removal, the assembly process between the 
MSP, POPC and drug molecules started. The unincorporated drug was then 
eliminated by SEC analysis. A series of methods - SEC, DLS, HPLC and UV-
spectroscopy – were applied to investigate the influence of lipid composition on 
the efficiency of the drug loading process and drug release kinetics. 
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Lipid composition within ND Physical properties of the bilayer domain within ND 
POPC115 The surface has no net charge 
POPS (up to 50%) Alter the charge density 
DLPC116 Create thinner membrane like systems 
DPPC115 Form gel phase ND at room temperature 
DOPE PEG550117 (10%) Steric protection of the ND 
Table 4.1 Table of lipid compositions and their properties within the ND 
 
Four distinct lipid mixtures were considered, each used to supplement the 
POPC in the reconstitution of ND. The first mixture of phospholipids consisted 
of negatively charged phosphatidylserine and zwitterionic phosphatidylcholine. 
The presence of anionic 1-palmitoyl- 2-oleoy l-sn-glycero -3-phospho-L-serine 
(POPS) (Figure 4.1) in the bilayer could potentially create a more stable system. 
This could be due to the favourable electrostatic interactions between the 
positively charged residues present in MSP and the negatively charged PS 
head group of the lipid.118 In addition, the inter-nanodisc repulsion, given by the 
high net charge of ND, would likely prevent aggregation. The variation in lipid 
composition, with up to 100% POPS in reconstituted ND, was frequently studied 
in literature by groups of researchers, describing the positive effect these 
anionic lipids have on binding membrane-associated signalling molecules to the 
bilayer surface.87, 91, 119  
The second mixture of phospholipids used to reconstitute ND was by adding to 
the zwitterionic phosphatidylcholine, a PEGylated phosphoethanolamine. In 
order to facilitate the reconstitution of ND with a favourable lipid distribution and 
no other large conglomerates,120 10% PEGylated 1,2 – dioleoyl - sn-glycero- 3 
– phosphoethanolamine - N - [methoxy (polyethylene glycol) - 550] (DOPE 
PEG550) was used (Figure 4.1). The incorporation of PEG into lipid structures 
was often used by researchers to protect the lipid surface by creating a steric 
barrier, and increase the blood circulation time of the carrier. Additionally, it was 
demonstrated by Johansson et al. that the distribution of drug molecules at the 
water/membrane interface reaches equilibrium regardless of the PEGylated 
lipid composition in the membrane.121 
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The first lipid composition to replace POPC entirely was another zwitterionic 
phosphatidylcholine lipid. In this case, the lipid, 1, 2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC), has smaller, saturated hydrocarbon chains 
(Figure 4.1). The presence of DLPC in the bilayer would create thinner bilayer 
that could potentially favour the incorporation of drugs with small MW. 
Additionally, the preloading of positively and negatively charged drug molecules 
could influence the favourable packing within the bilayer, leading to the 
reconstitution of stable and monodisperse assemblies. In literature, researchers 
have often used, in their studies, ND reconstituted with DLPC to investigate 
membrane proteins.122, 123 
To reconstitute the assemblies, the POPC composition was, again, replaced 
with another zwitterionic phosphatidylcholine lipid. Here, the lipid, 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) has both its hydrocarbon 
chains saturated, and, due to the length of these acyl chains, a transition 
temperature of 41 °C (Figure 4.1). This high transition temperature implies that, 
at room temperature, the ND systems will be in a gel phase. An investigation 
was carried out on how the high temperature for reconstituting ND would affect 
the homogeneity of the assemblies and how stable the ND system would be 
after preloading drug molecules.  
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Figure 4.1 Structure of A – POPC; B - 1 - palmitoyl- 2 – oleoyl – sn – glycero – 3 – 
phospho – L - serine (POPS) Transition Temp. 14 °C; C - 1, 2 - dioleoyl – sn – glycero 
– 3 – phosphoethanolamine - N - [methoxy (polyethylene glycol)-550] (DOPE 
PEG550); D - 1, 2 – dilauroyl – sn – glycero – 3 - phosphocholine (DLPC); Transition 
Temp. -2 °C; E - 1, 2 – dipalmitoyl – sn – glycero – 3 - phosphocholine (DPPC); 
Transition Temp. 41 °C 
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4.1.2 Assemblies reconstituted with POPC: POPS 
To confirm ND reconstitution and drug loading, the assemblies were analysed 
by SEC. Subsequently, the drug molecules were loaded in three quantities, for 
each drug, to the reconstitution mixture in order to observe the influence 
hydrophobic molecules incorporation has on the size and the formation of the 
ND assemblies. 
 The monodispersity and size distribution of ND 
Initial attempts to form empty ND led to a high yield of large lipid-MSP 
aggregates, as suggested, on the SEC chromatogram, by the presence of a 
broad peak with an attached shoulder (Figure 4.2, A). Consistent with literature 
findings,124 the remaining detergent molecules generated instability during ND 
formation, which resulted in the reconstitution of large spherical and 
polydisperse assemblies. However, the assembly of monodisperse and stable 
ND was demonstrated after increasing the POPS composition to 50% and 
effectively remove the cholate to allow the discoidal self-assembly between 
lipids and MSP. Subsequently after separation of monodisperse ND from large 
aggregates, the size distribution of the system was investigated. The analysis 
of ND showed peaks corresponding to stable empty ND revealing a diameter of 
10 nm, regardless of the POPS composition (Figure 4.3). 
The chromatograms suggest an optimal amiodarone addition of less than 20 
molecules, as the ND-drug peak relative to large lipid–protein-drug aggregates 
is maximised at this ratio (Figure 4.2, B). Additionally, these assemblies were 
seen to decrease in size from 10 nm, the diameter of empty ND (50% POPS), 
to 4.8 nm (Figure 4.3). This result is very unusual, because the diameter of ND 
is controlled by the MSP belt rather than the composition inside the bilayer 
domain. Increasing the number of amiodarone molecules led to alterations in 
the reconstitution of monodisperse assemblies. This was indicated by the height 
of void volume peaks. A presumable explanation could be that, at higher 
concentrations, rather than eluting as clusters of free drug, amiodarone formed 
clusters with the lipid head groups, leading to the ND surface being enlarged. 
This is consistent with literature studies, were high quantities of positively 
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charged thioridazine were found to create disorder within a POPC/POPS 
bilayer, resulting in expansion of the bilayer.125  
Analysing ND CLB via SEC showed that the incorporation of chlorambucil had 
similar results (Figure 4.2, C). At the lowest chlorambucil addition, the highest 
population of ND was observed, relative to other aggregates. Moreover, due to 
electrostatic repulsion with the anionic POPS, the drug molecules did not form 
large clusters eluted in the void volume. Instead, the excess chlorambucil, for 
all three ND CLB, was eliminated as free drug aggregates.  
 
Figure 4.2 SEC chromatograms of empty ND, ND AMD, ND CLB and the elution time 
of AD: A - empty ND reconstituted with 28% and 50% POPS (280 nm); B - ND AMD 
reconstituted by preadding 93, 35 and 18 molecules of AMD (242 nm); C - ND CLB 
reconstituted by preloading 270, 103 and 22 molecules of CLB (254 nm)  
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Figure 4.3 DLS of empty and amiodarone loaded ND, reconstituted with 28% and 50% 
POPS  
 
 Drug loading efficiency and release profile 
The HPLC technique was used to investigate how many drug molecules were 
loaded within the ND (Figure 4.4). Following the protocol used in the HPLC 
analysis of drug loaded POPC ND, an accurate calculation of the number of 
drug molecules loaded per ND was obtained. Subsequently, the rate of drug 
release were observed on the drugs preloaded ND, as previously described in 
Chapter 3. As in the previous chapter, an exponential curve was fitted to the 
drug release data, and using a first order rate equation (Eq. 3.2) the fractional 
release and half-life of the drug molecules were calculated.  
The release profile of amiodarone (1.9 ± 0.8 molecules loaded per ND) showed 
an initial burst effect, releasing around 60% of the preloaded drug within 3 hours 
(Figure 4.5, A). Following this burst, the amiodarone release reached a plateau. 
To interact with the phosphate groups of POPC, the drug molecules must travel 
further within the bilayer, pass the negatively charged POPS. Nevertheless, 
electrostatic interactions between POPS and amiodarone facilitated a 
prolonged anchoring of the drug at the lipid-water interface.125 This resulted in 
the formation of clusters between amiodarone and the lipid head groups, 
eventually leading to an initial burst and the overall dissociation of only 60% 
amiodarone. A similar release was observed for amiodarone post-loaded into 
ND reconstituted with 1:50 MSP to POPC (100% POPC), for which the initial 
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burst was thought to be associated with amiodarone accumulation near the 
POPC head groups. The half-life of the drug, calculated from the rate 
parameter, was 1.75 h ± 0.8. 
In comparison, when chlorambucil was preloaded to ND (8.5 ± 3.8 molecules 
loaded per ND), the drug profile had a constant release that reached completion 
within 24 h (Figure 4.5, B). The half-life for chlorambucil was calculated to be 
3.9 h ± 0.7. This lower half-life, compared to ND reconstituted with 100% POPC, 
indicated a faster release rate associated with electrostatic repulsions between 
the two negatively charged molecules, chlorambucil and serine head group of 
POPS. Similarly, the high fluctuation in chlorambucil loading which might 
indicate instability during drug incorporation, were presumably the result of 
these repulsive forces between the drug and POPS.  
 
Figure 4.4 HPLC chromatograms of: A - ND AMD (242 nm) and B – ND CLB (254 nm) 
reconstituted, at 4 °C, with 50% POPS; the inside chromatograms are of the same 
samples measured at 280 nm to identify the MSP retention time 
 
Figure 4.5 Fractional drug release at 37 oC from A - ND AMD (242 nm) and B – ND CLB 
(254 nm) reconstituted with 50% POPS; t1/2 were A - 1.75 h ± 0.8 and B - 3.9 h ± 0.7   
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4.1.3 Assemblies reconstituted with 100% DLPC 
 The monodispersity and size distribution of ND 
The reconstitution mixtures of empty ND assembled with 100% DLPC followed 
the same protocol, although the analysis indicated a lack of reproducible results. 
The chromatograms of empty ND suggested assemblies were formed with 
increased polydispersity (Figure 4.6, A). This is shown by the fluctuating width 
of the ND peak and the presence of a second peak, which could be attributed 
to monomeric protein assembled into conglomerates with few phospholipids 
(apparent MW of 38 kDa). However, based on the low absorbance of the 
second peak, ND are the predominant assemblies formed. Similar observations 
were seen when the reconstitution was repeated. Nevertheless, the 
proportionality between ND peak and 38 kDa clusters was lessened. An overall 
deduction would be that the MSP to DLPC molar ratio used in the ND 
reconstitution led to the assembly of unstable ND. As a result of keeping the 
MSP to lipid molar ratio constant (1:65), it was expected DLPC would form 
smaller ND, with a diameter of 7.5 nm. 
The SEC chromatograms of amiodarone loaded ND showed that incorporating 
the amphiphilic molecules had an effect on stabilising the ND, decreasing its 
polydispersity (Figure 4.6, B). Regardless of the amount of amiodarone added, 
the chromatograms indicated a single, narrow peak, corresponding to ND, with 
apparent MW of around 150 kDa. However, when the reconstitution was 
repeated, reproducibility of monodisperse ND proved to be an issue. Here, a 
second, less prominent peak, characteristic for the void volume, was observed. 
One possibility could be that, upon addition of amiodarone, phospholipids are 
expelled from the bilayer system, to minimise the energy losses within the 
system. These phospholipids together with drug molecules anchored to their 
head groups, potentially assemble into vesicles, with substantially bigger sizes. 
In the case of chlorambucil, the analysis showed similar results as to the 
amiodarone loading (Figure 4.6, C). The formation of small sized aggregates 
decreased with the addition of chlorambucil, dependent on the number of 
molecules preloaded. The excess chlorambucil was eliminated as free drug 
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aggregates. Additionally, for drug loaded ND, the size of the assemblies 
remained the same as for empty ND (7.5 nm) (Figure 4.7). This is further 
supported by literature, where one group has demonstrated that the scaffold 
protein has an adjustable circumference dependent on variations in the number 
of phospholipids loaded.122, 126  
 
Figure 4.6 SEC chromatograms of empty ND, ND AMD and ND CLB reconstituted with 
100% DLPC, and the elution time of AD: A – empty ND (280 nm); B - ND AMD 
reconstituted by preloading 30 and 23 molecules of AMD (242 nm); C - ND CLB 
reconstituted by preloading 77 and 38 molecules of CLB (254 nm)  
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Figure 4.7 DLS of empty ND, ND AMD and ND CLB, reconstituted with 100% DLPC 
 
 Drug loading efficiency and release profile 
The release profile indicated that most chlorambucil molecules (6.4 ± 1.3 
molecules per ND) were released in 24 h, and an equilibrium between the 
concentrations of free and incorporated chlorambucil was achieved 
(Figure 4.8). Subsequently, no initial burst was observed after the fractional 
release was plotted. The calculated value for half-life of chlorambucil was 
10.2 h ± 3.3. Although, the release of drug molecules from ND system 
reconstituted with DLPC was analysed with the idea of being used in future for 
intravenous delivery of drugs, these DLPC ND assemblies could be used as 
aerosol delivery to the lungs. In literature, researchers have demonstrated the 
importance of DLPC liposomes for the aerosol delivery and slow release of 
various anticancer drugs, such as paclitaxel conjugates127 and camptothecin.128  
The rate of amiodarone release was not investigated, due to the poor 
incorporation results (1.9 ± 0.2 molecules per ND), given by HPLC (Figure 4.9). 
The low number of amiodarone incorporated within the shorter chain DLPC 
could be related to the higher MW of amiodarone, relative to chlorambucil. The 
high efficiency of incorporating small molecules within DLPC bilayers was also 
observed in literature studies.129 Although the number of amiodarone molecules 
incorporated per ND was very low, the previously presented SEC analysis 
demonstrated the positive impact amiodarone addition had on increasing the 
stability within the ND systems. 
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Figure 4.8 Fractional CLB release at 37 oC from ND CLB (254 nm) reconstituted with 
DLPC; t1/2 was 10.2 h ± 3.3 
 
Figure 4.9 HPLC chromatograms of A – ND AMD (242 nm) and B – ND CLB (254 nm), 
reconstituted, at 4 °C, with 100% DLPC; the inside chromatograms are of the same 
samples measured at 280 nm to identify the MSP retention time 
4.1.4 Assemblies reconstituted with 100% DPPC 
 The monodispersity and size distribution of ND 
The reconstitution mixture of empty ND assembled with 100% DPPC was 
incubated at 42 °C, above the phase transition temperature of DPPC. Similar 
conclusions, to drug loaded DLPC ND, were drawn for the ND assembled with 
DPPC. In the SEC chromatogram of empty ND, transitioned to gel phase 
(analysis at 4 °C), the narrowness of the main peak associated with ND 
suggested monodisperse and stable ND were assembled (Figure 4.10, A). In 
order to eliminate the smaller aggregates and have a single peak, the MSP to 
DPPC molar ratio would need changing. Optimisation studies found in literature 
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have revealed that the ideal molar ratio for the highest yield of monodisperse 
ND reconstituted was 1:90.130 The lower MSP to DPPC molar ratio, compared 
to literature ratio,80, 131 presumably, also led to the formation of empty ND and 
drug loaded ND with a small diameter (8.7 nm) (Figure 4.11). A less stable 
system was consequently created, due to the incomplete DPPC loading within 
the ND and the need of molecules to adapt to the thickness of the hydrophobic 
belt at the lipid-protein interface80. 
When amiodarone molecules were preloaded within ND, the reconstitution of 
monodisperse assemblies was difficult to reproduce. Additionally, when 
transitioned to gel phase, by cooling down to room temperature and below, the 
solution became turbid. This could be a sign of aggregation into micrometer-
sized clusters. The SEC chromatogram indicated that incorporating the 
amiodarone molecules had a two-way effect (Figure 4.10, B). The stability of 
these systems was reduced proportionally with transition to gel phase and the 
amount of amiodarone preloaded. The optimal addition of amiodarone was 
suggested at below 15 molecules, as the peak corresponding to ND, compared 
to those of large lipid-drug aggregates and membrane protein oligomers, was 
maximised at this quantity. A presumable explanation could be that, at high 
amiodarone addition, the discoidal/elliptical131 ND were entropically forced to 
disassemble, while the phospholipids and drug molecules were rearranged into 
structures with favourable energy. A general trend observed for the gel phase 
assemblies was that, in addition to the tight packing of DPPC tilted hydrocarbon 
chains,132 incorporating the drug molecules had a shrinking effect on the size of 
the final ND-drug - relative to empty ND. A reason for this shrinkage and the 
presumed overall poor incorporation of cationic amiodarone could be correlated 
with the hypothesis developed by Baciu et al.133 The study conducted by this 
research group found that, at physiological pH, the positively charged groups of 
cationic amphiphilic molecules create instability across the phospholipid bilayer 
by acting as a catalyst for the separation of phospholipid into a fatty acid and a 
single-chain lipid. The decrease in lipid loaded into ND, caused by subsequent 
phase separation of the single-chain lipids, possibly led to adjustments in the 
circumference of scaffold protein, as mentioned previously. Due to aggregation 
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problems with amiodarone loaded ND, their loading and release investigation 
was stopped. 
The chromatograms of chlorambucil loaded ND suggested that decreasing the 
number of molecules preloaded with ND proportionally decreased the height of 
the peak corresponding to free drug and the shoulder attached to the ND peak 
(Figure 4.10, C). The absorbance height of this peak of free drug clusters, 
lowered with preloading less drug molecules, demonstrated that a maximum 
loading per ND might have been achieved.  
 
Figure 4.10 SEC chromatograms of empty ND, ND AMD, ND CLB reconstituted with 
100% DPPC, and the elution time of AD: A – empty ND (280 nm); B - ND AMD 
reconstituted by preloading 25 and 13 molecules of AMD (242 nm); C - ND CLB 
reconstituted by preloading 149, 59 and 41 molecules of CLB (254 nm) 
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Figure 4.11 DLS of empty ND, ND AMD and ND CLB reconstituted with 100% DPPC 
 
 Drug loading efficiency and release profile 
The rate of chlorambucil released from DPPC ND (7 ± 3.8 molecules loaded 
per ND, Figure 4.13) indicated that, after 24 h, only 65% of the chlorambucil 
was release, into the buffer, from the loaded ND (Figure 4.12). Similar to the 
release from DLPC ND, no initial burst of chlorambucil release was observed. 
However, the improvement in chlorambucil incorporation might be associated 
with the longer chains of DPPC.134 Although, the oscillation of the number of 
molecules loaded per ND could be a sign of increased chain-chain interactions. 
In addition, the calculated value for t1/2 of chlorambucil was 16.1 h ± 1.5. This 
slow release profile of chlorambucil from DPPC ND is in good agreement with 
literature findings. Boakye et al. showed, in a recent study, that, the release of 
doxorubicin from DPPC liposomes was minimal for the first 8 h.135 In another 
study involving DPPC liposomes, Dyondi et al. observed a slow and sustained 
paclitaxel release over a time period of 60 h.136  
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Figure 4.12 Fractional CLB release at 37 oC from ND CLB (254 nm) reconstituted with 
DPPC; t1/2 was 16.1 h ± 1.5 
 
Figure 4.13 HPLC chromatograms of ND CLB (254 nm) reconstituted, at 42 °C, with 
100% DPPC; the inside chromatogram is of the same sample measured at 280 nm to 
identify the MSP retention time 
4.1.5 Assemblies reconstituted with POPC: DOPE PEG550 
 The monodispersity and size distribution of ND 
The reconstitution mixtures of ND assembled with 10% DOPE PEG550 followed 
the same protocol, and, as in the case of DLPC ND, the analysis revealed the 
inability to reproduce monodisperse empty ND. The lack of consistency in 
forming monodisperse ND could be justified by a potential instability at the acyl 
chains level, created by repulsive interactions between the saturated and 
unsaturated pair chains of POPC and DOPE PEG, respectively. Another 
possibility could be related to steric repulsions caused by the PEG groups. The 
SEC chromatograms of empty ND indicated a higher apparent MW (210 kDa), 
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compared to that of empty POPC ND, could be explained by the addition of 
PEGylated DOPE, which would enlarge the bilayer thickness (Figure 4.14, A). 
These results were in good agreement with the polydisperse size distribution 
observed via DLS (Figure 4.15). For the empty systems, three different species 
were seen, with diameter between 11 nm and 396 nm. The most prominent 
peak is of the assemblies with the smallest diameter, which coincides with 
empty ND assemblies. The addition of PEGylated DOPE caused an increase in 
the thickness of the ND bilayer; this could be associated with the larger diameter 
of the ND, compared with other lipid ND systems. 
The chromatograms of ND AMD showed that increasing the number of 
amiodarone preloaded within ND had a negative influence on the reconstitution 
of monodisperse assemblies (Figure 4.14, B), as previously seen with the 
POPC and POPS bilayer. The high preloading of amiodarone within the 
stabilised bilayer might lead to increased electrostatic repulsive forces, creating 
an energetically unfavourable packing of lipids and molecules. Lowering the 
number of molecules preloaded to ND would minimise the repulsion. Hence, 
below an addition of 20 molecules, the chromatogram revealed a single, narrow 
peak similar to the elution time specific to ND. However, the appearance of a 
shoulder in repeated reconstitution indicated a high preference in assembling 
heterogeneous structures, as seen in one empty ND chromatogram trace.  
The analysis of ND CLB showed that, regardless of the number of molecules 
preloaded with ND, changes in the size of the ND assemblies are hardly 
noticeable (Figure 4.14, C). However, variations in the absorbance height of the 
peaks representative to free drug clusters, were observed to be correlated with 
a negligible increase in the apparent MW of the ND CLB assemblies. This 
relationship between the enlarged MW and the small peak of free drug, could 
be associated with drug molecules incorporation within the ND. As more drug 
molecules interact with the phospholipid head groups, less free molecules are, 
in solution, to be eliminated as clusters. However, analysis by DLS has found 
that two species, with a diameter of 6.5 nm and 15.7 nm, were formed. The 
smaller systems were seen to be predominant in the DLS analysis leading to 
the conclusion that the ND CLB became polydisperse over time. 
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Figure 4.14 SEC chromatograms of empty ND, ND AMD, ND CLB reconstituted with 
10% DOPE PEG550, and the elution time of AD: A – empty ND (280 nm); B - ND AMD 
reconstituted by preloading 49, 32, 19 and 18 molecules of AMD (242 nm); C - ND CLB 
reconstituted by preloading 71 and 45 molecules of CLB (254 nm) 
 
Figure 4.15 DLS of empty ND, ND AMD and ND CLB reconstituted with 10% DOPE 
PEG550  
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 Drug loading efficiency and release profile 
Both amiodarone (2.9 ± 2 molecules per ND) and chlorambucil (5.6 ± 0.35 
molecules per ND) were released constantly, with no observable initial burst 
(Figure 4.16, A - for amiodarone release and B – for chlorambucil release). More 
so, the dissociation of each drug loaded within ND assemblies occurred with an 
apparent 60% release for amiodarone and 70% for chlorambucil. The half-life 
of amiodarone and chlorambucil were calculated to be 12.9 h ± 1.3 and 
15.1 h ± 2.6, respectively. The low level of release, observed within 24 h, was 
also reported in literature, where Chan et al. has highlighted, in his studies, the 
effect of steric interactions, at the PEGylated head group level, on decreasing 
the amount of Docetaxel released from hybrid nanoparticles.56 
However, the addition of PEGylated lipids did not majorly affect the 
incorporation of chlorambucil. This was observed from the noticeably constant 
number of chlorambucil molecules incorporated per ND, indicated by the low 
standard error calculated based on three separate measurements 
(Figure 4.17). This is in good agreement with the literature, where researchers 
have reported the low impact on drug partitioning, of stabilised liposomes and 
disks through incorporation of PEGylated lipids.121 In addition, the amount 
loaded per ND was slightly lower than for the ND reconstituted with 100% 
POPC, however within the error range. The higher number of chlorambucil 
loaded per ND – comparative to amiodarone – would imply that the drug 
molecules sit within the bilayer close to the water/membrane interface, 
interacting with the phospholipid head groups. As the majority of lipids used 
have long hydrocarbon chains, enhanced van der Waals interactions, at this 
level, would create the need for a greater force in order to enter the 
membrane.137 
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Figure 4.16 Fractional drug release at 37 oC for ND reconstituted with 10% DOPE 
PEG550: A – ND AMD (242 nm); B – ND CLB (254 nm); t1/2 were A - 12.9 h ± 1.3 and 
B - 15.1 h ± 2.6 
 
 
Figure 4.17 HPLC chromatograms of A – ND AMD (242 nm) and B – ND CLB (254 nm) 
reconstituted, at 4 °C, with 10% DOPE PEG550; the inside chromatograms are of the 
same samples measured at 280 nm to identify the MSP retention time 
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 Part II – Influence of bilayer composition on ND reconstitution  
In previous chapters we have demonstrated the influence of lipid composition 
on the reconstitution, and incorporation and release of hydrophobic drug 
molecules from ND. Although, both MSP to lipid ratio and drug incorporation 
were seen to have a notable influence on the stability of the assemblies.  
In this part, one investigation was conducted on the effect of adding a cationic 
lipid to ND, on the stability of the system. Cationic lipids were chosen due to 
their potential in formulating nucleic acids138. The second investigation was 
done on ND formulated by replacing the phospholipid domain with block co-
polymers. The use of amphiphilic polymers has many advantages including 
structural robustness and longer circulation time. 
4.2.1 Nanodiscs reconstituted with POPC: DOTAP 
The ND were reconstituted by adding a cationic amphiphile to zwitterionic 
phosphatidylcholine, in ratios of 1 to 2, 5 and 9. Upon inclusion of positively 
charged 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), without a 
phosphate group (Figure 4.18), its effect on packing of the POPC bilayer and 
the formation of monodisperse ND assemblies was investigated. Recent 
literature studies highlighted the impact DOTAP addition, to DOPE bilayers, has 
on enhancing the therapeutic potential for in vivo delivery of cytochrome C to 
H460 cell line, and the efficiency of in vitro transfection.85, 139, 140  
The SEC chromatogram of empty ND assembled with 9:1 POPC: DOTAP molar 
ratio showed a single, main peak, corresponding to an apparent MW of 56 kDa 
(Figure 4.19). Although, the homogeneity of the sample is demonstrated by the 
absence of other peaks, the extremely low MW of the assemblies suggested 
that no ND were formed. Most likely, this peak could be the result of protein 
dimerisation.  
When empty ND were reconstituted with a ratio of 5:1 POPC to DOTAP, the 
corresponding apparent MW was observed to be 135 kDa, similar to ND 
reconstituted with 100% POPC. A shoulder, of lower relative absorbance, was 
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also observed, attached to the ND peak. Nevertheless, the stability of 
assembled ND was enhanced at 5:1 POPC DOTAP molar ratio.  
On the SEC chromatogram of empty ND assembled with 2:1 POPC: DOTAP 
molar ratio, multiple peaks were observed, of species with apparent MW of 
201 kDa, 87 kDa, and 38 kDa, respectively. This polydispersity within the 
sample suggested that electrostatic attractions between POPC and DOTAP 
head groups, which alter the spatial arrangement of the mixture,141 are 
preventing the interactions between lipids and the protein belt, required to form 
the ND. During the reconstitution of ND, the addition of DOTAP in such high 
ratio, might have facilitated the formation of large aggregates or the fusion of 
ND assemblies. Our findings are in good agreement with previous studies that 
have observed this aggregation phenomenon when DOTAP is added, up to 
30 mol%, to various PC bilayers.142, 143  
 
Figure 4.18 Structure of 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
(DOTAP); Transition Temp. <5°C  
 
Figure 4.19 SEC chromatograms of empty ND reconstituted with POPC to DOTAP 2:1, 
5:1 and 9:1, and the elution time of AD; all samples were measured at 280 nm; AD was 
eluted at 12.17 mL  
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4.2.2 Nanodiscs reconstituted with block co-polymers 
Going back to the origins of these self-assembled nanostructures, 
phospholipids were chosen to form the basic component because of their 
geometrical packing and the MSP affinity to bind to their hydrocarbon chains. 
From here, a question arose regarding the specificity of phospholipids for being 
the only amphiphilic nanostructures to assemble into stable and monodisperse 
ND. Therefore, we investigated the possibility of replacing phospholipids with a 
block co-polymer and analysed, by SEC, its efficiency in reconstituting stable 
ND. The block co-polymer chosen was poly(butadiene)-b-poly(ethylene oxide) 
(PB1200-b-PEO600). Block co-polymers are amphiphilic structures able to form 
vesicles in solution.144 The insoluble block, which forms the core of the vesicle, 
can entrap hydrophobic molecules145, 146 or act as a nanoreactor,147 protecting 
the cargo, while the soluble block acts as a protective corona, conferring 
stability to the system. Due to its low CMC,148 PB-b-PEO co-polymer is an 
attractive alternative in formulating nanocarriers for the delivery of hydrophobic 
drugs. Recent studies have demonstrated the ability of PB-b-PEO nanoparticles 
to act as carriers for the incorporation and delivery of small molecules such as 
paclitaxel149 or fluorescent and hydrophilic dyes.150, 151 
The ND were reconstituted following the method described in Chapter 3 as 
method B (Figure 4.20). The incubation temperature and time before adding 
bio-beads were varied to find the optimum conditions for the assembly of ND. 
PB-b-PEO was added in smaller quantities (from 1:15 to 1:30 molar ratios), 
compared to lipid ND, because the hydrophobic domain of this co-polymer is 
larger than that of lipid and therefore will require a thicker protein belt. 
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Figure 4.20 Schematic representation of the PB-b-PEO ND reconstitution process  
 
The analysis by SEC suggested that a combination of temperature and length 
of the incubation time before removing the detergent were necessary for the 
formation of ND (Figure 4.21). The chromatogram of ND assembled with 1:15 
MSP to co-polymer molar ratio and incubated at 55 °C for 2.5 h before removing 
the detergent, showed a high absorbance peak eluted in the void volume, and 
another peak, with an attached shoulder, corresponding to an apparent MW of 
46 kDa. The elution times of these peaks indicated that most co-polymer formed 
large vesicles with itself, whereas the MSP might have eluted as oligomeric 
structures. Similar observations were recorded when the incubation 
temperature was kept at 55 °C, but more PB-b-PEO was added to the mixture, 
and incubated for longer time before removing the detergent. When the 
temperature was decreased to room temperature and the amount of co-polymer 
increased again to 1:30 MSP to PB-b-PEO, the void volume peak was still 
present. However, the peak associated with oligomeric MSP disappeared. 
Instead, we observed a peak eluted at a similar time to alcohol dehydrogenase 
and POPC ND. When the temperature was decreased to 4 °C, the ND peak 
was almost inexistent compared to the void volume peak, suggesting that the 
co-polymer had preferably assembled into large vesicles. The height of this 
peak indicated that only a small quantity of co-polymer was assembled into ND, 
however it is a starting point in finding the optimum conditions to reconstitute 
PB-b-PEO and MSP ND.  
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Figure 4.21 SEC chromatograms of PB-b-PEO ND reconstituted with 1:15, 1:20 and 
1:30 molar ratio, incubated at temperatures between 4 °C and 55 °C; the length of time 
before removing the detergent was also varied, from 2.5 h to 5 h 
 Summary 
Using method B for preloading drug molecules, amiodarone and chlorambucil 
were incorporated into ND assembled with various lipid compositions. SEC 
analysis showed that DLPC, DPPC and POPC/DOPE PEG550 used in the 
reconstitution of amiodarone loaded ND had a shrinking effect on the size of the 
final systems. Whereas, for ND reconstituted with POPC/POPS, the 
incorporation of higher concentrations of amiodarone led to the formation of 
clusters with the lipid head groups, eventually, enlarging the ND surface 
(Table 4.2). Comparatively, changing the lipid composition within ND did not 
have a major effect on the formation of homogeneous assemblies with 
incorporated chlorambucil.  
The release profile of chlorambucil from ND with POPC/DOPE PEG550, DLPC 
and DPPC had a slow general trend, the exception being ND reconstituted with 
anionic POPS. This was probably due to electrostatic repulsions between the 
two negatively charged molecules. Additionally, similar slow release was 
observed for the dissociation of amiodarone from ND reconstituted with all the 
lipid mixtures. The combination of POPC and PEGylated lipid contributed the 
most to slowing the release of amiodarone, in such that the release did not 
achieve completion within 24 h. Whereas, for chlorambucil release, this effect 
was maximised when ND were reconstituted with DPPC composition.  
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Lipid 
composition 
Amiodarone Chlorambucil 
Drug 
molecules/ND 
t1/2 /h Drug 
molecules/ND 
t1/2 /h 
POPC 10 ± 6.8 5.4 ± 0.7 6.5 ± 1.7 5.8 ± 0.5 
50% POPS 1.9 ± 0.8 1.8 ± 0.8 8.5 ± 3.8 3.9 ± 0.7 
10%DOPEPEG 2.9 ± 2 12.9 ± 1.3 5.6 ± 0.4 15.1 ± 2.6 
DLPC 1.9 ± 0.2 nc 6.4 ± 1.3 10.2 ± 3.3 
DPPC nc nc 7 ± 3.8 16.1 ± 1.5 
Table 4.2 Table of number of amiodarone and chlorambucil incorporated per ND and 
their half-life for the ND reconstituted with different lipid compositions; nc – not 
calculated 
 
The efficiency of reconstituting stable and monodisperse ND was also 
investigated when cationic lipids were incorporated into the bilayer domain and 
when the phospholipids within the ND were replaced by PB-b-PEO. The 
analysis of ND formed with cationic DOTAP suggested that by increasing the 
concentration on DOTAP within the bilayer domain, the ND yield is considerably 
decreased. At the lowest addition of DOTAP, ND formation was absent, instead 
protein oligomers were presumably formed. In contrast, the highest addition of 
DOTAP, has promoted the formation of large aggregated vesicles. The 
appearance of a ND peak was observed only for the ND containing 20% 
DOTAP. However, the increased polydispersity suggested that further 
investigation is required to assess ND reconstituted with DOTAP and POPC. 
To find the optimum conditions for the assembly of ND, the incubation 
temperature and time before detergent removal, and the molar ratio between 
MSP and PB-b-PEO were varied. When the incubation temperature of the 
mixture was decreased to room temperature and the molar ratio was 1:30, the 
analysis revealed the formation of ND assemblies with a similar elution time to 
POPC ND. The small absorbance of the ND peak indicated that further 
investigation is required to determine the optimum conditions for the 
reconstitution of monodisperse PB-b-PEO ND.  
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5 Chapter 5 – Modified nanodiscs for traceable cellular delivery 
 Introduction 
The lipid ND systems have been particularly used in the characterisation of 
membrane proteins; however these self-assembled systems have potential to 
be used as carriers for drug delivery into cells. For example, recent studies have 
observed successful delivery of all-trans retinoic acid and curcumin to 
mammalian cells, from lipid nanodiscs formed with ApoA-I and ApoE.73, 152, 153 
The latter study indicated that an important role in drug uptake and nanodiscs 
dissociation or internalisation could be played by the cell line used. Here, ApoE 
was seen to be localised at the cell surface due to its strong affinity to bind to 
specific receptors found in the glioblastoma multiform cells used.  
Sortase A (SrtA) mediated ligation was used to site-specifically modify the 
scaffold protein, already incorporated in the ND, with fluorescein. Subsequently, 
their capabilities to enter and deliver chlorambucil to mammalian cells were 
tested.  
 Sortase A mediated modification of the MSP  
Prior to the SrtA mediated transpeptidation reaction, the POPC lipids were used 
to reconstitute the ND assemblies, as our previous investigation showed good 
results for chlorambucil incorporation and release from these ND. The empty 
and drug loaded ND assemblies were reconstituted as described in Chapter 3. 
Following the reconstitution of empty and drug loaded ND, the SrtA mediated 
ligation of the MSP within the ND was effected by modification of the protocol 
developed by Williamson et al.154, 155 In order for the MSP to be labelled via SrtA 
mediated ligation, the N-terminal glycine residue has to be accessible to the 
LPXTG recognition motif of the depsipeptide label156, 157 (Figure 8.19). To 
facilitate the purification process, MSP has a His6 attached on the N-terminus, 
however the MSP1D1 was engineered with a Tobacco Etch Virus (TEV) 
protease recognition site (ENLYFQG) incorporated between the His6 tag and 
the scaffold protein. This mean the His6 tag can be removed by specifically 
hydrolysing the amide bond between the QG amino acid residues,80 prior to 
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labelling. The full outline strategy is shown in Figure 5.1. TEV protease, SrtA 
and fluorescein-depsipeptide used in this study were provided by Dr Daniel 
Williamson from University of Leeds.  
 
Figure 5.1 SrtA mediated modification of MSP1D1 within ND; to expose the glycine 
residue on the N-terminus, first the His6 was removed by enzymatic cleavage; 
subsequently, SrtA was used to mediate the ligation of fluorescein-depsipeptide and 
MSP; on the figure, overnight is abbreviated o/n 
 
The reconstituted empty and chlorambucil loaded ND assemblies were 
incubated overnight at room temperature with TEV protease. We initially 
attempted to remove the His6 tag prior to ND formation, however the protein 
precipitated in solution due to the temperature required during incubation with 
TEV protease. The ND assemblies with the truncated MSP were separated from 
the cleavage mixture and non-truncated MSP via SEC. On the SEC analysis of 
ND CLB, a small difference in the elution time was observed between ND before 
and after HIS-tag removal (Figure 5.2). Further analysis of ND by MS showed 
a decrease in the MW of some MSP, from 24661 Da to 22043 Da, after the His6 
tag and TEV protease recognition site removal (Figure 5.3). Despite the longer 
incubation period and the temperature conditions, not all MSP had the His6 tag 
cleaved, as analysis by MS showed also the presence of protein with a MW of 
24661 Da. The truncation of MSP was also confirmed by SDS-PAGE analysis, 
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where the gel showed two bands, for empty ND and ND CLB, shifted down the 
gel from the position of the MSP with the His6 tag attached (Figure 5.4, Lane 1 
for MSP, Lane 2 and 4 for MSP after His6 tag removal, in empty ND and 
ND CLB, respectively). 
 
Figure 5.2 SEC chromatogram of ND CLB after His6 cleavage, showing a later elution 
time compared to ND CLB before the removal 
 
Figure 5.3 Screen shot of mass spectrum of the MSP within ND, after His6 cleavage 
(upper image), and simulation of the MSP without the His6 and TEV protease 
recognition sequence, based on the chemical formula calculated from the amino acid 
sequence of MSP158 (bottom image) 
 
After the His6 tag cleavage, the MSP incorporated in the ND assemblies was 
modified via SrtA mediated ligation, using fluorescein-depsipeptide for labelling 
(Figure 8.19, A). The ND were incubated overnight, at room temperature, with 
10 equivalents of fluorescein-depsipeptide and 20 mol% of SrtA (Figure 8.19, 
B). Because the SrtA transpeptidation reaction is reversible, to ensure a high 
protein modification yield, an excess of depsipeptide label and stoichiometric 
amounts of SrtA were added to the ND. The overnight incubation time was 
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another factor to ensure the protein labelling, as the low effective MSP 
concentration in solution kinetically limits the rate of the ligation.154  
Mass spectrometry and SDS-PAGE of the modified MSP in ND assemblies 
were, again, used to confirm labelling of ND. More so, the relative degree of 
fluorescent labelling was assessed by the SDS-PAGE analysis. On the gel a 
fluorescent MSP band was observed, indicating the successful labelling of the 
MSP with fluorescein, when in the ND formation (Figure 5.4, Lanes 7 and 8). In 
addition, when chlorambucil was preloaded within ND, a fluorescent MSP band 
was also observed. This suggests that drug loading does not affect the SrtA 
mediated ligation. Another fluorescent band was detected at a MW greater than 
that of fluorescein-MSP, probably corresponding to the auto labelled SrtA (has 
a N-terminal glycine), as the purification step was done after the SDS-PAGE 
analysis. Comparatively, the intensity of the fluorescent MSP band was weaker, 
however the SDS-PAGE gel showed both MSP unlabelled and fluorescein-MSP 
bands are barely visible, with only very little difference in their intensities. This 
could suggest that the majority of MSP was labelled with fluorescein via SrtA 
mediated ligation. The MW of fluorescein modified MSP was determined, via 
MS, to be 22959 Da, in good agreement with its theoretical MW calculated, 
22957 Da (Figure 5.5). 
The final step in labelling the MSP with fluorescein was removing the SrtA 
mixture and ND which were not cleaved by incubating overnight the fluorescein-
ND with Ni resin, as SrtA has a high affinity to bind to the Ni ions due to its N-
terminal His6 tag. The labelled ND were then separated from the resin by 
centrifugation. Further tests were selected to study the ability of the fluorescein-
ND and chlorambucil loaded fluorescein-ND to enter mammalian cells - Huh7159 
and HeLa cells.160 Subsequent to treating the cell lines with fluorescently 
labelled ND, confocal microscopy and MTT cytotoxicity assay were used to 
show if the MSP translocated into cells and the cytotoxic impact of ND CLB, 
respectively.  
113 
 Modified nanodiscs for traceable cellular delivery 
 
 
Figure 5.4 SDS-PAGE gel of: Lane 1: MSP; Lane 2: MSP in empty ND with His6 
removed; Lane 3: Fluorescein-MSP in empty ND; Lane 4: MSP in ND CLB with His6 
removed; Lane 5: Fluorescein-MSP in ND CLB; Lane 6: SrtA; Lane 7: UV irradiation of 
sample showed in Lane 3; Lane 8: UV irradiation of sample showed in Lane 5 
 
Figure 5.5 Screen shot of mass spectrum of the fluorescein-modified MSP within ND 
(upper image), and simulation of the modified MSP, based on the chemical formula 
calculated from the amino acid sequence of MSP158 and the formula for fluorescein-
depsipeptide (bottom image) 
 The transport of labelled nanodiscs into mammalian cells 
The fluorescein-ND assemblies were screened against Huh7 cells and HeLa 
cells; these cell lines are derived from human liver and cervical cancer tissues, 
respectively. The experimental procedures of screening against the cell lines 
were conducted by Darren Machin, from University of Leeds. Confocal 
fluorescence microscopy was performed, by myself with the guidance of Darren 
Machin, to investigate the uptake of empty fluorescein-ND and rhodamine-ND, 
and chlorambucil loaded fluorescein-ND.  
Huh7 cells were incubated with empty and chlorambucil preloaded fluorescein-
ND for 2 h and 24 h, before being chemically fixed. The level of background 
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fluorescence, showed in Figure 8.20, was obtained after exposure of the control 
Huh7 cells to the blue, green and red lasers; control cells refer to the Huh7 cells 
not treated with empty or chlorambucil loaded fluorescein-ND. In addition to the 
nucleus stain (DAPI) identified after excitation at 408 nm, lower intensity 
fluorescence was also detected with the green and red channels. This could be 
attributed to autofluorescence from the cells, as aldehyde based fixatives are 
known to induce fluorescence in cells, after reacting with tissue components.161 
The images taken using confocal fluorescence microscopy showed that very 
little or no amount of fluorescence, attributed to fluorescein-ND, was detected 
(Figure 5.6). However, in the image depicting the cells treated with chlorambucil 
loaded ND, changes in the structure of the nucleus, which could lead to 
disintegration of the nucleus and eventually apoptotic cell death, were identified 
(Figure 5.7). This observation suggested that chlorambucil has entered the 
cells, either subsequent or simultaneous to being separated from the ND 
assemblies. An evidence of fluorescein-MSP internalisation or binding on the 
cell surface could not be established, probably due to the concentration of ND 
in the cells being very low.  
 
Figure 5.6 Immunostained Huh7 cells incubated with fluorescein-ND assemblies, for 
2 h, at 37 °C; A – Merged image; B – green channel, excitation at 488 nm; C – Red 
channel, excitation at 555 nm  
  
A 
A 
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Figure 5.7 Immunostained Huh7 cells incubated with chlorambucil loaded fluorescein-
ND assemblies, for 24 h, at 37 °C; A – Merged image; B – green channel, excitation at 
488 nm; C – Red channel, excitation at 555 nm 
 
HeLa cells were, as well, incubated with empty fluorescein-ND and rhodamine-
ND, for 4 h and 24 h, before being chemically fixed, with 4% paraformaldehyde 
(PFA). After exposure of the control cells to the blue, green and red lasers, a 
high intensity background fluorescence was identified with the green channel 
(Figure 8.21). This, again, could be correlated with autofluorescence from the 
cells resulted after PFA fixation.  
When HeLa cells were incubated with empty fluorescein-ND, dots of higher 
intensity than the background autofluorescence were detected (Figure 5.8). 
This could be associated with internalisation of the fluorescent MSP into cells. 
This is in good agreement with a recent study that has demonstrated the 
preferential internalisation, by mammalian epithelial cells, of disc-shaped 
nanoparticles.162 However, further investigation with organelle-specific 
immunostaining assays is required to clarify the exact location of the 
fluorescein-MSP within the cell. A study was reported in literature, where ApoE 
was shown to bind to the surface of human glioblastoma cells prior to releasing 
drug molecules, rather than be internalised.153 Their findings along with our 
observations suggest that the cellular uptake is cell-line dependent. The 
analysis of HeLa cells incubated with empty rhodamine-ND by fluorescent 
A 
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microscopy showed no changes in the intensity of fluorescence (Figure 5.9). 
However, these findings might be related to very low rhodamine concentrations 
in the empty ND, rather than no internalisation of these ND within the cells. 
Another explanation could be related to the possible diffusion of rhodamine PE 
within the membrane of the cells. 
 
Figure 5.8 Immunostained HeLa cells incubated with empty fluorescein-ND 
assemblies, for 4 h, at 37 °C; A – Merged image; B – green channel, excitation at 
488 nm; C – Red channel, excitation at 555 nm 
 
Figure 5.9 Immunostained HeLa cells incubated with empty rhodamine-ND 
assemblies, for 4 h, at 37 °C; A – Merged image; B – green channel, excitation at 
488 nm; C – Red channel, excitation at 555 nm 
  
A 
A 
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The cytotoxicity of empty ND, chlorambucil loaded ND and free chlorambucil 
was determined on HeLa cells using a MTT assay ((3-(4, 5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay), as described 
in Chapter 7. The cells were treated for up to 24 h with the same concentration 
of empty ND, ND CLB and free drug, and the cell viability was determined after 
measuring the absorbance at 570 nm. Compared with untreated cells, the 
percentage of apoptotic cells was not affected by the addition of either empty 
ND, chlorambucil loaded ND or free drug (Figure 5.10). An explanation behind 
this could probably be related to a very low concentration of chlorambucil in the 
media. In literature, Singh et al. has reported that chlorambucil only at 
concentrations above 0.1 µg/mL could induce cellular death in breast cancer 
cells.163 More so, the reported IC50 of free chlorambucil in HeLa cells is 
10 µM.164 Comparatively, the concentration of chlorambucil in the ND 
assemblies and as a free drug added to the cells was around 0.05 µg/mL. For 
the ND-drug assemblies and free drug to have a better influence on the viability 
of the cells, the concentration of chlorambucil added has to be increased, by 
increasing the concentration of assemblies with which the cells are treated.  
 
Figure 5.10 MTT cytotoxicity assay of ND, ND CLB and free CLB on HeLa cells; CLB 
concentration was around 0.05 µg/mL 
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 Summary 
Using the SrtA mediated transpeptidation reaction, MSP was chemically 
modified with fluorescein. Prior to the SrtA mediated ligation, the POPC lipids 
were used to reconstitute ND assemblies, and the His6 tag on the N-terminus of 
MSP was cleaved. After cleavage, the glycine residue required for labelling was 
revealed. This approach allowed the modification of MSP, with a fluorescent 
label, while interacting with the phospholipids within the ND. SDS-PAGE and 
MS analysis were used to identify the fluorescein modified protein within the 
ND, which had a MW or 22959 Da.  
Studies on Huh7 and HeLa cells treated with empty ND and ND CLB were 
performed to investigate if the MSP was internalised by the cells. The results 
showed good internalisation of MSP (incorporated into empty ND) by HeLa 
cells, but little internalisation by Huh7 cells (for empty or drug loaded ND), and 
no cytotoxic activity of chlorambucil. This suggest that the cellular uptake is cell-
line dependent. The lack of cytotoxic activity is probably a consequence of low 
concentration of ND CLB, with which the cells were treated. Further 
investigation is required to determine the exact location of fluorescein-MSP 
within the mammalian cells and the effect of higher concentrations of ND CLB 
on cell viability.  
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6 Chapter 6 – Conclusions and future work 
After the initial optimisation of protein expression and purification which led to 
stabilising the protein in a solution of detergent, the ND reconstitution was 
simplified. This one-step formulation has been adapted for the reconstitution of 
ND assemblies, by using pure MSP stabilised in Na cholate micelles. The 
influence of MSP aggregation on the reconstitution and MW of the ND has also 
been demonstrated with a combination of SEC and DLS analysis.  
 Development of drug loaded ND systems 
6.1.1 Changes in cargo composition 
Conclusions 
A new strategy has been developed to generate the optimum conditions for 
incorporation and release of poorly water soluble drugs from ND. This was 
achieved by investigating two strategies for loading twelve hydrophobic drugs. 
The drugs were added either passively, under overnight shaking conditions, to 
a solution of ND (postloading), or by loading the drug during the reconstitution 
of ND (preloading). The analysis of drug loaded ND, by SEC and DLS, has 
demonstrated a minimum impact on the MW and size of the assemblies, with 
drug molecules preloaded to ND. The amount of hydrophobic molecules loaded 
into ND was accurately determined with the help of an optimised method of 
characterisation, using HPLC. When drug molecules were preincorporated into 
the phospholipid domain of ND reconstituted with the optimised method, an 
increase in drug incorporated per ND and a slower release rate was observed. 
The efficiency of drug loading within the POPC bilayer was additionally, 
correlated with a decrease in membrane thickness. It is reasonable to assume 
that this approach of optimised reconstitution and drug preload is the optimum 
option for maximising the efficiency of drug incorporation and increasing the 
half-life of the transported drug.  
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Future work 
ND have proven to be a versatile platform for incorporating small hydrophobic 
molecules. If two or more drug molecules would be incorporated into ND, the 
possibility of using this multiple drugs nanocarrier for combination therapies 
would increase. If successful, these multi-drug loaded ND could potentially be 
designed and developed as an optimised treatment for each patient, for clinical 
applications.  
6.1.2 Changes in bilayer domain 
Conclusions 
Using the optimised preloading methodology, the influence of lipid composition 
within ND on the formation of stable monodisperse drug loaded ND, on the drug 
loading capacity and release kinetics of two drugs was observed via analysis 
on SEC, DLS, HPLC and UV spectroscopy. The formation of homogeneous ND 
assemblies with loaded chlorambucil was insignificantly affected by changes in 
lipid composition. More so, improvements in the amount of chlorambucil loaded 
were observed. Comparatively, the analysis of amiodarone loaded ND by SEC 
has reported that DLPC, DPPC and POPC/DOPE PEG550 compositions had a 
shrinking effect on the size of the final ND systems. The addition of a negatively 
charged lipid has intensified the dependence between reconstituting stable 
monodisperse amiodarone loaded ND and the concentration of amiodarone 
incorporated –high amiodarone concentration led to the formation of large 
clusters. Additionally, the number of amiodarone incorporated per ND has 
significantly decreased when POPC domain within ND was changed. 
Comparative with release from POPC ND, ND with DOPE PEG550, DLPC and 
DPPC improved the rate of drug release, leading to a slower general trend. The 
exception was drug dissociation from ND reconstituted with negatively charged 
POPS. The combination of POPC and PEGylated lipids contributed the most to 
slowing the release of amiodarone, in such that the release did not achieve 
completion within 24 h. For the release profile of chlorambucil, this effect was 
maximised when ND were reconstituted with DPPC. 
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Future work 
If liposomes – which mimic the cell membrane – were added to the release 
media, when investigating the release kinetics, the rate of drug release may be 
affected. The drug release may have a more rapid trend due to the presence of 
a system into which the drug could be absorbed. More so, plasma could 
potentially replace the release media. This would lead to investigations into the 
influence of interactions between ND surface and blood components on the 
drug release kinetics.  
The drug loaded ND systems have been developed for future use in delivering 
therapeutics to tumour cells by passive targeting, via the enhanced permeability 
and retention (EPR) effect. However, certain limitations, such as poor drug 
penetration into pancreatic tumour,165 have stimulated the development of 
nanocarriers with an active targeting vector attached to the surface, to help 
improve drug delivery. This targeting ligand will have a high selectivity to bind 
to a specific receptor on the target cell. There are several ligands that could be 
used to improve the targeting to cells, and range from small molecules like folic 
acid,42 to macromolecules like antibodies.166  
Additional changes to the bilayer domain of the ND could be made by replacing 
the phospholipids with block co-polymers. Due to their low CMC,42 structural 
robustness and long circulating time, amphiphilic co-polymers are an attractive 
alternative in formulating nanodiscs for the incorporation and release of 
hydrophobic drugs. After initial investigation, assemblies with PB-b-PEO co-
polymer were observed to have formed with a similar apparent MW as lipid-ND. 
However, only a small quantity of co-polymer may have assembled into ND. To 
find the optimum conditions for the reconstitution of monodisperse PB-b-PEO 
ND, several reconstitution parameter could be altered, such as temperature or 
increasing the incubation time needed for the removal of detergent. Additionally, 
a different co-polymer could be used. 
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 Traceable delivery and release of drug 
Conclusions 
The site-specific modification of scaffold protein has been achieved with the use 
of SrtA mediated ligation reaction, to allow the label of ND with fluorescein, for 
in vitro imaging. Prior to the SrtA mediated ligation, the His6 tag on the N-
terminus of MSP was cleaved. The SrtA mediated modification approach has 
allowed the labelling of MSP, with a fluorescent probe, while interacting with the 
phospholipids within the ND. When mammalian cells were treated with empty 
and chlorambucil loaded ND good internalisation of MSP by HeLa cells, but little 
internalisation by Huh7 cells were observed. Chlorambucil showed no cytotoxic 
activity, presumably as a consequence of low concentration of chlorambucil 
loaded ND, with which the cells were treated. A new and robust one-step 
strategy has been developed for reconstituting and loading hydrophobic small 
molecules into ND systems. With this as a starting platform, several research 
routes could be investigated.  
Future work 
A strategy to optimise the labelling of scaffold protein at N-terminus need to be 
developed as preliminary investigation might have showed that the reaction 
started sooner than 8 h. However, no strong conclusions could be drawn. To 
improve the efficiency of the ligation reaction several parameters could be 
changed. These include reconstitution of ND with a higher concentration and 
finding a balance between the optimum time and temperature. This will promote 
the highest yield of labelled protein, in ND formation or free in solution. Finding 
the optimum balance at a low temperature should improve the imaging of 
fluorescein-MSP, as well as the efficiency of the ligation reaction. 
Although we have demonstrated good internalisation of empty and chlorambucil 
loaded ND by HeLa cells, further experiments with organelle-specific 
immunostaining would elucidate the intracellular pathway of the ND. Native HDL 
is thought to be disintegrated after endocytosis, its apolipoproteins transported 
to early and late endosomes and finally degraded in lysosomes.167 Therefore, 
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is important to identify the organelles involved in the transport and the exact 
location of fluorescein MSP within the mammalian cells.  
The ability of drug loaded ND to induce cellular death needs to be assed further, 
as preliminary investigation has shown that low concentrations of chlorambucil 
in loaded ND has prevented chlorambucil to have an apoptotic effect on the 
cells. Increasing the concentration of assemblies with which the cells are treated 
would lead to higher concentrations of chlorambucil and therefore influence the 
cell viability.  
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7 Chapter 7 – Experimental materials and methods  
 Instrumentation and materials 
Sterilisation of media, buffers and appropriate equipment was achieved using 
either a Prestige Medical bench top autoclave or a LTE Touchclave-R 
autoclave. Bacterial culture was grown using a Stuart Scientific shaker 
incubator. Cell disruption was performed by using TS series cell disruptor 
(Constant Systems Ltd, UK). Centrifugation was performed using Avanti J-26 
XP (Beckman) Centrifuge.  
Purification of MSP1D1 was achieved via a Ni-NTA column. SDS-PAGE 
electrophoresis was performed using a BioRad mini protean 3 apparatus. BIO 
RAD molecular imager® Gel Doc™ was employed to visualise the 
polyacrylamide gel using a combination of UV and white light. Mass 
spectroscopy analysis of ND without His6 tag and fluorescein-ND was done 
using a Bruker MicrOTOF accurate MS system.  
Drying the lipid film was performed under vacuum using the Edwards pump 
(model RV3). Nutating Mixer (VWR International) was used as a shaker during 
ND preparations. Maxi GeBAflex-tube Dialysis kit (MWCO 3.5kDa) (Gene Bio-
Application Ltd) was used for the dialysis of ND samples. Bio-Beads® SM-2 
Adsorbent (Bio-Rad Laboratories Inc.) was used for the removal of detergent. 
Size-exclusion chromatography experiments were carried out with Superdex 
200 10/300 Chromatographic Separation Columns and run using ÄKTApurifier™ 
system (GE Healthcare). Thermo scientific NanoDrop 2000 and the Perkin-
Elmer UV-vis spectrophotometer with the Lambda 900 software were used to 
measure the MSP1D1 and drugs absorbance, and to run Total Phosphorus 
Assays, respectively. DLS measurements were performed using Zetasizer 
Nano (Malvern) particle size analyser with Zetasizer software. The collected 
data from DLS and SEC was exported with Microsoft Excel software and 
analysed with OriginPro software. Circular dichroism spectroscopy of MSP1D1, 
empty and drug loaded ND was performed by Mr. Nasir Khan on an APP 
Chriscan CD spectropolarimeter. Reverse phase HPLC analysis was performed 
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on Agilent 1290 series HPLC system. SAXS experiments were conducted by 
Dr Amin Dilmaghani with SAXSpace camera (Anton Paar, Graz, Austria) 
connected to an analytical X-ray generating equipment (ISO-
DEBYEFLEX3003, GE Inspection Technologies GmbH).  
The phospholipids were obtained from Avanti Polar Lipids Inc. Analytical grade 
reagents were purchased from Sigma-Aldrich and Fisher Scientific. Plasmid 
MSP1D1 was purchased from AddGene.  
Mammalian cell culture manipulations were performed by Darren Machin inside 
a Thermo Scientific MSC-Advantage Class II Biological Safety Cabinet. A 
Sanyo CO2 cell incubator was used to grow the cells. Fluorescence microscopy 
analysis of mammalian cell culture slides was performed using a Zeiss LSM510 
META upright confocal microscope, coupled with ZEN imaging software. 
Wavelengths at 408 nm, 488 nm and 555 nm were used to excite the DAPI, 
fluorescein fluorophores and rhodamine.  
  Buffer solutions and media 
All solutions were made up to 1 L, with 18.2 MΩ purified water unless stated 
otherwise. The pH of solutions was adjusted using 6 M NaOH and/or 4 M HCl. 
7.2.1 Bacterial growth media 
Lysogeny broth media (LB): Tryptone (10 g), 172 mM NaCl and yeast extract 
(5 g). The solution was autoclaved at 121 °C for 20 min.  
Terrific Broth media (TB): tryptone (12 g), yeast extract (24 g) and glycerol 
(4 mL). After autoclaving at 121 °C, TB media was left to cool, and filter sterilised 
KH2PO4 and K2HPO4 solutions were added to a final concentration of 17 mM 
and 72 mM, respectively. 
Auto Induction media (AIM): Tryptone (10 g), yeast extract (5 g), MgCl2 (2 mM), 
1000 x Metals (200 µl), 50 x Salts (20 mL), 50 % (v/v) glycerol. After autoclaving 
at 121 °C, 50 % (w/v) glucose and 50 % (w/v) lactose were added. 
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50 x Salts: 1.25 mM Na2HPO4, 1.25 mM KH2PO4, 2.5 mM NH4Cl and 250 mM 
NaSO4. 
1000 x Metals stock (100 mL): 50 mM FeCl3•6H2O, 20 mM CaCl2•6H2O, 
100 mM MnCl2•4H2O, 100 mM ZnSO4•7H2O, 1.7 mM CoCl2•6H2O, 2 mM 
CuCl2•2H2O, 4.1 mM Na2MoO4•2H2O, 2 mM Na2SeO3, 2 mM H3BO3, 2 mM 
NiCl2•6H2O, 2 mM NiSO4•6H2O and HCl (5 mL/L). 
7.2.2 Protein purification buffers 
Phosphate buffer saline (PBS): 20 mM NaH2PO4 titrated to pH 7.4 
Lysis buffer (50 mL): 20 mM PBS pH 7.4. After resuspending the cells, 10% 
Triton X-100 was added to make 1% 
Wash buffers:  
Tris buffer I: 40 mM Tris, 0.3 M NaCl, 1% Triton X-100, pH 8  
Tris buffer II: 40 mM Tris, 0.3 M NaCl, 50 mM Na-Cholate, 20 mM Imidazole, 
pH 8 
Tris buffer III: 40 mM Tris, 0.3 M NaCl, 50 mM Imidazole, pH 8 
Elute buffer: 40 mM Tris, 0.3 M NaCl, 0.4 M Imidazole, 40 mM Na cholate, pH 
8  
7.2.3 Buffers for SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE loading buffer (pH 6.8): 50 mM Tris HCl, 100 mM DTT, 2% (w/v) 
sodium dodecyl sulphate (SDS), 10% (v/v) glycerol, 0.1% (v/v) bromophenol 
blue and complete to volume with water 
5x SDS-PAGE running buffer: 125 mM Tris base, 960 mM glycine, 0.5% (w/v) 
SDS  
7.2.4 ND and ND-drug assembly buffer 
Method A: 20 mM Tris pH 7.4, 0.1 M NaCl  
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Method B: 40 mM Tris pH 8, 0.3 M NaCl  
7.2.5 SEC chromatography and release studies buffer 
20 mM Tris pH 7.4, 0.1 M NaCl  
 Methods 
7.3.1 Purification of DNA 
DNA was purified using QIAprep Spin Miniprep Kit (QIAGEN). A pipette tip of 
cells from the glycerol stock was resuspended in P1 buffer (250 µL). To lyse the 
cells, P2 buffer (250 µL) was added and gently mixed 4-5 times, causing the 
solution to go blue. N3 buffer (350 µL) was added and immediately mixed gently 
4-5 times. The white precipitate formed was discarded by centrifugation (17000 
rcf, for 10 min) and the supernatant was applied to a QIAprep spin column 
before further centrifugation at 17000 rcf, for 1 min. The column was washed 
first with PB buffer (500 µL) followed by PE buffer (750 µL) and the supernatant 
removed after each wash by centrifugation at 17000 rcf, for 1 min. The column 
was centrifuged again at 17000 rcf, for 1 min to separate any residual buffer. 
Sterile H2O (50 µL) was applied to the centre of the column, left at room 
temperature for 1 min before the column was centrifuged at 17000 rcf, for 1 min 
to elute the purified DNA which was then submitted for sequencing to GATC 
Biotech. The results were analysed using BioEdit sequence alignment editor 
ClustalW. 
7.3.2 Protein overexpression, purification and analysis 
The cell preparation was conducted under sterile conditions. 2 µL of plasmid 
pMSP1D1 was added to 50 µL of competent E. coli BL21 Gold (DE3), incubated 
on ice for 30 min and heat-shocked at 42 °C for 45 s before returning on ice for 
a further 5 min. 200 µL of LB media was inoculated with the cell/plasmid mixture 
and incubated at 37 °C, with shaking at 200 rpm, for 1 h. 200 µL of transformed 
cells were platted on Agar plates containing kanamycin (50 µg/mL) and 
incubated overnight at 37 °C, with shaking at 200 rpm. 
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A single colony of E. coli BL21 Gold (DE3) cells harbouring the pMSP1D1 was 
used to inoculate LB media (10 mL, 50 µg/mL kanamycin). The starter culture 
was incubated overnight at 37 °C before adding it to TB or AIM media (1 L, 
50 µg/mL kanamycin). For TB media – the culture was grown at 37 °C and 
induced with 1 mM IPTG (isopropylthio-β-galactoside) when the optical density 
(OD600) reached 2.5. One hour after induction, the temperature was lowered to 
28 °C. Four hour after induction, the cells were harvested. For AIM media - the 
culture was grown at 20 °C for 24 h before harvesting. The cells were isolated 
by centrifugation (10000 rpm, 10 min), the supernatant discarded and the 
bacterial pellet stored at -80 °C. 
 Protein purification 
The frozen cell pellet was resuspended in lysis buffer (50 mL) and left on ice for 
30 min. The suspension was mechanically disrupted using a Constant Systems 
Cell disruptor (35 kpsi, 4 °C), the lysate cleared by centrifugation (48000×g, 20 
min), the pellet discarded and the supernatant passed down on a Ni-NTA 
column (Qiagen, at rt or 4 °C) pre-equilibrated with PBS buffer. The column was 
washed sequentially with Tris buffer I, II and III (3×CV each), before the protein 
was eluted with elution buffer (1×CV). Protein-containing fractions and their 
purity were identified by SDS-PAGE. The protein was dialysed against 40 mM 
Tris, 0.3 M NaCl, 40 mM Na cholate, pH 8 before measuring its concentration 
by UV spectroscopy at 280 nm, using a theoretical extinction coefficient of 
21430 M-1 cm-1. 
  Protein analysis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE was performed using BioRad tetragel apparatus (1 mm plates). A 
resolving gel of appropriate percentage was prepared using the materials listed 
in Table 7.1, with the addition of TEMED immediately prior to pouring the gel. 
The resolving gel was poured to approximately ¾ the height of the plate and 
saturated butanol (0.5 mL) added to the surface. Once the resolving gel has 
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set, the butanol was removed by washing with water and a stacking gel (5%) 
was prepared using the materials in Table 7.1. TEMED was added immediately 
prior to applying the gel to the top of the resolving gel. A comb with a suitable 
number of lanes was inserted into the stacking gel and left to set.  
 
Components 
Resolving gel 
Volume/mL 
12% 
Stacking gel 
Volume/mL 
5% 
H2O 3.2 2.45 
30% acrylamide/bisacrylamide mix 4 0.67 
1.5 M Tris, pH 8.8 2.5 na 
1.5 M Tris, pH 6.8 na 0.75 
10 % Sodium dodecyl persulfate (SDS) 0.1 0.04 
15% (w/v) Ammonium persulphate (APS) 0.1 0.04 
Tetramethylethylenediamine(TEMED) 0.005 0.005 
Table 7.1 Components and quantities for SDS-PAGE resolving and stacking gels; na 
– not applicable  
Once the gel has set, it was put inside an electrophoresis tank, an optimum 
volume of SDS running buffer was added and the comb was removed. Samples 
of MSP1D1, ND and fluorescein-ND (10 µL) were mixed with an equal volume 
of loading buffer and heated at 95 °C for 5 min. The samples were loaded into 
different lanes of the gel using a syringe, along with Invitrogen Mark 12 standard 
protein marker (5 µL). Electrophoresis was performed at a limiting power of 200 
V until the samples were seen to reach the bottom of the gel. The gel was 
imaged directly by staining with Instant Blue stain. The gels were imaged using 
EPI-white illumination in the BIO RAD Molecular Imager® Gel Doc™. The gel 
containing fluorescently labelled MSP1D1 was imaged prior to staining. 
Protein concentrations 
The absorbance was measured at 280 nm to determine the concentration of 
MSP1D1. The concentration of protein was calculated with Beer-Lambert Law: 
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𝐴 =  𝜀 × 𝑐 × 𝑙 
Equation 7.1 Beer-Lambert Law; 𝐴 = absorbance, 𝜀 = molar extinction coefficient (mol-
1cm-1), 𝑐 = concentration (mol) and 𝑙 = path length (cm). 
7.3.3 The reconstitution of nanodisc assemblies  
 Phospholipid concentrations  
Assay of Total Phosphorus was used to determine the lipid composition - one 
phosphorus atom corresponds to one phospholipid. In this analysis the 
inorganic phosphate is digested from organic sample to phospho-molybdic acid 
by the addition of ammonium molybdate. During heating at 100 °C, the colour 
of the reduced complex turns blue and gives the complex an absorbance at 
820 nm, which facilitates the calculation of phosphorus concentration. The 
assay was done before every ND preparation, as the lipid is stored in chloroform 
that evaporates over time even at -20 °C, leading to a change in lipid 
concentration. 
Lipid/ND samples were placed into the bottom of each tube. Into extra six 
separate tubes the following quantities of phosphorus standard solution were 
placed: 0 µmoles, 0.0325 µmoles, 0.065 µmoles, 0.114 µmoles, 0.163 µmoles, 
and 0.228 µmoles. The phosphorus standard solution at different 
concentrations was used to generate a calibration curve. Subsequently, 
0.45 mL 8.9 N H2SO4 was added to each tube, before being heated at 200 - 
215 °C for 25 min. The tubes were cooled for 5 min before 150 µL H2O2 was 
added. Heating was continued for an additional 30 min, before cooling the tubes 
to room temperature. To the cooled solutions, deionized water (3.9 mL), 2.5% 
ammonium molybdate (VI) tetrahydrate solution (0.5 mL) and 10% ascorbic acid 
solution (0.5 mL) were added to all tubes, then vortexed and heated at 100 °C 
for 7 min. 
The absorbance of each standard calibrant was plotted against its number of 
moles. A linear function was fitted to the resulting calibration curve and the 
concentration of phosphorus in each sample was calculated (Figure 7.1). The 
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lipid concentrations calculated using the equation generated by the calibrants 
were found to be between 26 mM and 31 mM. 
 
Figure 7.1 Calibration curve for determining the total phosphorus in the phospholipid 
samples generated using the phosphorus standard solution at different concentrations 
 Method A of reconstitution 
An appropriate volume of lipid dissolved in chloroform (concentration calculated 
with phosphorus assay) was dried to a thin film under vacuum. The prepared 
lipid was then dispersed in a solution of Na cholate in ND buffer (1:1.54 and 1:2 
POPC to Na cholate molar ratio), to form micelles, at room temperature, by 
gentle vortexing and sonication. The detergent was added at a concentration of 
50 mM so that its final concentration would be around the critical micelle 
concentration. Following this, an appropriate volume of MSP1D1 (1:65 and 1:50 
MSP to lipid molar ratio) in elution buffer was added. The solution was incubated 
with gentle shaking for 90 min, close to the transition temperature of the lipid 
(4 °C for POPC, 50% POPS, DLPC, 10% DOPEPEG, and 42 °C for DPPC). An 
appropriate amount of wet bio-beads (0.3 g per mL of ND), previously washed 
with 2 volumes of methanol and 4 volumes of ND buffer, were added. The 
mixture was incubated for 5-6 h, close to the transition temperature of the lipid. 
The bio-beads were then separated by careful pipetting.  
 Method B of reconstitution 
An appropriate volume of lipid dissolved in chloroform (concentration calculated 
with phosphorus assay) was dried to a thin film under vacuum. The prepared 
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lipid was then incubated with a solution of MSP stabilised in Na cholate micelles 
(MSP in elution buffer) (1:65:100 and 1:50:100 MSP to lipid to Na cholate molar 
ratio), by gentle shaking for 2.5 h, close to the transition temperature of the lipid. 
From here, the reconstitution followed method A. Briefly, an appropriate amount 
of wet bio-beads (0.3 g per mL of ND) were added and the mixture and 
incubated for 4 to 5 h, close to the transition temperature of the lipid. The bio-
beads were then separated. 
The size and monodispersity of the reconstituted ND were verified by analysis 
via size exclusion chromatography and dynamic light scattering.  
7.3.4 The reconstitution of ND with block co-polymers  
The ND were formulated following method B of reconstitution. The molar ratios 
of MSP to polymer used were 1:15, 1:20 and 1:30. The incubation temperature 
and time before adding bio-beads were varied to find the optimum conditions 
for the assembly of ND. The conditions used were as followed: 1:15 MSP to 
polymer, mixtures incubated at 55 °C for 2.5 h before adding the bio-beads; 
1:20 MSP to polymer, mixtures incubated at 55 °C for 2.5, 4 or 5 h before adding 
the bio-beads; 1:30 MSP to polymer, mixtures incubated at 4 °C or room 
temperature for 2.5  h before adding the bio-beads. Subsequently, for all 
mixtures, the bio-beads were separated after 5 h.  
7.3.5 The reconstitution of drug loaded ND  
For each drug incorporation method the ND were formed following both 
methods of reconstitution. 
 Method 1 – postloading 
Firstly, empty ND were reconstituted using the above methods. To the solution 
of empty ND, an appropriate amount of drug (in powder form) was added. The 
mixture was incubated overnight with gentle shaking, close to the transition 
temperature of the lipid. The unincorporated drug was separated by size 
exclusion chromatography.  
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 Method 2 – preloading 
An appropriate volume of drug and lipid were dissolved in chloroform 
(concentration of lipid calculated with phosphorus assay) and dried to a thin film 
under vacuum. The prepared lipid and drug were then incubated with a solution 
of 50 mM Na cholate or with a solution of MSP stabilised in Na cholate micelles 
(MSP in elution buffer) (1:65:100 and 1:50:100 MSP to lipid to Na cholate molar 
ratio). Subsequently, the preloading of drug followed method A or method B of 
ND reconstitution.  
The size, monodispersity, loading efficiency and rate of drug release of the 
reconstituted drug loaded ND were verified by analysis via size exclusion 
chromatography, dynamic light scattering, HPLC and UV spectroscopy. 
7.3.6 Analysis of MSP1D1 and of empty and drug loaded ND 
 Analysis by mass spectrometry  
Samples were diluted to 50% (v/v) with H2O before being loaded directly into 
the instrument. Prior to MS analysis, the samples were automatically diluted 
with 0.1% TFA 50%, MeCN (v/v) in H2O. Processing and deconvolution of 
multiple charge states was performed using BioPharma Compass 1.1 Software. 
 Analysis by circular dichroism 
CD spectroscopy was used to observe how the secondary structure of the 
scaffold protein changes when interacting with the lipid domain of the ND and 
with the drug molecules incorporated. The secondary structure is determined 
by measurements in the far-UV region (190 - 250 nm). In this region, the signal 
appears when the peptide bond is located in a regular, folded environment. 
Three different conformations, α-helix, β-sheet and random coil structures, 
generate a characteristic shape and magnitude of CD specta (Figure 7.2). 
Samples of MSP, ND and ND-drug suspended in elution buffer were measured 
on CD spectropolarimeter. For measurements in the far-UV (190-260 nm) the 
CD signal is recorded in a 1 mm path-length cell using a sample with 
concentration of around 20 µM. 
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Figure 7.2 CD spectra of poly-L-lysine in α-helix, β-sheet and random coil 
conformations168 
 Analysis of size and monodispersity by size exclusion 
chromatography 
Size-exclusion chromatography can be used to separate components based on 
their molecular size and shape by using a bed of porous particles. These solid 
phase beads contain spaces of different sizes that will control the elution path 
of the analysed sample. Molecules smaller than the pore size enter the porous 
particles and have a longer path and retention time than larger molecules that 
can only enter the gel bed but not the pore bed. The size and shape of the 
analysed molecules is proportional with the fraction of pores the molecules can 
enter. Hence, the molecules will have an average resistance time in the 
pores.169 However, only molecules with masses between the higher and lower 
pore size can be separated. Samples that surpass these margins will not be 
separated and therefore cannot be analysed by SEC. 
Samples of MSP1D1 (in elution buffer), ND and drug-loaded ND (250 µL) were 
applied to a Superdex 200 10/300 Chromatographic Separation Column (GE 
Healthcare), previously equilibrated with filtered 20 mM Tris pH 7.4, 0.1 M NaCl 
(1×CV), using the ÄKTA purifier™ system. The analysis was run at 280 nm and 
the absorbance wavelength characteristic for every drug molecule (Table 7.2). 
The samples were eluted in 20 mM Tris buffer, 0.1 M NaCl, at a flow rate of 0.5 
mL/min. Fractions were collected at 0.25 mL. All fractions containing MSP1D1, 
ND or ND-drug were identified using UV-vis spectroscopy (absorbance 
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measured at 280 nm). The identified MSP1D1, ND and ND-drug samples were 
stored at 4 °C. Data collected was exported with Microsoft Excel and plotted 
with Origin Pro.  
Drug molecule UV absorbance used 
in the SEC analysis 
Amiodarone (AMD) 242 nm 
Chloroquine (CLQ) 343 nm 
Chlorambucil (CLB) 254 nm 
Thioridazine (TRD) 262 nm 
Oxymethazoline (OXM) 315 nm 
Novobiocin (NVB) 324 nm 
Tamoxifen (TMX) 277 nm 
Camptothecin (CPT) 218 nm 
Indomethacin (IND) 318 nm 
Clofazimine (CFZ) 486 nm 
Rimantadine (RMD), Curcumin 
(CCM) and Fluorescein (FLC) 
280 nm 
Table 7.2 Drug molecule and their absorbance wavelength at which the analysis by 
SEC was conducted  
A set of calibrants with different MW, were run through the column (Figure 7.3). 
Blue Dextran, which has a MW of 2 MDa, was used to identify the void volume 
of the column. This void volume is associated with the fastest elution time it 
takes a sample to pass through the column. The close elution time between 
Blue Dextran and Thyroglobulin is presumably related with the highest pore size 
of the column. For this reason we can speculate that the largest samples which 
can elute in the void volume might be smaller than 2 MDa. The subsequent 
analysis of purified protein, ND and ND-drug were not affected by this 
conclusion. 
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Figure 7.3 SEC chromatograms of the calibrants with known MW used to calculate the 
apparent MW of all samples passed through the column 
To compare the estimated mass of ND to its expected MW,80 the elution volume 
found during SEC analysis was placed on a calibration graph. The known MW 
of each standard calibrant was plotted against the ratio of its elution volume (Ve) 
and the void volume (Vo) of the column (Figure 7.4). The resulting calibration 
curve was modelled by a linear function and the apparent MW of the sample 
was calculated. The equation generated by the calibrants was used to further 
estimate the ND’s apparent mass. 
 
Figure 7.4 Calibration curve of the SEC elution times of calibrants with known MW and 
POPC; ND have an apparent MW of 150 kDa 
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 Analysis of size distribution by dynamic light scattering 
The principle behind the technique of DLS is that a sample is illuminated by a 
laser beam and the intensity of the scattered light fluctuations is detected at a 
known scattering angle θ. The intensity fluctuations of the scattered light are 
determined by the size, shape and interactions of the particles. 
DLS measures the speed at which the particles are diffusing due to Brownian 
motion and relates it to the size of the particles. The larger particles will have a 
slower Brownian motion, while smaller particles will move more rapidly. This is 
related with slower changes in signal for large particles while the correlation 
continues for a long time. In the case of small particles, the correlation will 
decrease more rapidly. The signal arose from the random Brownian motion of 
the particles can be defined as an autocorrelation function (Eq. 7.2), which is 
extracted as a function of delay time (τ) from the data processed using a 
correlator.  
G (τ) = exp-2 Гτ 
Equation 7.2 Autocorrelation function; τ = the time difference of the correlator; Γ = the 
decay rate. 
 
The correlator measures the degree of similarity between two signals or one 
signal with itself at different time intervals and converts the fluctuations into an 
intensity correlation function. By analysing the intensity correlation function, the 
translational diffusion coefficient is obtained: 
Γ= q2 D 
Equation 7.3 Γ = decay rate; D = translational diffusion coefficient; q = wave vector;  
The wave vector reflects the distance the particles are travelling and is 
dependent on the scattering angle: 
q=
4πn
λ
 sin
θ
2
 
Equation 7.4 n = refractive index of dispersant; λ = wavelength of the laser; θ = 
scattering angle.  
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From the translational diffusion coefficient, D, which describes the rate of the 
Brownian motion, the diameter of a particle is calculated using the Stokes-
Einstein equation: 
d(H)=
kT
3πηD
 
Equation 7.5 Stokes-Einstein equation; d(H) = hydrodynamic diameter; k = 
Boltzmann’s constant; the value is 1.380650 × 10−23 J K -1; T = absolute temperature; 
η = viscosity. 
The hydrodynamic diameter is a value that indicates how a particle diffuses 
within a fluid and, for non-spherical particles is the diameter of a sphere that 
has the same average translational diffusion coefficient as the particle being 
measured. 
Unfiltered samples of MSP1D1, ND and drug-loaded ND collected from SEC 
were characterised by size and polydispersity with a Zetasizer Nano (Malvern) 
particle size analyser. The samples were measured using a disposable micro 
cuvette (70 µL), at 4 °C. For accurate results, the samples were equilibrated for 
5 min and, for each sample, three measurements were made. Data collected 
was exported with Microsoft Excel and plotted with Origin Pro.  
 Analysis of drug loading per ND using HPLC 
In this separation technique the solvent used is polar and the silica bed particles 
within the column have long hydrocarbon chains attached to the surface in order 
to make it non-polar. Attractions will tend to form between non-polar compounds 
in the sample and the hydrocarbon groups. These interactions will make them 
less soluble in the polar solvent and slow them down on their way through the 
column.170 
Samples of drug loaded ND were analysed by reverse phase HPLC at 280 nm 
and drugs absorbance wavelengths to evaluate the number of drug molecules 
incorporated per ND. The drug loaded ND samples were resuspended in TFE 
in order to disassemble the systems. MSP and free drug in TFE were run on 
the HPLC column to obtain a calibration curve which was used by the Agilent 
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Chemstation software to automatically generate a calculated amount of the 
analysed components. The given amount of components was further used to 
calculate the number of drug molecules loaded per ND, by dividing the 
concentration of drug loaded ND by the concentration of empty ND. 
 Analysis of drug loading per ND using UV spectroscopy 
Similarly to HPLC analysis, UV spectroscopy was employed to determine the 
number of drug molecules loaded per ND, using two methods of calculation 
described in Chapter 3. Prior to analysis, drug loaded ND, MSP and drugs were 
suspended in TFE. 
 Analysis of rate of drug release from ND by UV spectroscopy 
Dialysis tubes containing ND with loaded drug were put in 900 mL of 20 mM 
Tris pH 7.4, 100 mM NaCl. Samples of ND containing drug (10 µL) were taken 
at specific time intervals and the concentration of drug was determined by UV-
vis spectroscopy measurements on a NanoDrop. The release studies of all 
drug-loaded ND assemblies were performed in triplicate. The fractional release 
and half-life of drug molecules were calculated as described in Chapter 3.  
7.3.7 The reconstitution of drug loaded MLV and ULV and their analysis 
by SAXS 
An appropriate volume of POPC (5 wt%) and drug (20 mol%) dissolved in 
chloroform were dried overnight into a thin film under vacuum. The prepared 
lipid and drug were then dispersed in dH2O (200 µL), at room temperature, by 
gentle vortexing. The vortexing was conducted in 10 cycles, each of 15-20 sec, 
with 5 minutes break in between. The drug loaded MLVs and ULVs were then 
kept in the fridge prior to analysis by Dr Amin Dilmaghani. 
 
 
140 
Experimental materials and methods 
 
7.3.8 Sortase mediated ligation of MSP with a fluorescent probe 
SrtA and fluorescein depsipeptide were prepared in HEPES buffer by Dr Daniel 
Williamson, at University of Leeds. 
Prior to the SrtA mediated ligation, TEV protease was used for the cleavage of 
His6 tag attached to the N-terminus of MSP1D1. ND (137 µL, 27 µM) was 
incubated, overnight, in the presence of TEV protease (2.74 µL, 1 µM final 
concentration), at 4 °C. The reaction was monitored by MS, however complete 
cleavage was not observed. The reaction mixture was separated by SEC. 
SrtA (8.6 µM final concentration, 480 µM stock concentration), ND (27 µM) and 
fluorescein depsipeptide (5 equivalents, 2 mM stock concentration) were mixed 
together to form a total volume of 55.5 µL. The mixture was then left at room 
temperature. After 6 h, an additional 4 equivalents of depsipeptide was added 
and the incubation continued overnight. The reaction mixture was monitored by 
MS and SDS-PAGE. Once the MSP had been modified, the ND mixture was 
immediately purified either using nickel resin or by SEC.  
The reaction mixture was incubated with nickel affinity resin (Qiagen) for up to 
4 h, by gently shaking. The mixture was subsequently separated from the resin 
by centrifugation and careful pipetting, and washed with ND buffer.  
 Mammalian cell culture 
Media, buffers and reagents 
PBS (100 mL): A single PBS tablet was dissolved in H2O. The solution was 
autoclaved for 20 minutes at 121 °C. 
1% or 4% BSA (50 mL): 1% or 4% bovine serum albumin (BSA) was dissolved 
in PBS 
0.1% Triton (50 mL): 0.1% (v/v) triton was dissolved in PBS 
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4% PFA (100 mL): 4% (w/v) paraformaldehyde was dissolved in PBS with 
heating at 70 °C, filtered (0.2 µm) and left to cool to room temperature before 
use. 
General passage procedure, cell preparation before transfection and the protein 
transfection procedure were conducted by Mr Darren Machin, at University of 
Leeds. 
Cell fixation 
The growth media or transfection solution was removed from each well plate 
and the cells were washed with PBS (2 × 1 mL) before being treated with 4% 
PFA (1 mL) for 10 minutes at room temperature. The cells were washed and 
stored in PBS (2 × 1 mL) at 4 °C for no longer than a week. Transfection 
experiments were stored in the dark to prevent photo-bleaching of the 
fluorophore. 
Cell immobilisation and confocal fluorescence microscopy 
The cells were plated at 150000 cells/well, on round coverslips in 12-well plates. 
After 24 h, the medium was replaced and the cells were incubated with 2 µL 
samples (empty and chlorambucil loaded fluorescein-ND, empty rhodamine-
ND) or left untreated. After 4 h and 24 h, the medium was removed and cells 
were washed with 2 × 1 mL PBS, fixed with 4% PFA for 10 minutes and washed 
again with 2 × 1 mL PBS. The cells were mounted onto a glass slide with 
Prolong® Gold Antifade Reagent with DAPI (15 µL) – used to stain nuclei. The 
slides were left overnight in the dark before being sealed with nail varnish to 
preserve the cells. The cells were stored at 4 °C in the dark for weeks to months 
without degradation. Confocal images were acquired on a Zeiss LSM510 META 
upright confocal microscope. 
 MTT assay 
The cytotoxicity of empty ND, chlorambucil loaded ND and free chlorambucil 
was determined on HeLa cells using a MTT assay. Cells were plated out in 96 
well plate - 1×104 cells per well. These were left overnight to grow up in 100 µL 
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medium. On the day, MTT Mw414 (Sigma) was dissolved in serum free medium 
at 1 mg/mL – conducted in sterile conditions. After removing the medium from 
wells, 100 µL MTT solution was added per well, covered with aluminium foil and 
incubated at 37 °C for 30 minutes. The MTT solution was discarded and 
replaced with 100 µL DMSO and shook for 5 min at 60 rpm, to dissolve the 
purple precipitate. The cells were treated for up to 24 h with the same 
concentration of empty ND, ND CLB and free drug, and the cell viability was 
determined after measuring the absorbance at 570 nm. 
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8 Chapter 8 – Appendix 
 
Figure 8.1 DNA sequence of MSP1D1 
10 20 30 40 50 60
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ACCATGGGT
Seq Data GATGGAGAATTCCCCCTCTAGAATATTTTGTTTACTTTAAGAAGGAGATAT.........
70 80 90 100 110 120
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 CATCATCATCATCATCATCACGATTATGATATTCCTACTACTGAGAATTTGTATTTTCAG
Seq Data ............................................................
130 140 150 160 170 180
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 GGTTCTACCTTCAGTAAACTTCGCGAACAACTGGGCCCCGTGACGCAGGAATTCTGGGAC
Seq Data ............................................................
190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 AACCTGGAAAAAGAAACCGAGGGACTGCGTCAGGAAATGTCCAAAGATTTAGAAGAGGTG
Seq Data ............................................................
250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 AAGGCCAAGGTTCAGCCATATCTCGATGACTTTCAGAAAAAATGGCAGGAAGAGATGGAA
Seq Data ............................................................
310 320 330 340 350 360
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 TTATATCGTCAAAAGGTGGAACCGCTGCGTGCGGAACTGCAAGAGGGGGCACGCCAAAAA
Seq Data ............................................................
370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 CTCCATGAGCTCCAAGAGAAGCTCAGCCCATTAGGCGAAGAAATGCGCGATCGCGCCCGT
Seq Data ............................................................
430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 GCACATGTTGATGCACTCCGGACTCATTTGGCGCCGTATTCGGATGAACTTCGCCAGCGT
Seq Data ............................................................
490 500 510 520 530 540
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 TTGGCCGCACGTCTCGAGGCGCTGAAAGAAAACGGGGGTGCCCGCTTGGCTGAGTACCAC
Seq Data ............................................................
550 560 570 580 590 600
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 GCGAAAGCGACAGAACACCTGAGCACCTTGAGCGAAAAAGCGAAACCGGCGCTGGAAGAT
Seq Data ............................................................
610 620 630 640 650 660
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 CTACGCCAGGGCTTATTGCCTGTTCTTGAGAGCTTTAAAGTCAGTTTTCTGTCAGCTCTG
Seq Data ............................................................
670 680 690 700 710 720
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 GAAGAATATACTAAAAAGCTGAATACCCAGTAAGCTT--~~~~~~~~~~~~~~~~~~~~~
Seq Data .....................................GCGGCCGCACTCGAGCACCACCA
730 740 750 760 770 780
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Seq Data CCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGC
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Figure 8.2 Amino acids sequence of MSP1D1 
 
Figure 8.3 Calibration curve generated after HPLC analysis, at 280 nm, of a series of 
MSP with known concentrations  
10 20 30 40 50 60
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~TMGHHHHHHHDYDIPTTENLYFQGSTFSKLREQLGPVTQEFWD
Seq Data DGEFPL*NILFTLRRRY...........................................
70 80 90 100 110 120
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 NLEKETEGLRQEMSKDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQK
Seq Data ............................................................
130 140 150 160 170 180
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 LHELQEKLSPLGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYH
Seq Data ............................................................
190 200 210 220 230 240
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 AKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ*AX~~~~~~~
Seq Data ..................................................*.CGRTRAPP
250 260 270 280 290 300
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Seq Data PPPLRSGC*QSPKGS*VGCCHR*AITSITPWGL*TGLEGFFAERRNYIRIGEWDAPCSGA
310 320 330 340 350 360
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Seq Data LSAAGVVVTRSVTATLASALAPAPFAFFPSFLATFAGFPRQALNRGLPLGFRFSALRHLD
370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Seq Data PKKLD*GDGSRNGPSP**TVFRPLTLESTFFNSGLLVQTGTTLNPIPGYSFDLKGILPIS
430 440 450 460
....|....|....|....|....|....|....|....|...
MSP1D1 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Seq Data AYWVKN*PDLPKIYPEF*QNFTAYNLGGTFPGKWAGNPNLVIF
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Figure 8.4 Calibration curve generated after HPLC analysis, at 242 nm, of a series of 
AMD with known concentrations  
 
Figure 8.5 Calibration curve generated after HPLC analysis, at 254 nm, of a series of 
CLB with known concentrations  
 
Figure 8.6 HPLC chromatogram of ND CLB measured at 254 nm; the inside 
chromatograms are an example of CLB and MSP with a known concentration 
measured at 254 nm and 280 nm, respectively; CLB was preloaded to ND reconstituted 
using method B  
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Figure 8.7 DLS of: A – CCM postloaded to ND (1:50 and 1:65 molar ratios); B - CCM 
preloaded to ND (1:65 molar ratio); reconstituted using method A 
 
Figure 8.8 CD spectras of ND and ND CCM; CCM was postloaded to ND (1:65 molar 
ratio) using method A 
 
Figure 8.9 UV spectras of ND CCM resuspended in TFE: A – CCM was postloaded to 
ND using method A; B - CCM was preloaded to ND using method A; the analysis was 
conducted at 430 nm 
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Figure 8.10 HPLC chromatogram of ND TRD, at 262 nm, the inside chromatograms 
are an example of TRD and MSP with a known concentration measured at 262 nm and 
280 nm, respectively; TRD was preloaded to ND reconstituted with method B 
 
Figure 8.11 Calibration curve generated after analysis, at 324 nm, of a series of NVB 
with known concentrations by HPLC 
 
Figure 8.12 HPLC chromatograms of ND NVB, at 280 nm (upper), and 324 nm (lower); 
drugs were preloaded to ND reconstituted with method B  
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Figure 8.13 Calibration curve generated after analysis, 218 nm, of a series of CPT with 
known concentrations by HPLC 
 
Figure 8.14 HPLC chromatogram of ND CPT, at 218 nm, the inside chromatograms 
are an example of CPT and MSP with a known concentration measured at 218 nm and 
280 nm, respectively; CPT was preloaded to ND reconstituted with method B 
 
Figure 8.15 Calibration curve generated after analysis, 277 nm, of a series of TMX with 
known concentrations by HPLC  
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Figure 8.16 HPLC chromatogram of ND TMX, at 277 nm, the inside chromatograms 
are an example of TMX and MSP with a known concentration measured at 277 nm and 
280 nm, respectively; TMX was preloaded to ND reconstituted with method B 
 
Figure 8.17 HPLC chromatograms of ND CLF, at 486 nm (upper), and 280 nm (lower); 
samples prepared by Noha and analysed by me; drugs were postloaded to ND 
reconstituted with method B 
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Figure 8.18 HPLC chromatogram of IND at 318 nm (upper) and of MSP at 280 nm 
(lower)  
 
Figure 8.19 Structures of: A - fluorescein-depsipeptide; B - fluorescein modified MSP, 
within ND assemblies 
 
Figure 8.20 Immunostained Huh7 cells, control cells, after 24 h, at 37 °C; A – Merged 
image; B – green channel, excitation at 488 nm; C – Red channel, excitation at 555 nm  
A 
A 
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Figure 8.21 Immunostained HeLa cells, control cells, after 24 h, at 37 °C; A – Merged 
image; B – green channel, excitation at 488 nm; C – Red channel, excitation at 555 nm  
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